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1
GENERAL INTRODUCTION
Type 1 diabetes mellitus – prevalence and pathophysiology
Diabetes mellitus—in short diabetes—is a chronic condition caused by an absolute or 
relative inability of the body to produce insulin, leading to raised blood glucose levels.1 
The prevalence of diabetes is high and rapidly increasing: currently, approximately 415 
million people worldwide have diabetes, a number expected to rise to 642 million by 
2040.1 In the Netherlands, the number of people suffering from diabetes was about one 
million in 2015.2 There are two main types of diabetes: type 1 and type 2 diabetes. As the 
present thesis focuses on patients with type 1 diabetes, type 2 diabetes is not discussed 
here. Type 1 diabetes is often referred to as juvenile-onset diabetes, as the onset usually 
occurs at childhood or early adulthood, but it can also occur in older adults, i.e., presenting 
as Latent Auto-immune Diabetes of the Adult (LADA).3 In Western countries, type 1 
diabetes accounts for approximately 7% to 12% of all diabetes cases. Type 1 diabetes is an 
autoimmune disease in which β-cell destruction leads to absolute insulin deficiency,3,4 
requiring lifelong insulin replacement therapy. Over time, chronic hyperglycemia can lead to 
several microvascular (retinopathy, nephropathy, neuropathy) and macrovascular complications 
(cardiovascular, cerebrovascular, peripheral vascular disease); hence, the primary goal of 
diabetes treatment is prevention of these complications through the achievement of 
near-normal blood glucose concentrations.4 
Psychosocial aspects of type 1 diabetes
Successful control of blood glucose levels requires optimal self-management by the 
patient. This is often referred to as a “24/7 challenge,” as it demands frequent self-monitoring 
of blood glucose levels and adjustment of insulin dose, accounting for carbohydrate 
intake and physical activity, and many other factors less frequently documented. It has 
been estimated that life with type 1 diabetes requires about 180 health-related decisions 
per day.5 The complexity of diabetes care, with its frequent adjustments to treatment and 
uncertainty of long-term health, can significantly impact patients’ well-being. Psycho -
social—i.e., social, behavioral and emotional—factors are also known to play an important 
role in type 1 diabetes. For example, the risk for depression is twice as high in patients with 
diabetes, compared to nondiabetic control subjects; the prevalence of depression for 
both types of diabetes is as high as 31% when assessed by self-report questionnaires and 
11% when assessed by diagnostic interviews.6 Other common psychosocial problems 
include eating disorders, stress and anxiety, or diabetes burnout.7,8 These problems can 
adversely affect management of the illness: for example, low adherence rates to 
treatment,9 or even poor glycemic control.10 In 2016, the American Diabetes Association 
released a position statement on psychosocial care for patients with diabetes advising 
personalized, patient-centered psychosocial care, including screening and management 
of common psychosocial co-morbidities conducted by health-care providers.11 
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CHAPTER 1
Fatigue in type 1 diabetes 
Researchers and clinicians have proposed numerous definitions of fatigue.12 It is important 
to distinguish between acute and chronic fatigue. Chronic fatigue is defined as persisting, 
severe fatigue that lasts for at least six months and has a substantial adverse impact on 
daily functioning.13 Acute fatigue is a classical sign at the presentation of (type 1) diabetes, 
as are polyuria (excessive production of urine), polydipsia (excessive thirst) and weight 
loss.4 Acute fatigue or tiredness has been reported as a symptom of hyperglycemia (blood 
glucose values above normal)14 and hypoglycemia (blood glucose values below normal),13,15 
and usually subsides after normalization of glucose levels.
The prevalence of chronic fatigue is high in several chronic medical conditions; however, 
although fatigue is a frequent complaint encountered in clinical practice, research on 
chronic fatigue in type 1 diabetes is scarce.16 A recently published cross-sectional study 
conducted by our research group demonstrates that chronic fatigue is highly prevalent, 
afflicting approximately 40% of adult patients with type 1 diabetes.17 Chronic fatigue has 
a negative impact on patients’ well-being: severely fatigued patients reported more 
impairment in all domains of daily functioning, compared to non-fatigued patients. 
Additionally, patients reported that fatigue was one of the most disturbing symptoms of 
their disease.17 These findings are consistent with those in another cross-sectional study 
showing that patients with type 1 diabetes had significant higher fatigue scores than 
people from the general population.18
Associated factors of fatigue in type 1 diabetes
The etiology of chronic fatigue in type 1 diabetes is unclear, but it has been suggested that 
fatigue can be explained by a combination of physiological, psychological and lifestyle 
factors.13 While it is widely assumed that fatigue is associated with clinical factors of diabetes, 
e.g., glycemic control, two separate studies—one investigating fatigue in type 1 and one in 
type 2 diabetes—found no relationship between fatigue and HbA1c (hemoglobin A1c) 
values.17,19 HbA1c is an index of mean blood glucose levels over a 6-8 week period.3 One 
study in patients with type 2 diabetes revealed an indirect relationship between fatigue and 
HbA1c in a subgroup of patients with suboptimal glycemic control.20 As all studies reported 
here are cross-sectional, it is possible that HbA1c and fatigue are related to each other over 
time, or, as demonstrated by the study of Park and colleagues,20 related to each other in a 
subgroup of patients. A potential relationship between HbA1c and fatigue over time, or in 
a sub-group of patients, has not been investigated in type 1 diabetes. Recent literature 
suggest that fatigue is not related to glucose variability, the variation in blood glucose 
values.17,19 It has been found that patients with higher fatigue severity have more frequently 
neuropathy, nephropathy and cardiovascular disease,17 as well as were stroke and ischemic 
heart disease (IHD) found to be associated with higher fatigue scores.18 Additionally, a higher 
number of diabetes complications was associated with higher fatigue scores.17 
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GENERAL INTRODUCTION
Whilst studies thus far suggest that glycemic control is not an important associated factor 
of fatigue, fatigue in type 1 diabetes may be associated with several cognitive and 
behavioral factors.17 There is a relationship between fatigue severity in type 1 diabetes 
and beliefs about fatigue—such as self-efficacy concerning fatigue, fatigue catastrophizing, 
focusing on fatigue, and illness-related attributions with regard to fatigue—as well as 
between fatigue severity and diabetes-related beliefs concerning self-efficacy with respect 
to diabetes, as well as diabetes distress.17 Additionally, behavioral factors such as sleep 
disturbances and physical inactivity were found to be correlated to fatigue in type 1 
diabetes;17 however, this study was conducted at one time point, making it impossible to 
draw conclusions on the direction of the relationships. Studies using longitudinal designs 
could provide more insight into factors that contribute to fatigue in type 1 diabetes, aiding 
in development of effective interventions. To date, such longitudinal studies have not 
been performed. 
In addition to cognitive-behavioral factors, relevant literature suggests that current 
health-related factors are associated with fatigue. Pain has been repeatedly found to be 
related to severe fatigue in several chronic diseases such as neuromuscular disorders,21 
rheumatoid arthritis22 or Ehlers-Danlos syndrome.23 Recent research suggests that pain is 
also associated with fatigue in type 1 diabetes;17 however, the scope of the problem is not 
yet known. As pain could be an important perpetuating factor in fatigue—one that could 
be addressed in interventions for fatigue in type 1 diabetes—it is important to gain further 
information about the role of pain in patients with severe fatigue and type 1 diabetes. 
Also, depressive symptoms appear to be associated with fatigue in both type 117 and type 2 
diabetes.19 However, the presence of depressive symptoms does not necessarily mean 
that a patient meets the criteria for major depression: it is important to distinguish 
between them, as the prevalence of clinical depression is high in type 1 diabetes.6 Clinical 
depression, or major depression, is a mood disorder characterized by the loss of interest in 
nearly all activities and a depressed mood; meeting the criteria described in the Diagnostic 
and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).24
Cognitive behavioral model of fatigue in type 1 diabetes
We introduce a cognitive behavioral model that assumes that the disease—and/or dis-
ease-specific factors such as hyperglycemia and diabetes-related complications, trigger 
fatigue—and that cognitive-behavioral factors perpetuate fatigue (Figure 1). This model 
has been supported by findings from studies on fatigue in other chronic diseases, such as 
multiple sclerosis25 or rheumatoid arthritis.26 The model for patients with type 1 diabetes 
delineates the specific perpetuating factors that are associated with chronic fatigue in 
type 1 diabetes.17 These factors include dysfunctional cognitions with regard to fatigue, 
such as reduced self-efficacy concerning fatigue or catastrophizing about fatigue,17 as 
well as behaviors, such as a deregulated sleep-wake pattern and physical inactivity.17 
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CHAPTER 1
Additionally, pain and diabetes distress have been added to the model, as these seem 
to be prevalent in type 1 diabetes,8,27 and have also been found to be associated with 
fatigue.17 Previous research has shown that severely fatigued patients with type 1 diabetes 
scored significantly higher on impairments of social functioning than non-severely 
patients.17 Social support and interactions with significant others are associated with 
fatigue in other chronic diseases, for example cancer survivors.28 This suggests that a lack 
of social support and/or a discrepancy between the amount of desired and received 
social support could also be an important perpetuating factor of chronic fatigue in type 1 
diabetes. For this reason, the lack of social support and/or negative social interactions with 
significant others was added to the cognitive behavioral model of chronic fatigue in type 1 
diabetes. 
Cognitive behavioral therapy for chronic fatigue 
In recent years, research has found that cognitive behavioral therapy (CBT) can be effective 
in reducing fatigue severity for patients with chronic diseases and disorders causing 
long-term disability, including those with multiple sclerosis,29 FSHD,30 and chronic fatigue 
syndrome,31 as well as cancer survivors.32 In this context, CBT addresses cognitive and 
behavioral factors that are thought to maintain fatigue. During the therapy, patients learn to 
change dysfunctional beliefs about fatigue and to gradually increase their daily activities. 
Factors addressed in CBT are often similar across different chronic diseases,21-23,33 but 
fatigue is usually viewed as a disease-specific symptom, consequently requiring disease- 
specific fatigue treatments.25,26
Blended care and tailored treatment
To date, most CBT for patients with chronic disease-related fatigue has occurred in face- 
to-face sessions with a therapist,30,32 but in recent years, increasing numbers of web-based 
Figure 1  Cognitive-behavioral model for fatigue in type 1 diabetes
Triggers
- Somatic co-morbidity
- Complications due to diabetes
- Hyperglycemia  
Fatigue Perpetuating factors
1. Decreased or deregulated levels
 of physical activity
2. Sleep disturbances and disrupted 
 sleep-wake rhythm
3. Dysfunctional cognitions
4. Pain and pain-related cognitions
5. Lack of social support and/or  
 negative social interactions
6. Diabetes-related distress      
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GENERAL INTRODUCTION
interventions for various psychological problems have been developed and tested for 
efficacy,34 including a web-based intervention for depression in diabetes35 and a web- 
based self-management therapy for psychological adjustment after breast cancer.36 
However, despite the advantages of web-based therapy—such as time efficiency or 
reduction of travel time to the treatment center—internet therapy also has disadvantages. 
For example, the absence of face-to-face contact can make it difficult for therapists to 
detect patients’ nonverbal communication cues and body language.34 Blended care is a 
combination of face-to-face and online therapy that incorporates and obtains optimal 
benefits from both treatment modalities.37 Blended care benefits from the interchange-
ability of the two therapy modalities, as it can account for patients’ needs and preferences 
with regard to personal contact during treatment. To optimize care, many psychological 
interventions use an individualized approach in which the treatment is tailored to the 
patients’ specific needs.38 CBT for fatigue in breast cancer survivors39 or patients with 
multiple sclerosis29 uses such an approach with patients receiving only those modules of 
the CBT treatment that are relevant to them. Tailored interventions appear to have several 
benefits, including increased treatment motivation, adherence and patient satisfaction.38  
The mechanisms of change by cognitive behavioral therapy
CBT for chronic fatigue is known to be effective in reducing fatigue in various chronic 
conditions; however, it is important to unravel the mechanisms of change behind the 
treatment effect, in order to increase understanding of why CBT works and improve future 
treatment. Mediation analysis is one technique that can help determine potential 
mechanisms of change, as it detects factors that mediate the relationship between 
treatment and outcome.40 Recently, several studies on the mechanisms of change in CBT 
for patients with chronic fatigue syndrome and multiple sclerosis have been completed, 
finding that changes in fatigue-related cognitions—such as self-efficacy concerning 
fatigue, focusing on fatigue as symptom, and negative representations of fatigue—can 
likely explain the effects of CBT on the decrease of fatigue.41-43 These findings demonstrate 
the importance of addressing specific fatigue-related cognitions during treatment. 
Research on the mechanisms of change in CBT—for example mediation analysis—can 
provide important information about potential mediators that explain the decrease of 
fatigue and can help to further improve newly developed treatment or make it more 
efficient. 
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CHAPTER 1
Expert Center for Chronic Fatigue 
All studies carried out for this thesis have been conducted at the Expert Center for 
Chronic Fatigue (ECCF), formerly situated at the Radboud university medical center, 
but currently at the VU University Medical Center (VUmc) and the Academic Medical 
Center (AMC), Amsterdam, the Netherlands. The ECCF is a treatment facility and multi- 
disciplinary research center for chronic fatigue. Research focuses on: (1) chronic fatigue 
in chronic illness,22,30,44 (2) cancer-related fatigue,28,32,45 and (3) chronic fatigue 
syndrome.31,33,46,47 More information can be found at the website: http://nkcv.nl.
Aims and outline of the thesis
The central purpose of this thesis is to investigate chronic fatigue—from its predictors and 
associated factors to its treatment—in patients with type 1 diabetes.
First, we investigated the course and predictors of severe fatigue in a prospective study 
in patients with type 1 diabetes. As it is likely that health-related and cognitive-behavioral 
factors are relevant in fatigue and type 1 diabetes, several of those factors were studied 
to determine predictors of severe fatigue. We also examined the relationship between 
fatigue severity and HbA1c over time; results are presented in Chapter 2. 
As noted, pain is an important associated factor of fatigue in several chronic diseases, 
including type 1 diabetes. Because pain seems relevant for the management of fatigue, 
we performed a cross-sectional study to gain more insight about the prevalence, location 
and severity of pain in severely fatigued patients with type 1 diabetes. Additionally, 
the relationship of pain to clinical and psychosocial variables was studied, with results 
described in Chapter 3.
Despite the high prevalence and severe impact of chronic fatigue in patients with type 1 
diabetes, to date, no effective treatment has been available. As cognitive-behavioral 
factors seem to be related to fatigue in type 1 diabetes, and as cognitive behavioral 
therapy (CBT) aimed at these factors has been found effective in the treatment of chronic 
fatigue for patients with other chronic diseases, CBT seems a promising treatment for 
chronic fatigue in type 1 diabetes. Therefore, we designed Dia-Fit, a CBT program 
addressing cognitive-behavioral factors found to be relevant in the maintenance of 
chronic fatigue in type 1 diabetes. Dia-Fit is a tailored treatment accounting for patients’ 
individual needs, delivered in blended form via a combination of face-to-face sessions 
and web-based modules. The efficacy of the treatment was investigated in the Dia-Fit 
study, a randomized controlled trial (RCT) comparing patients who receive Dia-Fit to 
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patients allocated to a waiting list group. Chapter 4 reports on the design and rationale 
of the Dia-Fit study. In Chapter 5, the results of the Dia-Fit RCT are presented. More 
specifically, the chapter reports on the treatment’s effects on fatigue severity, functional 
impairment, HbA1c and glucose variability, compared with the waiting list group. To further 
develop and improve the treatment, it is important to gain insight into the mechanisms 
of underlying factors that explain the expected positive change. Chapter 6 presents 
the results of a mediation analysis that investigated the mechanisms of change in the 
Dia-Fit treatment. 
It seems likely that factors which maintain fatigue and are addressed in CBT are generic 
across different chronic diseases; nonetheless, several disease-specific fatigue models and 
treatments have been developed. It is often assumed that dysfunctional disease-specific 
somatic processes are related to fatigue, such as glycemic control in diabetes or inflammation 
in rheumatoid arthritis. However, several studies were unable to confirm these relation-
ships. To further optimize fatigue treatments in chronic diseases, including type 1 diabetes, 
we investigated whether fatigue is a disease-specific or a generic symptom across different 
chronic diseases. The results of this study are presented in Chapter 7. 
The results of the studies described in this thesis are summarized in Chapter 8. Finally, 
Chapter 9 contains a general discussion about the findings of the previous chapters in 
the context of existing literature. Additionally, the chapter discusses directions for future 
research and implications for clinical practice.
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ABSTRACT
Aims: To prospectively identify the course of severe fatigue, its predictors and the 
relationship with HbA1c in patients with type 1 diabetes.
Methods: 214 adult patients completed questionnaires on fatigue severity and fatigue- 
related factors at baseline. HbA1c was retrieved from medical records. After 43 months, 
fatigue severity and HbA1c were reassessed in 194 patients. A logistic regression analysis 
was used to determine predictors of severe fatigue at follow-up with various cognitive- 
behavioral and clinical factors as potential predictors. The relationship between fatigue 
and HbA1c was investigated in a sub-analysis by differentiating between patients with 
suboptimal glucose control [HbA1c >7% (53 mmol/mol)] and optimal glucose control 
[HbA1c ≤7% (53 mmol/mol)].
Results: The prevalence of severe fatigue was 40% at baseline and 42% at follow-up. 
In three out of four severely fatigued patients at baseline (76%), severe fatigue persisted 
over time. More depressive symptoms, more pain, sleep disturbances, lower self-efficacy 
concerning fatigue, less confidence in diabetes self-care, more fatigue severity at baseline 
and more diabetes complications predicted severe fatigue at follow-up. Over time, HbA1c 
at baseline was positively associated with fatigue severity at follow-up in both groups 
(suboptimal glucose control: r=.18, p<.05; optimal glucose control: r=.09, p<.05).
Conclusions: About three quarters of fatigued patients with type 1 diabetes suffer from 
persistent fatigue. Aside from the number of diabetes complications, no clinical factors 
explained the persistence of fatigue. HbA1c and fatigue were weakly associated in a 
sub-analysis. Since the strongest predictors of severe fatigue were cognitive-behavioral 
factors, behavioral interventions might be effective in decreasing fatigue.
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INTRODUCTION
Severe fatigue is a common and disabling symptom in type 1 diabetes. Cross-sectional 
studies found that significantly more patients with type 1 diabetes suffered from severe 
fatigue and reported higher fatigue scores than people from the general population.1,2 
Severe fatigue has been found to have an adverse impact on patients: it is associated 
with impairments in daily functioning and is reported as one of the most burdensome 
symptoms of type 1 diabetes.1 The etiology of fatigue in diabetes is unclear, but it is 
assumed that fatigue is caused by a combination of different aspects since physiological 
factors such as diabetes complications, psychological factors such as depression and 
lifestyle factors such as physical activity are found to be associated with fatigue.3
Despite the high prevalence of fatigue and its adverse impact on patients, prospective 
studies on fatigue in type 1 diabetes are lacking and it is unclear whether fatigue is a 
persistent symptom and which factors predict fatigue in type 1 diabetes. This is important, 
as insights into the mechanisms that underlie the development and maintenance of 
fatigue over time, can help to establish effective interventions for the management of 
fatigue. In other chronic diseases, severe fatigue is found to be associated with cognitive- 
behavioral factors such as sleep disturbances, physical inactivity and a low self-efficacy 
concerning fatigue.4-6 These factors can contribute to the maintenance of severe fatigue. 
Also in type 1 diabetes, severe fatigue is associated with such cognitive-behavioral factors, 
but also with pain, depressive symptoms and a lack of confidence in diabetes self-care.1 
It has also been shown that fatigue in diabetes is associated with physiological factors 
such as diabetes-related symptoms,3 the number of diabetes-related complications,1 and 
especially macrovascular complications as a recent study found that the presence of 
vascular diseases is a predictor of fatigue in type 1 diabetes.2
Because these findings were obtained in cross-sectional studies, they do not allow us to infer 
any cause and effect relationship with severe fatigue. Studies on the factors that influence 
severe fatigue over time could help us to develop interventions that address persistent and 
severe fatigue, such as cognitive behavioral therapy or exercise training, which have been 
found to be effective in reducing severe fatigue in other chronic diseases.7,8
While it is often assumed that poor glucose control, reflected by high HbA1c levels, causes 
fatigue in diabetes, most studies investigating the relationship between fatigue and HbA1c 
both in type 1 and type 2 diabetes have not been able to confirm this association.1,9,10 
None of these studies differentiated between patients with an optimal and suboptimal 
glucose control, which seems relevant, because a recent study showed a positive 
relationship between severe fatigue and HbA1c in patients with suboptimal glucose 
control [HbA1c >7% (53 mmol/mol)], while this relationship was absent in patients with an 
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optimal glucose control [HbA1c ≤7% (53 mmol/mol)].11 It seems that the relationship 
between HbA1c and fatigue changes, dependent on the glucose control of patients. 
It could also be that the relationship between HbA1c and fatigue does not exist cross- 
sectionally, but over time, which will be able to test with prospective designs.
The aim of the present study was threefold: (1) to investigate the natural course of fatigue 
in type 1 diabetes over time, (2) to determine predictors of severe fatigue, and (3) to assess 
the relationship between fatigue and glucose control (HbA1c) over time by differentiating 
between patients with suboptimal and optimal blood glucose control.
SUBJECTS, MATERIALS AND METHODS
Participants were patients with type 1 diabetes from the diabetes outpatient clinic of the 
Radboud university medical center Nijmegen, the Netherlands. Data were collected at 
baseline (2011) and follow-up (2014). At baseline, 350 patients were randomly selected 
from the population of the outpatient clinic (n=831 patients). Inclusion criteria were: (1) 
type 1 diabetes for at least one year, (2) age between 18 and 75 years, and (3) able to speak, 
read and write Dutch. Patients who were hospitalized or terminally ill were excluded. Out 
of the 350 approached patients, 214 participated (response rate 61%) and filled in 
questionnaires regarding fatigue severity and fatigue-related factors between April and 
October 2011. HbA1c was derived from medical records. All 214 patients were asked to 
participate in the follow-up study between July 2014 and December 2014. The follow-up 
consisted of a short questionnaire on fatigue severity and the presence of co-morbidity 
and diabetes complications. HbA1c values were again retrieved from medical records. 
Patients received the questionnaire at home and returned it via mail. Patients who did not 
fill in the questionnaire got up to three reminders by mail and by telephone. The medical 
ethical committee of the Radboud university medical center approved the study and all 
patients provided written informed consent.
Measures
Fatigue severity
Fatigue was assessed with the Checklist Individual Strength (CIS),12 which consists of 20 
items and four subscales: fatigue severity (CIS-F), concentration problems, decreased 
motivation, and decreased physical activity. The CIS-F subscale measures the severity of 
fatigue in the last two weeks and consists of eight items scored on a 7-point Likert Scale 
from (1) ‘‘Yes, that is true” to (7) ‘‘No, that is not true”. The score on the CIS-F ranges from 8 
to 56. A score of 35 or higher, two standard deviations above the mean of a healthy group, 
is an indication for the presence of severe fatigue.13 The CIS has excellent psychometric 
properties.12
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Potential predictors of severe fatigue
 Sleep disturbances were measured with the Sickness Impact Profile-8 (SIP-8), subscale 
sleep and rest.14 The SIP-8 is a commonly used instrument with high reliability and validity, 
which consists of eight categories. 
 Physical activity was measured with the Internal Physical Activity Questionnaire (IPAQ), 
a self-report instrument consisting of 9 items, which assesses three types of activities 
during the previous seven days: walking, moderate activities and vigorous activities.15 The 
frequency, measured in days per week, and the duration, measured per day, are assessed 
for each type of activity.15 The IPAQ has reasonable measurement properties.15 
 Self-efficacy concerning fatigue was assessed with the Self-efficacy Scale (SES). The scale 
measures the sense of control over fatigue, experienced by patients.16 The questionnaire 
consists of 7 items with each a 4-point Likert scale. Scores range from 7 to 28, with higher 
scores indicating more self-efficacy. 
 Confidence in diabetes self-care is the patients’ confidence in his or her own ability to 
perform diabetes management and was assessed with the Confidence in Diabetes 
Self-Care Scale (CIDS).17 The CIDS is a 20-item questionnaire, which is rated on a 5-point 
Likert Scale from (1) “No, I am sure I cannot” to (5) “Yes, I am sure I can”. The scores range 
from 0 to 100. Higher scores indicate more confidence in diabetes self-care. The CIDS is a 
reliable and valid measure in Dutch and U.S. patients with type 1 diabetes.17 
 Pain severity was assessed with the Health Survey Short Form-36 (SF-36), subscale 
bodily pain. The SF-36 consist of 36 items and is a valid questionnaire.18 Higher scores on 
the SF-36 indicate a better health status and accordingly less pain. 
 Depressive symptoms were assessed with the Beck Depression Inventory Primary Care 
(BDI-PC).19 The BDI-PC consists of 7 item. Scores range from 0 to 21. A score of 4 or higher 
is indicated as clinically relevant depressive symptom. 
 HbA1c and body mass index (BMI, kg/m2) were retrieved from medical records. Presence 
of co-morbidity was assessed with self-report and reported as dichotomous variable (yes/
no). Presence and number of diabetes complications was assessed with a self-report 
questionnaire that measured whether patients had one or more of the following seven 
common diabetes complications: retinopathy, nephropathy, neuropathy, numbness in 
the feet, cardiovascular disease, heart attack and stroke.
Statistical analyses
IBM SPSS Statistics Version 22.020 and LISREL 9.221 were used for the statistical analyses. 
Descriptive statistics were presented as mean ± SD or count and frequency. Differences 
between patients with persistent (CIS-F ≥35 at baseline and follow-up) and without 
persistent fatigue were tested with independent t-tests. The course of fatigue was 
analyzed by comparing the number of severely fatigued patients (CIS-F score ≥35) and 
non-severely-fatigued patients (CIS-F score <35) across time. To analyze which variables 
predict severe fatigue at follow-up, we performed a multiple logistic regression with the 
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stepwise enter method and reported odds ratios (OR) and their 95% confidence intervals 
(CI). The outcome variable was severe fatigue at follow-up, dichotomized into severe 
(CIS-F ≥35) and non-severe fatigue (CIS-F <35). We selected eleven variables as potential 
predictors and analyzed them in three steps: age, depressive symptoms, pain, sleep 
disturbances, physical activity, confidence in diabetes self-care and self-efficacy concerning 
fatigue were selected for the first step. These variables were chosen because they were 
found to be significantly associated with severe fatigue in the study of Goedendorp 
and colleagues,1 which was the baseline data for the present study. In the second step, 
we added the autoregressor fatigue severity at baseline. In the third step, the three clinical 
factors HbA1c, co-morbidity and number of diabetes complications were added. 
All continuous variables were standardized to improve the interpretability of the OR’s. 
The models were evaluated using the Hosmer and Lemeshow test, the omnibus test for 
the model parameters and Nagelkerke’s R2.22
To test the relationship between fatigue and glucose control, we estimated a multigroup 
cross-lagged panel model23 in a sub-analysis. Two groups were created by splitting the 
sample, based on a cut-off HbA1c threshold of 7% (53 mmol/mol) at the baseline: optimal 
and suboptimal glucose control. In clinical practice, this threshold is widely used as an 
upper limit for optimal glucose control.24 Patients scoring 7% (53 mmol/mol) or lower 
were defined as patients with an optimal glucose control and patients scoring higher than 
7% (53 mmol/mol) were allocated to the group of suboptimal glucose control. In order to 
test for differences between the groups, the model was estimated with between group 
equality constraints on the structural parameters. The model was evaluated with the CHI2 
statistics (any model with a p-value larger than .05 is an acceptable model) and the RMSEA 
(any model with a RMSEA lower than .06 is an acceptable model).25 All p-values and 
estimates were considered to be significant at p<.05.
RESULTS
Of the 214 patients who participated at baseline, six (3%) had died. 194 (93%) of the 
remaining 208 patients, completed and returned the follow-up questionnaire. Five patients 
could not be reached and nine patients refused to participate. Mean time between 
baseline and follow-up was 43 ± 1.8 months. Table 1 shows the demographic variables of 
the sample.
When comparing patients with persistent fatigue (CIS-F ≥35 at baseline and follow-up) 
and patients without persistent fatigue, significant differences were found between the 
clinical factors co-morbidity and diabetes complications. Patients with persistent fatigue 
reported more co-morbidity (p=.048) and had significantly more diabetes complications 
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Table 1   Sample characteristics and differences between patients with persistent 
fatigue and without persistent fatigue
Persistent severe fatigue*
All patients 
(n=194)
Yes 
(n=59)
No 
(n=135)
Difference
p-value**
Age, years (mean, SD) 51.5 (12.7) 49.4 (12.7) 52.4 (12.6) .128
Gender (female, %) 53.6 61 50.4 .171
Diabetes duration, years (mean, SD) 32.8 (13.4) 32.9 (12.9) 32.8 (13.6) .971
Married (yes/no, %) 78.9/21.1 79.7/20.3 78.5/21.5 .859
Education (low/high, %) 46.9/53.1 47.5/52.5 46.7/53.3 .920
HbA1c baseline 
% (mean, SD) 7.8 (1.1) 7.9 (1.1) 7.6 (1.1) .101
mmol/mol (mean, SD) 62 (12) 63 (12) 60 (12) .101
HbA1c follow-up† 
% (mean, SD) 8.1 (1.1) 8.1 (1.2) 8.0 (1.1) .534
mmol/mol (mean, SD) 65 (12) 65 (13) 64 (12) .534
Body mass index, kg/m2 (mean, SD)†† 26.1 (4.5) 27 (4.8) 25.7 (4.3) .073
Co-morbidity (yes, %) 46.9 57.6 42.2 .048
Number of complications (mean, SD) 1.1 (1.4) 1.8 (1.8) 0.8 (1.2) .000
Diabetes complications
Retinopathy (yes, %) 38.1 49.2 33.3 .043
Nephropathy (yes, %) 10.3 20.3 5.9 .013
Neuropathy (yes, %) 23.7 37.3 17.8 .008
Numbness in the feet (yes, %) 18.6 28.8 14.1 .030
Cardiovascular disease (yes, %) 12.9 28.8 5.9 .001
Heart attack (yes, %) 4.1 6.8 3.0 .294
Stroke (yes, %) 4.1 6.8 3.0 .294
Depressive symptoms 0.1 (0.3) 0.3 (0.5) 0.1 (0.2) .000
Pain 79.1 (22.7) 65.3 (25.5) 85.1 (18.4) .000
Sleep disturbances 48.3 (58.2) 81.1 (62.9) 33.9 (49.8) .000
Physical activity 249.8 (296.6) 161.7 (188.8) 287.3 (325.5) .001
Confidence in diabetes self-care 87.5 (11.3) 84.5 (12.3) 88.8 (10.6) .013
Self-efficacy concerning fatigue 20.6 (4.1) 17.8 (3.4) 21.8 (3.7) .000
Note. Depressive symptoms=BDI ≥4 yes/no at baseline; pain=SF-36 subscale bodily pain at baseline (a higher 
score on the SF-36 indicates a better health status and accordingly less pain); sleep disturbances=SIP-8 subscale 
sleep/rest at baseline; self-reported physical activity=IPAQ at baseline; confidence in diabetes self-care=CIDS at 
baseline; self-efficacy concerning fatigue=SES at baseline. 
*Persistent severe fatigue=CIS-F baseline ≥35 and CIS-F follow-up ≥35.
**Difference between patients with persistent fatigue (n=59) and patients without persistent fatigue (n=135), 
significant at p<.05. 
†n=10 missing.
††n=20 missing.
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(p<.001) than patients without persistent fatigue. In particular, they reported significantly 
more diabetes complications of retinopathy (p=.043), nephropathy (p=.013), neuropathy 
(p=.008), numbness in the feet (p=.030) and cardiovascular disease (p<.001). Significant 
differences between the two groups were found in all tested cognitive-behavioral 
variables (Table 1).
Figure 1 demonstrates the course of fatigue in type 1 diabetes. The prevalence rate of 
severe fatigue at baseline was 40.2% and at follow-up 42.3%. Three out of four patients 
who experienced severe fatigue at baseline, also suffered from severe fatigue at follow-up 
(75.6%).
Table 2 presents the results of the multiple logistic regression analysis. The Hosmer & 
Lemeshow test was not significant in all three steps, indicating that the model fits the data 
in all three steps. In step one, age, depressive symptoms, pain, sleep disturbances, physical 
activity, confidence in diabetes self-care and self-efficacy concerning fatigue were entered 
as independent variables to the model. More depressive symptoms, more pain and a 
lower self-efficacy concerning fatigue were significant predictors of severe fatigue at 
follow-up. A higher score on depressive symptoms was associated with an increase in the 
odds of becoming severely fatigued at follow-up (OR=3.20; 95% CI, 1.01-10.14, p=.048) and 
a higher score on the SF-36 pain subscale was associated with a decrease in the odds of 
becoming severely fatigued at follow-up (OR=.62; 95% CI, .42-.93, p=.019). A high score on 
the SF-36 pain subscale means less pain and disability. A higher score on self-efficacy 
concerning fatigue was also associated with a decrease in the odds of being severely 
Figure 1   Number of patients that were severely and non-severely fatigued at  
baseline and follow-up
75,6% 24,4%
Severe fatigue
baseline (n=78)  
Non-severe fatigue
follow-up (n=19) 
Severe fatigue
follow-up (n=59) 
19,8% 80,2%
Non-severe fatigue
baseline (n=116)  
Non-severe fatigue
follow-up (n=93)  
Severe fatigue
follow-up (n=23) 
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fatigued (OR=.44; 95% CI, .28-.69, p<.001). In step two, fatigue severity at baseline was 
added to the model. Lower confidence in diabetes self-care and more fatigue at baseline 
significantly predicted severe fatigue at follow-up. A higher score on confidence in 
diabetes self-care was associated with a decrease in the odds of becoming severely 
fatigued at follow-up, with an odds ratios of .65 (95% CI, .43-.98, p=.038). A higher score on 
fatigue severity at baseline was associated with an increase in the odds of becoming 
severely fatigued at follow-up, with an odds ratio of 1.13 (95% CI, 1.07-1.18, p<.001). In step 
three, the clinical factors HbA1c, co-morbidity and number of diabetes complications were 
added to the model. Sleep disturbances with an odds ratio of .57 (95% CI, .36-.91, p=.019) 
and number of complications with an odds ratio of 2.55 (95% CI, 1.47-4.44, p=.001) were 
Table 2   Results of logistic regression with severe fatigue at follow-up as  
dependent variable
Block 1 Block 2 Block 3
OR 95% CI OR 95% CI OR 95% CI
Constant .60 .02 .01
Age .72 .50-1.04 1.07 .70-1.66 .72 .43-1.20
Depressive symptoms 3.20* 1.01-10.14 1.33 .39-4.46 .98 .27-3.59
Pain .62* .42-.93 1.02 .64-1.64 1.06 .64-1.75
Sleep disturbances .95 .63-1.43 .73 .47-1.12 .57* .36-.91
Physical activity 1.00 1.00-1.00 1.00 1.00-1.00 1.00 1.00-1.00
Confidence in diabetes self-care .71 .49-1.05 .65* .43-.98 .59* .38-.91
Self-efficacy concerning fatigue .44* .28-.69 .81 .48-1.37 .77 .44-1.36
Fatigue severity at baseline 1.13* 1.07-1.18 1.13* 1.07-1.19
HbA1c .92 .60-1.42
Co-morbidity 2.05 .89-4.70
Number of complications 2.55* 1.47-4.44
Omnibus test [X2 (df )] 59.01 (7) 29.99 (1) 15.26 (3)
Nagelkerke R2 .37 .52 .58
Hosmer & Lemeshow test [X2 (df )] 7.21 (8) 15.5 (8) 5.25 (8)
Note. Logistic regression, enter method; OR=odds ratio; 95% CI=confidence interval; dependent variable= 
severely fatigued at follow-up (0<35, 1≥35); age=age at baseline, depressive symptoms=BDI ≥4 yes/no at 
baseline; pain=SF-36 subscale bodily pain at baseline (a higher score on the SF-36 indicates a better health status 
and accordingly less pain); sleep disturbances=SIP-8 subscale sleep/rest at baseline; self-reported physical 
activity=IPAQ at baseline; confidence in diabetes self-care=CIDS at baseline; self-efficacy concerning fatigue=SES 
at baseline; fatigue severity at baseline=CIS-F at baseline; HbA1c=HbA1c at follow-up; co-morbidity=co-morbidity 
at follow-up (yes/no); number of complications=number of diabetes complications at follow-up. 
*bold font=significant at p<.05.
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found to be significant predictors of severe fatigue at follow-up. The predicted variance of 
the models increased in all three steps with respectively 37%, 52% and 58% (Table 2).
A post hoc analysis with the presence of the three macrovascular complications 
(cardiovascular disease, heart attack, stroke) as predictors instead of the number of 
complications revealed that the presence of cardiovascular disease was a significant 
predictor of severe fatigue at follow-up with an odds ratio of 21.6 (95% CI, 3.29-141.63, 
p=.001).
Figure 2   Cross-lagged panel model for the two groups of patients with  
type 1 diabetes
Note. Dotted line=not significant; Maximum Likelihood estimates: the figure shows the within group standardized 
estimates. The equality constraints were set on the unstandardized estimates; fatigue severity baseline=CIS-F at 
baseline; fatigue severity follow-up=CIS-F at follow-up.
*p<.05
Patients with suboptimal glucose control [n=138; HbA1c >7,0% (53mmol/mol)] 
Patients with optimal glucose control [n=46; HbA1c ≤7% (53mmol/mol)] 
-.02  
.18 * 
.72 * 
.69 * 
.09  -.01  
.53 * HbA1c  
baseline  
Fatigue severity 
baseline  
HbA1c  
follow-up 
Fatigue severity 
follow-up 
.43 * 
.09 * 
-.02  
.69 * 
.39 * 
-.26  -.02  
.85 * HbA1c  
baseline  
Fatigue severity 
baseline  
HbA1c   
follow-up 
Fatigue severity 
follow-up 
.55 * 
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Figure 2 displays the cross-lagged panel model. The model fit was good with CHI2=5.11 
(df=4, p=.28) and RMSEA=.06. The correlation between HbA1c at baseline and fatigue 
severity at baseline was neither significant in patients with suboptimal glucose control 
(r=.09, p=.30) nor in patients with optimal glucose control (r=-.26, p=.08). The cross-lagged 
effect of HbA1c at baseline on fatigue severity at follow-up was significant and positive in 
both groups (suboptimal glucose control group: r=.18, p<.05; optimal glucose control 
group: r=.09, p<.05).
DISCUSSION
This prospective study investigating the course of fatigue in type 1 diabetes revealed that 
(1) severe fatigue is prevalent and persistent, (2) more depressive symptoms, more pain, 
fatigue severity at baseline, sleep disturbances, a lower self-efficacy concerning fatigue, a 
lower confidence in diabetes self-care and a higher number of diabetes complications are 
significant predictors of severe fatigue over time, and (3) in a sub-analysis, higher HbA1c at 
baseline was significantly associated with worse fatigue scores at follow-up.
Almost half of the patients (40%) reported severe fatigue scores at baseline. This number 
was replicated at follow-up with 42% of the patients reporting severely fatigued scores. In 
about three quarters of patients (76%) who reported severe fatigue at baseline, fatigue 
remained stable and severe at follow-up. These findings strongly show that severe fatigue 
in type 1 diabetes is not only prevalent, but also persistent over time, which is consistent 
with findings of studies investigating fatigue in other chronic diseases.26-28 The persistence 
of clinically relevant levels of fatigue over time and the association with disability urge for 
the development of interventions aimed at reducing fatigue levels. Such an approach 
needs identification of fatigue predictors that are accessible to an intervention. In our 
study, we found a number of predictors of severe fatigue. Depressive symptoms and pain 
predicted severe fatigue at follow-up, which is in agreement with earlier cross-sectional 
studies in diabetes,1,10,11 and studies in other chronic diseases such as for example 
rheumatoid arthritis.4 Given the high prevalence of depressive symptoms in patients with 
diabetes,29 it seems important to screen patients with severe fatigue also for a clinically 
relevant depression as adequate treatment of depression is likely to reduce fatigue in this 
subgroup.
Consistent with previous research showing that cognitive-behavioral variables are 
associated with fatigue,1,4,6,30 we found several cognitive-behavioral factors to be 
predictors of severe fatigue at follow-up. Less self-efficacy concerning fatigue and less 
confidence in diabetes self-care were significant cognitive predictors. Both cognitions 
were also related to fatigue in the cross-sectional study.1 Previous literature on fatigue in 
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chronic diseases confirmed that self-efficacy concerning fatigue is a strong predictor of 
fatigue severity.4,30 Also fatigue severity at baseline significantly predicted severe fatigue 
at follow-up, which reflects our finding that the majority of patients remain severely 
fatigued over time. In addition to the cognitive factors, sleep disturbances were found as 
significant predictor of fatigue severity. Surprisingly, the direction of this effect was 
negative meaning that less sleep disturbances are associated with more fatigue severity. 
This is rather unlikely as previous literature consistently found associations between more 
sleep disturbances and more severe fatigue.3,4 A possible explanation for our finding 
might be the multicollinearity between sleep disturbances and other variables in the multi- 
variate regression analysis as we found positive associations between sleep disturbances 
and fatigue severity when testing the relation with univariate analysis.
We did not find physical activity to be a significant predictor of fatigue severity, but 
patients with persistent fatigue significantly scored lower on physical activity than patients 
without persistent fatigue. In our study, physical activity was measured with the 
International Physical Activity Questionnaire (IPAQ), a self-report questionnaire asking for 
the physical activity during the last seven days,15 which may not necessarily reflect 
objective physical activity. As physical activity seems an important factor for patients with 
persistent fatigue and was found to be associated with chronic fatigue in a cross-sectional 
study,1 it would be interesting to relate severe fatigue with an objective measure of 
physical activity in the future, for example an actigraphy system.31 In our study, almost 
40% of the predicted variance was explained by cognitive-behavioral factors. For this 
reason, it seems important to focus on behavioral interventions in managing and treating 
fatigue in type 1 diabetes as these have been found to effectively reduce severe fatigue 
in other chronic diseases.7,8 Currently, the efficacy of a cognitive behavioral intervention 
for severe fatigue in type 1 diabetes is being tested in a randomized controlled trial.32
When adding the clinical factors to our regression model, the predicted variance increased 
slightly with 6%. From the clinical predictors HbA1c, co-morbidity and the number of diabetes 
complications, only the number of diabetes complications contributed significantly to 
severe fatigue at follow-up. Also when comparing the group of patients with persistent 
fatigue and without persistent fatigue, the number and presence of diabetes complications 
was higher in the persistent fatigue group with large differences found between those 
groups in the presence of neuropathy and cardiovascular disease. When the presence of 
macrovascular complications was added in a post hoc analysis of the regression model, 
the presence of cardiovascular disease was a significant predictor of severe fatigue. Literature 
on fatigue in type 1 and type 2 diabetes confirms the association between fatigue and 
long-term complications,3,33 but the strong effects of complications on severe fatigue in 
our study could also be explained by our study group of patients with rather longstanding 
diabetes (mean diabetes duration of 33 years).
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Interestingly, other variables such as depressive symptoms and pain fell out of the model 
after adding the clinical factors into the regression analysis, which could be an indication 
for an common underlying physiological process. Recent studies in patients with type 2 
diabetes or with multiple sclerosis have shown that the levels of specific inflammatory 
markers are associated with fatigue34,35 and also cardiovascular diseases.36 As we did not 
assess the presence of inflammatory markers in our study, we cannot further study this 
relationship. It would be interesting for future studies to focus on the potential relation 
between such markers and fatigue in more detail.
In the sub-analysis comparing the relationship between HbA1c and fatigue severity in 
the group of patients with optimal and suboptimal glucose control, we did not find any 
relationship between fatigue severity and HbA1c at baseline. This is in accordance with 
previous research that investigated the relation between fatigue and HbA1c cross- 
sectionally.1,9,10 We could not replicate the findings of Park and colleagues,11 who found a 
relationship between fatigue and HbA1c in patients with suboptimal glucose levels. In adding 
fatigue and HbA1c scores of a second measurement moment to our analysis, we were able 
to investigate the effects of HbA1c at baseline on fatigue severity at follow-up, and the 
other way around. Interestingly, we found that higher HbA1c values at baseline were 
positively associated with fatigue severity at follow-up, irrespective of having optimal or 
suboptimal blood glucose control. The effects were not found the other way around. 
However, these effects were rather small and HbA1c was not found as a significant 
predictor in the logistic regression analysis. Due to the limited sample size in the 
sub-analysis, we could not test whether the relationship between HbA1c and fatigue 
severity was mediated through other factors, for example, diabetes complications while 
several large prospective studies have clearly shown that high glucose levels and HbA1c 
values are associated with diabetes-related complications.37,38 However, the lack of a 
strong direct effect of HbA1c on fatigue severity suggests that we cannot expect a clinically 
relevant decrease in fatigue scores with improved glucose control.
Beside the strengths of the present study such as the prospective design and the high 
response rate, there are limitations. We used a prospective design with two time points 
without data of the course of fatigue between those time points. It could be that fatigue 
levels are more variable and change frequently over time. We did not ask for the duration 
of fatigue at follow-up. It is possible that patients experienced severe fatigue at follow-up, 
but were not chronically severely fatigued. Another limitation was the small sample size 
for the cross-lagged panel model making it impossible to add other factors that could be 
related to fatigue and HbA1c, such as diabetes complications. Participants in our study 
were recruited from a tertiary care center at a single university in the Netherlands and 
hence may be selected in terms of more complex disease history and/or more complications 
and co-morbidities, compared to patients from peripheral hospitals. An additional limitation 
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was the assessment of self-efficacy concerning fatigue with the Self-Efficacy Scale (SES), 
which is not tested before on reliability and validity in a population of type 1 diabetes. 
As this cognitive variable significantly predicted severe fatigue in our sample, self-efficacy 
seems to be an important factor in the management of fatigue and future studies should 
address the reliability and validity of this measurement.
In summary, this prospective study clearly demonstrates the high prevalence and persistence 
of severe fatigue in patients with type 1 diabetes. More depressive symptoms, more pain, 
sleep disturbances, fatigue severity at baseline, a lower self-efficacy concerning fatigue, 
a lower confidence in diabetes self-care and the number of diabetes complications 
predicted severe fatigue at follow-up. There was a relationship between fatigue and HbA1c 
over time in a sub-analysis, but not in the logistic regression analysis. Since the number of 
complications and cognitive-behavioral factors were the strongest predictors of severe 
fatigue at follow-up, the latter may be accessible to behavioral interventions.
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ABSTRACT
Objective: To investigate the prevalence, location and severity of pain, as well as its 
association with psychosocial and clinical variables, and its impact on functional impairment 
in fatigued patients with type 1 diabetes. 
Methods: 120 severely fatigued patients with type 1 diabetes completed questionnaires 
on pain (McGill Pain Questionnaire, MPQ; Short Form Health Survey subscale bodily pain, 
SF-36), fatigue severity (Checklist Individual Strength subscale fatigue severity, CIS), depressive 
symptoms (Beck Depression Inventory Primary Care, BDI-PC) and functional impairment 
(Sickness Impact Profile-8, SIP-8). HbA1c and diabetes-related complications were assessed, 
and physical activity was measured using actigraphy.
Results: 72% of patients reported pain. Muscle, joint and back pain, and headache were 
most common. Patients with pain were more often female (69 vs. 44%, p=.013), reported 
more complications (mean number: 0.7 vs. 0.3, p=.009) and scored higher on the BDI-PC 
measuring depressive symptoms (mean score: 3.8 vs. 2.3, p=.002), compared to patients 
without pain. Pain was associated with diabetes duration, the number of complications, 
fatigue severity, depressive symptoms and functional impairment, but not with HbA1c 
or physical activity. Of patients with pain, 26% reported a high impact of pain. Both pain 
(β=−0.31, t(117)=−3.39, p=.001) and fatigue severity (β=0.18, t(117)=2.04, p=.044) contributed 
to functional impairment.
Conclusion: Pain was highly prevalent in fatigued patients with type 1 diabetes, although 
pain impact and severity were relatively low, and the location of some pain symptoms 
was similar to the location of those in the general population. As pain is related to fatigue 
and contributes independently to functional impairment, fatigue interventions should 
address pain.
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INTRODUCTION
Numerous complications and conditions associated with diabetes mellitus are known to 
cause pain. For example, painful peripheral neuropathy is a microvascular complication 
affecting 16% of patients with type 1 and type 2 diabetes.1 Painful co-morbidities such 
as entrapment neuropathy, e.g., carpal tunnel syndrome and trigger fingers,2,3 or less 
frequently described rheumatic manifestations in diabetes such as cheiroarthropathy, are 
common and associated with pain.4 Pain in diabetes is not only present in relation to the 
complications of the disease. A recently published study investigating the prevalence of 
pain in a sample of 11,689 patients with primarily type 2 diabetes found that approximately 
58% of all participants reported moderate or severe pain,5 demonstrating that pain in 
diabetes is highly prevalent. The impact of pain in diabetes is substantial as patients with 
diabetes and co-morbid chronic pain report a lower quality of life6 and poorer diabetes 
self-management.7
Recent research has shown that pain is associated with severe and chronic fatigue, both 
in type 18,9 and type 2 diabetes.10 Chronic fatigue has been found to be a highly prevalent 
and disturbing symptom in patients with type 1 diabetes.8 One study examining 
persistently fatigued patients with type 1 diabetes demonstrated that pain is a predictor 
of severe fatigue,9 which suggests the importance of addressing pain in the management 
of fatigue in patients with type 1 diabetes. Recently, a treatment protocol for fatigue in type 1 
diabetes has been developed that addresses pain as a perpetuating factor of fatigue.11 
Although a relationship between pain and fatigue has been demonstrated, and pain has 
been shown to have an adverse impact on patients’ health, we have not yet identified the 
scope of the problem; specifically, the prevalence and severity of pain, and its associations 
with psychosocial and clinical variables in fatigued patients with type 1 diabetes.
The present study investigated (1) the prevalence, location and severity of pain in fatigued 
patients with type 1 diabetes, as well as (2) the differences between patients with and 
without pain in this group. As review of the literature has shown that pain is associated 
with lower levels of physical activity,12 more depressive symptoms,13 and fatigue,8 we (3) 
investigated the relationship between pain and these variables. We also studied the 
relationship between pain and glycemic control (i.e., HbA1c=glycated hemoglobin) and 
diabetes complications. To determine if pain and fatigue contribute independently to 
functional impairment, we (4) analyzed the extent to which functional impairment was 
predicted by pain and fatigue severity.
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METHOD
Participants and procedure
The present study relied on the baseline data collected for a randomized controlled trial 
testing the efficacy of a cognitive behavioral therapy for chronic fatigue in type 1 diabetes. 
Details of this study have been published.11 Briefly, the objectives of this trial were to 
investigate whether cognitive behavioral therapy aimed at changing behaviors and 
beliefs thought to maintain fatigue reduces fatigue severity in chronically fatigued 
patients with type 1 diabetes, compared to a waitlist control condition. Patients were 
recruited between February 2014 and March 2016 from hospitals in the south-east of the 
Netherlands, and via social media. Out of 1816 patients who were screened for the study, 
120 patients between 18 and 70 years old who were diagnosed with type 1 diabetes of at 
least one year duration, participated in the study. Type 1 diabetes diagnoses were based 
on clinical criteria; symptoms and signs documenting absolute insulin deficiency, often 
combined with C-peptide negativity and anti-GAD antibody positivity. At the time of the 
study, all patients were receiving treatment consisting of multiple daily insulin injections 
or insulin pump therapy. All patients were severely fatigued—as defined by a score of ≥35 
on the Checklist Individual Strength (CIS), subscale fatigue severity14—and fatigue had 
been present for at least six months. Exclusion criteria were (1) moderate to severe renal 
failure, (2) blindness or severe visual impairment, (3) medical history of congestive heart 
failure, (4) medical history of stroke in the past five years, (5) body mass index of 40 or 
higher, (6) wheelchair-dependent, and (7) other concurrent psychiatric or medical 
co-morbidity that could explain the fatigue. All patients gave written consent for 
participation, and the study was approved by each hospital’s local ethics committee.
Measures
Pain – prevalence, severity, location and impact
The prevalence and location of pain were assessed using the McGill Pain Questionnaire 
(MPQ).15 The first question of the MPQ, “Do you experience pain?,” measures the presence of 
pain. Patients who answered “yes” on this question completed the other two parts of the 
MPQ questionnaire: a figure to indicate the location of the pain, and the visual analogue 
scale (VAS) to measure the magnitude of pain at the current moment. The VAS scale ranges 
from 0 cm (no pain) to 10 cm (the most severe pain). The MPQ is a reliable instrument.16
The Short Form Health Survey (SF-36), subscale bodily pain was used to assess pain 
severity and impact over the last four weeks.17 The scale ranges from 0 to 100, with higher 
scores indicating less severe, lower impact pain. A dichotomous variable, “low and high 
impact of pain,” was defined with a cut-off of 54 on the SF-36, subscale bodily pain, i.e., 
the mean minus one standard deviation of the general population. Scores of >54 indicated 
low impact of pain, and scores of ≤54 indicated high impact.18
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Participants used a paper diary to assess daily observed pain (DOP) over twelve consecutive 
days. Four times a day, patients reported the severity of pain on a scale of 0 (no pain) to 4 
(severe pain). The twelve DOP scores were averaged into one score ranging from 0 to 16.19 
Using the same diary, patients reported the presence of any headache, muscle pain, 
sore throat, joint pain, stomach ache and/or back pain, four times per day (0=not present, 
1=present). Parts of the diary that have been used to assess daily observed fatigue in 
other studies have demonstrated good reliability and validity.20,21 We investigated the 
reliability and validity of the DOP in our sample, and found a good split-half reliability 
measured by the correlation between scores of week one and week two of the diary 
(r=0.87, p<.001) and a good convergent validity measured by the correlation between the 
DOP and other pain measures, i.e., the VAS current pain (r=0.703 p<.001) and the SF-36 
subscale bodily pain (r=−0.653 p<.001). A previous study has shown that the DOP is 
sensitive to change and can detect the effects of behavioral interventions.19 To increase 
compliance, patients received a detailed explanation of how to use the diary, and the 
12-day period was linked to the assessment of an actigraphy system to measure the level 
of physical activity.
Fatigue severity
Fatigue severity was assessed with the Checklist Individual Strength (CIS), subscale fatigue 
severity.14 The CIS consists of four subscales; the subscale fatigue severity contains eight 
items with scores ranging from 8 to 56. Higher scores indicate higher levels of fatigue. The 
items are scored on a Likert scale from (1) “Yes, that is true” to (7) “No, that is not true”. The 
CIS has excellent psychometric properties with a Cronbach’s alpha coefficient of .90 and a 
split-half reliability coefficient of .92.14
Physical activity
The level of physical activity was assessed with an actigraphy system using the actometer 
(©Actilog V3.0); a small, light motion-sensing device manufactured by the Department of 
Electronics and Instrumental Services of the Radboud University Nijmegen (43x29x16mm; 
41g).22 The actometer detects accelerations by a piezoelectric sensor, storing those that 
meet a predefined threshold for physical activity into an internal memory. Each second, 
a microcontroller reads and resets the actometer’s counter. The integration counter is set 
to produce a physical activity score every 5 min.22,23 Patients wore the actometer around 
their ankle for twelve consecutive days, after which the data was uploaded into a computer 
software program. Mean scores from the five minute intervals were used to determine the 
level of physical activity, and a mean activity score over the 12 consecutive days was 
calculated.
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Additionally, we differentiated between three types of physical activity: (1) pervasively 
passive activity levels, (2) relatively active activity levels and (3) pervasively active activity 
levels. Patients whose average daily physical activity score remained below a mean reference 
value of 66 at 11 or 12 days were defined as pervasively passive.23 Patients who scored 
above the reference value at two to ten days were defined as relatively active, and patients 
who scored above the reference value at 11 or 12 days were defined as pervasively active.
Depressive symptoms
The Beck Depression Inventory Primary Care (BDI-PC) was used to assess depressive 
symptoms.24 The BDI-PC consists of seven items scored on a four-point Likert Scale. Scores 
range from 0 to 21, with higher scores indicating more depressive symptoms.
Clinical variables
HbA1c was measured by high-performance liquid chromatography (Menarini Diagnostics, 
Neuss, Germany). HbA1c values were obtained from medical records whenever possible. 
Patients reported the presence of seven common diabetes-related complications: retinopathy, 
nephropathy, neuropathy, numbness in the feet, cardiovascular disease, myocardial infarction 
and stroke (0=not present, 1=present). In addition, patients were asked to report whether 
they experienced any co-morbidity (0=not present, 1=present).
Functional impairment
Functional impairment was assessed using the Sickness Impact Profile-8 (SIP-8),25 which 
measures limitations in daily functioning across eight domains: sleep and rest, home- 
making, mobility, social interactions, ambulation, leisure activities, alertness behavior, and 
work limitations. The subscales were added to provide a total score of the SIP-8, with 
higher scores indicating more impairment.
Statistical analysis
Data analysis was performed using IBM SPSS Statistics Version 22.0.26 Descriptive statistics 
were reported with means and standard deviations, or frequencies and percentages. 
Independent t-tests and Chi-square tests (χ2) were used to test for differences between 
patients with and without pain. Associations were analyzed using Pearson’s correlation 
coefficients. Linear multiple regression analysis was performed using functional 
impairment as the dependent variable, and pain assessed with the SF-36 subscale bodily 
pain and fatigue severity as the independent variables. Of patients who experienced pain 
(MPQ “Do you experience pain?”=”yes”), pain location was reported, whereas for the 
associations and multiple regression, data from all patients (n=120) was used. Since 
neuropathy is a diabetes-related complication that is often related to pain, we performed 
a sub-analysis with respect to pain and fatigue, comparing patients with and without 
neuropathy. P-values <.05 were regarded to be statistically significant.
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RESULTS
The demographical and clinical characteristics are shown in Table 1. Retinopathy (23%) 
and neuropathy (19%) were the most frequently reported diabetes-related complications.
Severity, location and impact of pain
More than two-thirds of participants (n=86; 72%) indicated the presence of pain. Of 
patients who reported pain, the mean VAS current pain score was 3.3 (SD=2.6, Table 2). 
Pain was most frequently located in the head and lower back (30-40%; Figure 1). In 20-30% 
of participants, the pain was present in the shoulders, neck and upper back. About 10-20% 
of patients reported pain in their lower limbs and or feet. A small number of participants 
indicated the presence of pain in the arms (slightly more in the right arm), chest and 
thighs. When measuring pain four times daily using the self-observation list, the most 
frequently reported pain was joint pain (33%), muscle pain (22.5%), headache (20%) and 
back pain (19.4%). The mean pain severity and impact (SF-36 subscale bodily pain) was 
66.7 (SD=23.7). Out of the patients who experienced pain, about 26% reported a high 
impact of pain (SF-36 bodily pain ≤54).
Differences between patients with and without pain
Patients with and without pain differed significantly on several variables. Patients with 
pain were more often female (χ2(1)=6.18, p=.013), experienced more diabetes-related 
complications (t(118)=2.67, p=.009), especially neuropathy (χ2(1)=8.1, p=.005) and more 
co-morbidity (χ2(1)=5.4, p=.021). They scored higher on depressive symptoms (t(118)=3.18, 
p=.002), fatigue severity (t(118)=2.97, p=.004) and functioning impairment (t(118)=2.38, 
p=.019) (Table 1), but did not differ in age (t(118)=0.27, p=.784), HbA1c (t(117)=1.28, p=.204), 
or diabetes duration (t(118)=1.27, p=.207), nor on either mean level of physical activity 
(t(117)=0.19, p=.846) nor type of physical activity (χ2(2)=1.3, p=.726). When comparing 
patients with and without neuropathy in a sub-analysis, we found that patients with 
neuropathy reported significant higher scores on the SF-36 subscale bodily pain 
[t(118)=3.17, p=.002] and the DOP [t(112)=-2.32, p=.022]. Furthermore, patients with 
neuropathy reported significant more pain symptoms in the shoulders [χ2(1)=13, p≤.001], 
lower arms and hands [χ2(1)=3.85, p=.05], and feet [χ2(1)=10.74, p=.001], but there was no 
difference in the prevalence of pain in other locations. We found no difference in fatigue 
severity [t(118)=0.62, p=.54].
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Table 1   Demographics and clinical variables of the overall sample and differences 
between patients with and without pain 
Overall  
sample 
(n=120)
Patients  
with pain 
(n=86)
Patients 
without pain 
(n=34)
Difference 
p-value
Female sex 74 (62%) 59 (69%) 15 (44%) .013
Age in years 43.6 (12.3) 43.7 (12.4) 43.1 (12.1) ns
HbA1c*
% 8.0 (1.0) 8.1 (0.9) 7.8 (1.1) ns
Mmol/mol 64 (11) 65 (10) 62 (12) ns
Diabetes duration in years 24.1 (13.5) 25.1 (13.2) 21.6 (14.3) ns
Diabetes complications**
Retinopathy, yes 27 (23%) 21 (24%) 6 (18%) ns
Nephropathy, yes 6 (5%) 5 (6%) 1 (3%) ns
Neuropathy, yes 23 (19%) 22 (26%) 1 (3%) .005
Numbness in the feet, yes 10 (8%) 8 (9%) 2 (6%) ns
Cardiovascular disease, yes 6 (5%) 6 (7%) 0 (0%) ns
Myocardial infarction, yes 1 (1%) 1 (1%) 0 (0%) ns
Stroke, yes 1 (1%) 1 (1%) 0 (0%) ns
Number of diabetes complications 0.6 (1.1) 0.7 (1.2) 0.3 (0.6) .009
Co-morbidity, yes** 48 (40%) 40 (47%) 8 (24) .021
Fatigue severity, CIS fatigue 45.9 (5.9) 46.9 (5.9) 43.5 (5.0) .004
Depressive symptoms, BDI-PC 3.4 (2.4) 3.8 (2.4) 2.3 (2.1) .002
Functional impairment, SIP-8 total 892 (589.5) 971.2 (616.7) 691.9 (464.4) .019
Mean physical activity, actometer 72.0 (18.3) 72.2 (18.8) 71.5 (17.0) ns
Types of physical activity, actometer†
Pervasively passive, yes 11 (9%) 9 (11%) 2 (6%) ns
Relatively active, yes 81 (68%) 57 (66%) 24 (71%) ns
Pervasively active, yes 25 (21%) 19 (22%) 6 (18%) ns
Note. Scores are means (SD), n (%), unless otherwise indicated; SD=standard deviation; p-values are significant at 
p<.05; ns=non-significant; HbA1c=glycated hemoglobin; CIS fatigue=Checklist Individual Strength, subscale 
fatigue severity; BDI-PC=Beck Depression Inventory Primary Care; SIP-8 total=Sickness Impact Profile-8 total 
score. 
*1 missing.
**Self-reported.
†2 unknown, 1 missing.
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Associations of pain
Severity and impact of pain as measured with the SF-36 subscale bodily pain was 
significantly correlated with diabetes duration in years (r=-0.242, p=.008), also when 
controlling for age (r=-0.183, p=.047), with the number of complications (r=-0.204, p=.025), 
but not with HbA1c. Pain severity and impact were associated with fatigue severity 
(r=-0.358, p<.001), depressive symptoms (r=-0.286, p=.002) and functional impairment 
(r=-0.372, p<.001). Mean level of physical activity was not correlated with pain severity and 
impact. There was also no significant correlation between mean level of physical activity 
and pain assessed with the daily observed pain score (DOP). Both pain (β=-0.31, t(117)=-3.39, 
p=.001) and fatigue severity (β=0.18, t(117)=2.04, p=.044) significantly predicted functional 
impairment with an explained variance of R2=0.168.
Table 2   Pain descriptives of patients with pain (n=86)
Instruments Mean scores or percentages
MPQ
VAS current pain (range 0-10) 3.3 (2.6)
Self Observation List
Daily observed pain, DOP (range 0-16)* 4.1 (3.2)
Headache, mean percentage 20.0
Muscle pain, mean percentage 22.5
Sore throat, mean percentage 5.9
Joint pain, mean percentage 33.0
Stomach ache, mean percentage 7.7
Back pain, mean percentage 19.4
SF-36, bodily pain
Pain severity and impact 66.7 (23.7)
Prevalence of high pain impact, yes** 22 (26%)
Note. Scores are means (SD), n (%), unless otherwise indicated; SD=standard deviation; MPQ=McGill Pain 
Questionnaire; VAS=visual analogue scale; SF-36 bodily pain=Short Form Health Survey, subscale bodily pain.
*n=5 missing because fewer than 50% of the diary scores was answered.
**low impact of pain=SF-36 bodily pain >54, high impact of pain=SF-36 bodily pain ≤54.
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DISCUSSION
The present study shows that pain is highly prevalent in fatigued patients with type 1 
diabetes, as it was experienced by nearly three-quarters of patients. Joint and muscle pain 
were the most frequently described pain symptoms, together with headache and low 
back pain. The latter two were likewise described as the most prevalent pain symptoms 
when patients were asked to specify the location of pain at the current moment. It is 
unlikely that headache and back pain are directly related to diabetes as both are also 
common pain symptoms in the general population,27 with prevalence rates varying from 
18% to 38% for low back pain28 and 11% to 42% for migraine or tension-type headache,29 
which are in the same range as the prevalence rates in our study. Joint and muscle pain 
may be related to diabetes and may reflect entrapment neuropathy, which is a prevalent 
co-morbidity of diabetes,2 or diabetic arthropathy, a less frequently described and less 
well-characterized diabetes complication.4
Figure 1   Location of pain in fatigued patients with type 1 diabetes (%, n=86)
0-10% 10-20% 20-30% 30-40% 
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The prevalence rate of pain in our study was high (72%), which matches the findings of 
Krein and colleagues7 who revealed that 60% of patients with diabetes reported chronic 
pain. The high prevalence rate in our study could be explained by the fact that we asked 
a broad group of patients with type 1 diabetes about the presence of pain at the current 
moment. We did not distinguish between acute and chronic pain, nor in etiology of pain, 
which could have influenced our findings. Whilst the prevalence of pain in our study was 
high, the mean pain severity of 3.3 at the current moment, measured with the visual 
analogue scale (VAS), was relatively low; several studies across different populations have 
revealed that a score of four or lower on a visual analogue or numeric rating scale can be 
indicated as a cut-off point for mild pain.30-32 The mean pain severity score measured over 
two consecutive weeks (DOP) was higher than the mean score of 1.0 in a group of 90 
healthy people,19 but still in the lowest of four percentiles. The mean pain severity and 
impact over the last four weeks, assessed with the SF-36 subscale bodily pain, was found 
to be somewhat higher than in norm groups of the general population.17,18 About 
one-quarter of patients with pain experienced a high impact of pain, which is lower than 
those numbers found in earlier studies, with rates of 30-60% of moderate or severe pain.5,7 
These inconsistent findings could be explained by the different measurements and cut-off 
values used for pain impact, emphasizing the importance of matching pain instruments 
and cut-off values in future studies.
The most frequently described diabetes-related complications in our sample were 
retinopathy (23%) and neuropathy (19%). The latter can cause pain, and its prevalence rate 
is comparable to the rate of chronic painful neuropathy (16%) determined by Daousi and 
colleagues.1 We compared patients with and without neuropathy in a sub-analysis to look 
for differences in pain intensity and location, and found that patients with neuropathy 
had significantly higher scores on pain severity, as well as more pain symptoms in the 
shoulders, lower arms and hands, and feet. However, we did not find a difference in fatigue 
severity.
Patients with and without pain differed significantly in gender, as patients with pain were 
more often female. This result is common and has been repeatedly found across diverse 
patient populations,33,34 so it is not specific to diabetes. Patients with pain had more 
diabetes- related complications, which may be explained by the fact that certain diabetes- 
related complications are associated with pain. Our study determined that patients with 
pain experienced more depressive symptoms, more severe fatigue and more functional 
impairments. These factors were also found to be significantly related to pain, which is 
consistent with other research studying pain and its correlates in diabetes13 and other 
conditions.35,36 Chronic hyperglycemia is associated with glycation of virtually all proteins—i.e., 
glycated hemoglobin but also elastic and collagen protein—and the accumulation of 
advanced glycation end products (AGEs), which have been found to be linked to diabetes- 
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related complications, for example limited joint mobility.37,38 Consequently, it may be 
possible that advanced glycation and the build-up of AGEs contribute to pain complaints; 
this should be considered as a possible associating factor of pain in diabetes in future 
research.
Contrary to our results, two recent studies did find a significant relationship between pain 
and HbA1c.5,39 It was found that poorer HbA1c values correlated with more severe pain; 
however, in one study, this relationship disappeared when using multivariate analysis.5 
The non-significant correlation in our study may be explained by the relatively low impact 
of pain reported by patients, or by our group of severely fatigued patients as no clear 
relationship has been found between glycemic control (i.e., HbA1c) or glucose variability 
and fatigue, either in type 18 or type 2 diabetes.10 As HbA1c values represent patients’ 
mean glucose values over several weeks, and not the daily fluctuations of blood glucose 
levels including hyperglycemia and hypoglycemia, it would be interesting to investigate 
the relationship between pain and glucose variability in future studies, as these might be 
relevant to fatigue. In a previous study, we did not find a clear relationship between fatigue 
and fluctuations in blood glucose levels.8
People experiencing pain are often assumed to be less physically active; however, our 
study found no correlation between the level of physical activity assessed with the mean 
physical activity score and pain, either with the SF-36 subscale bodily pain or with the 
DOP. Although the mean physical activity score in our sample of 72 was lower compared 
to a score of 91 in healthy controls,23 we saw that only a small percentage of our sample 
(9%) scored as pervasively passive, defined as (very) low physical activity. The percentage 
of relatively active (68%) and pervasively active (21%) activity types in our study are 
comparable to those of healthy controls, with 59% and 41% respectively.23 It may be 
possible that the relatively low pain levels found in our study have influenced the effect 
on the level of physical activity. Another explanation for our findings could be the duration 
of pain. A recent meta-analysis differentiated between (sub)acute and chronic low back 
pain and examined the relationship between the level of physical activity and pain-related 
disability.12 That study found a significant relationship between high levels of disability 
and low levels of physical activity in people with chronic low back pain, but this relationship 
was not clinically significant in people with acute pain. This could explain why we did not 
find a significant relationship between pain and the level of physical activity, as we 
investigated only current pain rather than chronic, long-lasting pain. Both pain and fatigue 
severity were associated with, and clearly contributed to, functional impairment in daily 
life. Interventions aimed at fatigue should take account for these findings, addressing pain 
in order to reduce fatigue and functional limitations, especially in the subgroup of patients 
with more severe pain.
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Besides the benefits of addressing pain in a large, well-phenotyped cohort of patients 
with type 1 diabetes, the present study has limitations. First, we assessed the prevalence 
and location of current pain, but did not ask for the duration of pain, nor did we assess 
painful neuropathy or other painful complications and symptoms typical for diabetes 
(such as foot pain). Therefore, it was not possible to identify patients suffering from chronic 
pain or patients with diabetes-specific pain such as painful neuropathy. However, it is 
highly unlikely that 70% of our study’s participants are diagnosed with painful neuropathy, 
as this complication is only present in approximately 16% of people with diabetes,1 and 
the symptoms of painful neuropathy are unrelated to headache and back pain.3 Second, 
we used a self-report questionnaire to assess diabetes-related complications and co-
morbidities. It is possible that patients under- or overrated the presence of complications, 
compared to data from medical records. A recent study showed that self-reporting can 
lead to an overestimation of complications,40 as was confirmed by a study of our own 
research group that found a true positive and negative rate of 65% between patient- 
reported co-morbidity (49%) and co-morbidity based on medical records (24%) in patients 
with type 1 diabetes.8 Third, our study sample was a select group, with patients initially 
included for a randomized controlled trial. All 120 patients were severely fatigued, which 
did not allow us to determine pain levels in an unselected group of patients with diabetes, 
nor can we extrapolate the results of the current study to non-fatigued patients. Fourth, 
the data was collected cross-sectionally from one time-point. Therefore, it was not possible 
to draw conclusions regarding the cause-and-effect relationship between pain and the 
studied correlates, such as depressive symptoms, the level of physical activity, and clinical 
variables such as diabetes-related complications.
Overall, the present study found that pain is highly prevalent in fatigued patients with 
type 1 diabetes. Aside from muscle- and joint pain that can be explained by diabetes-re-
lated complications, pain symptoms were mostly located in the lower back or head. These 
pain symptoms resemble those reported in the general population and do not seem to 
be specific to diabetes. Pain was significantly related to diabetes-related complications, 
depressive symptoms, fatigue severity and functional impairment, but not to HbA1c or the 
level of physical activity. As pain was significantly associated with fatigue severity, and 
both pain and fatigue severity contributed to functional impairment, it seems important 
that future fatigue treatments for type 1 diabetes address pain.
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CHAPTER 4
ABSTRACT
Background: Fatigue is frequently reported by patients with type 1 diabetes mellitus. 
A recent study showed that 40% of patients experienced severe fatigue that lasted for more 
than six months and was accompanied by substantial impairments in daily functioning. 
Currently, there is no effective treatment available for chronic fatigue in patients with type 
1 diabetes. Cognitive behavior therapy aimed at cognitions and behaviors that perpetuate 
fatigue is effective in reducing fatigue in other chronic diseases. Recent research showed 
that these cognitions and behaviors are also potential determinants of fatigue in type 1 
diabetes. We designed Dia-Fit, a web-based cognitive behavior therapy for severe and 
chronic fatigue in patients with type 1 diabetes. This patient-tailored intervention is aimed 
at reducing fatigue by changing cognitions and behaviors assumed to maintain fatigue. 
The efficacy of Dia-Fit will be investigated in this study.
Methods/design: A randomized controlled trial will be conducted in 120 patients with 
type 1 diabetes who are chronically and severely fatigued. Patients will be randomized to 
a treatment or waiting list group. The treatment group will receive Dia-Fit, a blended care 
therapy consisting of up to eight internet modules and face-to-face sessions with a 
therapist during a five month period. The treatment will be tailored to the fatigue 
maintaining cognitions and behaviors that are relevant for the patient and are determined 
at baseline. The waiting list group will receive Dia-fit after a waiting period of five months. 
The primary outcome measure is fatigue severity. Secondary outcome measures are 
functional impairment and glucose control determined by hemoglobin A1c and blood 
glucose variability. 
Discussion: To our knowledge, this is the first study investigating the efficacy of a cognitive 
behavioral intervention for chronic fatigue in patients with type 1 diabetes. 
Trial registration: Dutch trial register NTR4312 (10 December 2013).
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 55
55
4
CBT FOR CHRONIC FATIGUE IN TYPE 1 DIABETES: STUDY PROTOCOL
BACKGROUND
Diabetes mellitus is a highly prevalent health care problem: about 380 million adults are 
affected by diabetes worldwide and the number is expected to rise to 590 million adults 
by the year 2035.1 About 10% of patients are diagnosed with type 1 diabetes mellitus 
(T1DM). T1DM is an autoimmune disorder, mostly diagnosed in childhood or adolescence, 
leading to beta cell destruction and an insulin secretion defect.2 Patients need to inject 
insulin to control their blood glucose levels. T1DM is associated with medical complications 
both acute and long term, such as cardiovascular diseases, nephropathy, neuropathy, and 
retinopathy.2 The goal of diabetes treatment is to control blood glucose levels at a near 
normal level to delay or prevent medical complications and to increase the quality of life 
of patients. Optimal diabetes control requires continuous diabetes self-management.
The proposed study described in this paper will focus on severely fatigued patients with 
T1DM. Fatigue is an often-reported symptom by patients with T1DM. In a cross-sectional 
study by our research group of 214 patients with T1DM, 40% of patients suffered from 
severe fatigue lasting at least for six months.3 Chronic fatigue was associated with more 
impairment in daily functioning, and fatigue was the most burdensome symptom of all 
assessed diabetes-related symptoms.3 Other studies that have investigated fatigue in 
patients with T1DM provide limited information about the impact and chronicity of 
fatigue.4,5 However, fatigue is also a highly prevalent symptom in other chronic diseases. 
Fatigue was found to be a burdensome and invalidating symptom in patients with type 2 
diabetes,6-8 and highly prevalent in patients with rheumatoid arthritis and neuromuscular 
disorders.9-11 
The etiology of severe fatigue in T1DM is not well understood. It seems obvious that 
physiological diabetes-related factors such as hemoglobin A1c (HbA1c) levels or variations 
in blood-glucose levels are associated with fatigue. While fatigue is a classical presenting 
symptom of hyperglycemia, in our cross-sectional study no relationship between glucose 
control (HbA1c levels) and fatigue severity was found.3 Also, parameters gathered during 
continuous glucose monitoring such as the blood glucose variability were unrelated to 
persistent fatigue. Other diabetes-related factors were correlated to fatigue: the number 
of complications due to diabetes, diabetes-related distress and diabetes specific self- 
efficacy. Also, there was a univariate relationship between fatigue and somatic co-morbidity. 
In a multiple regression, several cognitive-behavioral factors were found to be potential 
determinants of fatigue: disrupted sleep-wake patterns, low physical activity, catastrophising 
thoughts about fatigue, and low self-efficacy with respect to fatigue and pain. These 
cognitive- behavioral factors are also known to be determinants of fatigue in other chronic 
diseases.12-15 Based on the available literature on diabetes and chronic fatigue in other 
chronic illnesses, we designed a cognitive-behavioral model of fatigue in T1DM (Figure 1). 
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We assume that fatigue in T1DM is initially triggered by hyperglycemia and/or diabetes- 
related factors such as the number of complications due to diabetes and/or somatic co-
morbidities. Once the fatigue has been triggered, other factors perpetuate it. We assume 
that these perpetuating factors are cognitive-behavioral factors such as 1) a decreased or 
deregulated level of physical activity, 2) sleep disturbances and disrupted sleep-wake 
rhythm and 3) dysfunctional cognitions with respect to fatigue. Furthermore, we assume 
4) pain and pain-related cognitions and 5) a lack of social support and/or negative social 
interactions to be perpetuating factors of fatigue in T1DM. All the aforementioned factors 
have been identified as determinants of fatigue in patients with T1DM and/or have 
repeatedly been found to be perpetuating factors of fatigue in other chronic illnesses.3,12-15 
Finally, 6) diabetes-related distress is added to the model, because an association between 
fatigue and diabetes-related distress was found.3 These six perpetuating factors can be 
addressed in cognitive behavior therapy (CBT) for fatigue. Previous research has shown 
that CBT is effective in reducing fatigue in other chronic diseases and conditions.16-18 
To our knowledge, there are no studies that tested the efficacy of interventions specifically 
aimed at chronic fatigue in patients with T1DM. We propose that CBT aimed at the 
maintaining factors of fatigue will lead to a reduction of fatigue and associated disabilities. 
For this purpose, we developed Dia-Fit, a web-based cognitive behavioral intervention 
aimed at reducing fatigue. Dia-Fit is a blended care therapy that consists of web-based 
modules supported by face-to-face sessions with a therapist. Blended care has the 
advantage of limiting the therapist time needed to deliver the intervention and reducing 
travel time, expenses, and rigid appointments for patients. The primary objective of this 
study is to investigate the efficacy of Dia-Fit for chronic fatigue in patients with T1DM in a 
randomized controlled trial. The primary outcome measure is fatigue severity. Secondary 
outcome measures are the level of disabilities, HbA1c, and blood glucose variability. We will 
Figure 1   Cognitive-behavioral model for fatigue in type 1 diabetes
Triggers
- Somatic co-morbidity
- Complications due to diabetes
- Hyperglycemia  
Fatigue Perpetuating factors
1. Decreased or deregulated levels 
 of physical activity
2. Sleep disturbances and disrupted 
 sleep-wake rhythm
3. Dysfunctional cognitions
4. Pain and pain-related cognitions
5. Lack of social support and/or 
 negative social interactions
6. Diabetes-related distress    
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also investigate the long-term effects of Dia-Fit in a follow-up, six months after the 
intervention. If Dia-Fit leads to the expected improvement in fatigue severity compared to 
the waiting list, we will perform a mediation analysis to determine whether changes in the 
proposed fatigue maintaining factors mediate the effect of Dia-Fit on fatigue severity. 
METHODS/DESIGN
Study design 
The study is a randomized controlled trial (RCT) and will be conducted at the Expert 
Center for Chronic Fatigue (ECCF) of the Radboud university medical center. Patients who 
are eligible to participate will be randomly allocated to either the intervention group or a 
waiting list group. Patients allocated to the intervention group will directly receive the 
Dia-Fit intervention, while patients allocated to the waiting list group will receive the 
Dia-Fit intervention after a waiting period of five months. Assessments are planned before 
and after the intervention and the waiting list period. In both conditions, patients will be 
assessed again at a follow-up, six months after receiving the treatment (Figure 2). 
Recruitment process and study population
One hundred and twenty chronically fatigued patients with T1DM will be included. Patients 
will be recruited from the diabetes outpatient clinic of the Radboud university medical center 
and three general hospitals all located in the South East Netherlands. Patients will also be 
recruited through websites and social media. Patients of the diabetic outpatient clinics 
will be screened by their treating consultant for the sociodemografic and medical criteria 
of eligibility (criteria 1, 2 and 3 of the inclusion criteria, and criteria 1 through 7 of the exclusion 
criteria). Inclusion criteria and exclusion criteria are listed in Table 1. 
Patients who are eligible will receive a letter from their consultant with information about 
the possibility of receiving treatment for persistent fatigue in the context of this research 
project. Attached to the letter, patients will receive a short screening questionnaire 
consisting of the Checklist Individual Strength (CIS)19 and a question about the duration of 
the fatigue (criteria 4 and 5 of the inclusion criteria). Patients who are interested in 
participating can fill in the questionnaire and send it back, together with a written consent 
giving permission to the researcher (JM) to contact them. Patients who have a score of 
35 or higher on the subscale fatigue severity of the CIS and who indicate that they are 
fatigued for six months or longer will receive further information about the study, both by 
telephone and in writing. Patients can decide to participate in the study within a period of 
two weeks from the time that the researcher contacted them. If patients are willing to 
participate, they will be asked to give written informed consent for participation in the 
study. They will then be invited for a baseline assessment at the ECCF. During baseline 
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 58
58
CHAPTER 4
Fi
gu
re
 2
   F
lo
w
ch
ar
t o
f t
he
 tr
ia
l d
es
ig
n
N
ot
e.
 T
0=
b
as
el
in
e 
as
se
ss
m
en
t; 
T 1
=
se
co
nd
 a
ss
es
sm
en
t; 
T 2
=
p
os
t-
tr
ea
tm
en
t a
ss
es
sm
en
t f
or
 p
at
ie
nt
s 
on
 th
e 
w
ai
tin
g 
lis
t; 
T 3
=
fo
llo
w
-u
p 
as
se
ss
m
en
t.
6 
m
on
th
s 
5 
m
on
th
s 
Sc
re
en
in
g 
an
d 
re
cr
ui
tm
en
t 
T 0
 
Ra
nd
om
iz
at
io
n 
(n
=
12
0)
 
Q
ue
st
io
nn
ai
re
s, 
sl
ee
p-
w
ak
e 
pa
tt
er
n 
re
gi
st
ra
tio
n,
ac
to
m
et
er
, H
bA
1c
 ,
gl
uc
os
e 
va
ria
bi
lit
y
Q
ue
st
io
nn
ai
re
s, 
sl
ee
p-
w
ak
e 
pa
tt
er
n 
re
gi
st
ra
tio
n,
ac
to
m
et
er
, H
bA
1c
 ,
gl
uc
os
e 
va
ria
bi
lit
y
 
CB
T 
(n
=
60
) 
T 1
5 
m
on
th
s 
6 
m
on
th
s 
5 
m
on
th
s 
W
ai
tin
g 
lis
t (
n=
60
)
T 1 T 3
T 3
Q
ue
st
io
nn
ai
re
s, 
H
bA
1c
 ,
gl
uc
os
e 
va
ria
bi
lit
y 
Q
ue
st
io
nn
ai
re
s, 
H
bA
1c
 ,
gl
uc
os
e 
va
ria
bi
lit
y 
 
CB
T
 
T 2
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 59
59
4
CBT FOR CHRONIC FATIGUE IN TYPE 1 DIABETES: STUDY PROTOCOL
assessment, patients fill in the Beck Depression Inventory (BDI)20 and the Symptom Check 
List (SCL90).21 Patients with a score of 4 or higher on the BDI and/or a total score of 164 or 
higher on the SCL90, which is higher than the mean and two standard deviations of 
healthy people from the general population,21 will be screened for the presence of a 
psychiatric disorder using the Mini-International Neuropsychiatric Interview (M.I.N.I.).22 
Patients will be excluded if they meet the criteria of the M.I.N.I. for: depressive episode, 
suicidality, (hypo)manic episode, panic disorder, obsessive-compulsive disorder, posttraumatic 
stress disorder, alcohol dependence and alcohol abuse, substance dependence and 
substance abuse, psychotic disorders, anorexia nervosa, bulimia nervosa, and/or generalized 
anxiety disorder. 
Patients who contact the researcher in response to information about the study in the 
media and are not treated in one of the four participating hospitals will first be screened 
for eligibility by a consultant of the diabetes outpatient clinic of the Radboud university 
medical center. 
Ethical approval
This study has been reviewed and approved by the Medical Ethical Committee of the 
Radboud university medical center (registration number 2013/165, NL43178.091.13). The study 
has also been approved and registered by the local ethical committees of the involved 
general hospitals: Rijnstate Ziekenhuis, Canisius-Wilhelmina Ziekenhuis and VieCuri Medisch 
Table 1   Inclusion and exclusion criteria 
Inclusion criteria
(1) Diagnosis of type 1 diabetes for at least 1 year 
(2) Between 18 and 70 years old
(3) Able to read, speak and write Dutch 
(4) Severely fatigued operationalised as scoring ≥35 on the subscale fatigue severity of the CIS 
(Checklist Individual Strength)
(5) Fatigued for at least 6 months
Exclusion criteria
(1) Moderate to severe renal failure operationalised as having a glomerular filtration rate (GFR) ≤45
(2) Blindness or severe visual impairment
(3) Medical history of congestive heart failure
(4) Medical history of a stroke in the past five years
(5) Body Mass Index (BMI) ≥40
(6) Wheelchair-dependent
(7) Other concurrent psychiatric or medical co-morbidity that could explain the fatigue 
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Centrum. The study has been registered in the Dutch Trial Register (trial number NTR4312). 
All patients will receive verbal and written information about the study, and all patients 
must give written informed consent before randomization and inclusion. 
Intervention
Dia-Fit consists of blended care, a combination of assignments, information and e-mail 
contact delivered via an internet portal and individual face-to-face sessions with a 
therapist. Total duration of the intervention is five months. During these months patients 
get online information and assignments, have e-mail contact with their therapist every 
two weeks, and receive five to eight face-to-face sessions. The intervention is aimed at 
changing cognitions and behaviors thought to maintain fatigue; these are depicted in 
Figure 1. Which cognitions and behaviors are relevant and applicable for the individual 
patient will be determined on the basis of cut-off scores on various questionnaires filled in 
at baseline assessment and the clinical interview by the therapist. For each fatigue- 
perpetuating factor, a treatment module is developed. In this way the intervention can be 
tailored based on the applicable factors. Patients can follow from three up to eight of the 
following modules: 
 1. Goals setting. All patients receive this module. The module is the start of the Dia-Fit 
intervention and consists of psycho-education about fatigue in T1DM and the cognitive- 
behavioral model of fatigue in T1DM. There will be a discussion about which modules are 
relevant for the patient. The patient will formulate goals of the therapy that, if attained, 
imply that a patient is no longer severely fatigued and no longer limited by fatigue in daily 
functioning. 
 2. Regulation of the sleep-wake pattern. At baseline, patients register bedtimes, times 
that they get up, and the time slept during the day for two consecutive weeks. This 
module is indicated if patients score 60 or higher on the subscale sleep of the Sickness 
Impact Profile-8 (SIP-8)23 and/or if their bedtime and get-up time registration shows 
evidence of a disrupted sleep-wake pattern. In this module, the importance of a regular 
sleep wake cycle is discussed. Patients are asked to maintain fixed bedtimes and get-up 
times and stop sleeping or lying down during the day.
 3. Formulating helpful fatigue-related beliefs. This module addresses low self-efficacy 
with respect to fatigue, fatigue catastrophising, and the tendency of patients to focus on 
fatigue. Dysfunctional beliefs will be reformulated and patients will practice applying 
helpful beliefs in their daily life. If patients score 19 or lower on the Self Efficacy Scale for 
fatigue (SES)24 and/or 16 or higher on the Fatigue Catastrophising Scale (FCS),25 they will 
receive this module. The tendency to focus on fatigue will be addressed if patients score 
30 or higher on the Illness Management Questionnaire subscale focusing on symptoms 
(IMQ).26 Patients will learn how to shift their attention to other things instead of fatigue, 
such as activities or the environment. Patients will also be asked to stop talking about 
fatigue and to ask significant others stop talking about fatigue.  
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 4. Activity regulation and increasing the level of activity. This module is applicable for all 
patients and focuses on gradually increasing activity. The physical activity pattern of 
patients will be assessed with an actometer at baseline. An actometer is a small device 
which is worn at the ankle during two consecutive weeks.27 On the basis of the scores of 
the actometer, each patient will be categorized in one of the two activity patterns: 
relatively active or low active. The physical activity of relatively active patients varies from 
day to day and is often characterized by “all or nothing” behavior. Relatively active patients 
first learn to divide their activities more evenly across the day and week and then increase 
their physical activity with a graded activity program. Patients can choose to increase their 
physical activity level either by walking or biking. They start walking or biking at least two 
times a day and increase their walking or biking time step by step. Patients with a low 
active pattern immediately start by increasing their physical activity. After patients have 
increased their physical activity, they apply the same principles to social or mental 
activities. Only patients who experience specific problems with social or mental activities 
will receive these elements of the module. Patient who do not need this specific step and 
believe that they are able to increase their level of activity will proceed with other modules 
and the realization of their goals. 
 5. Coping with pain. This module focuses on dysfunctional cognitions regarding to 
pain. It is assumed that catastrophising thoughts with respect to pain will make it difficult 
for patients to increase their activity level. Therefore, patients learn to use more helpful 
beliefs with respect to pain. Patients who score 55 or lower on the pain subscale of the 
SF3628 and/or 16 or higher on one of the two subscales, magnification and ruminating, of 
the Pain Catastrophizing Scale (PCS)29 will receive this module. 
 6. Optimization of social support and interactions. Patients with T1DM and severe fatigue 
can experience problems in their interactions with significant others due to a lack of under- 
standing or support. In this module, patients learn how to improve their communication with 
significant others about fatigue. In exercises they learn how to communicate with others 
about fatigue and how to be more assertive. There is also an emphasis on having more 
realistic expectations with respect to the reaction of others. This module is indicated if 
patients score 50 or higher on the subscale discrepancy and/or score 14 or higher on the 
subscale negative interactions of the Sonderen Social Support Inventory (SSI).30 
 7. Reducing diabetes-related distress. T1DM is a chronic disease, and its management 
is demanding for patients. Patients can develop diabetes-related distress, for example, 
related to the fear of the development of medical complications, hypoglycemia or 
deregulated blood glucose values. In this module, patients concretize the elements 
of diabetes that they find stressful and learn how to better cope with these elements. 
The module is indicated if patients score 30 or higher on the Problem Areas in Diabetes 
questionnaire (PAID).31
 8. Step-by-step realization of goals. All patients end Dia-Fit with the realization of goals. 
Patients realize the preset goals and evaluate the treatment effects. Patients who work less 
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because of their fatigue will resume work in this module. Therapists will discuss with 
patients how to prevent relapse. 
Development of Dia-Fit and usability testing
The information and assignments provided on the Dia-Fit portal are developed by experts 
on chronic fatigue and type 1 diabetes. Usability testing was used to test the portal. 
Three patients with T1DM, recruited from the diabetes outpatient clinic of the Radboud 
university medical center, participated in the usability tests. They were interviewed about 
the usability of the portal and completed various tasks on the website in the presence of 
a researcher using the “think aloud” technique. The intervention was improved on the 
basis of the findings of the usability test.
Training, supervision and treatment integrity
All therapists are experienced cognitive behavior therapists working at the ECCF. Therapists 
will be trained in delivering Dia-Fit. They will receive bi-weekly supervision from an 
experienced clinical psychologist (HK). 
Treatment integrity will be determined by digitally recording all face-to-face sessions and 
saving all e-mail contacts of Dia-Fit. At the end of the study, 5% of the sessions and the 
e-mail contacts will be randomly selected and evaluated to assess to what extent the 
Dia-Fit treatment was delivered according to protocol. 
Outcome measures
The primary outcome measure is fatigue severity measured with the fatigue severity 
subscale of the CIS.19 The CIS subscale fatigue consists of eight items that are scored on a 
7-point Likert scale from (1) “Yes, that is true” to (7) “No, that is not true”. Scores range from 
8 to 56 with higher scores indicating more severe fatigue. Severe fatigue is operationalised 
as scoring 35 and higher, which is higher than the mean plus two standard deviations of a 
healthy control group.32 The CIS is a valid and reliable instrument that has been used 
before in patient groups with chronic diseases.12,13 
Secondary outcome measures are limitations in daily functioning and diabetes control. 
Limitations in daily functioning will be measured with the total score on the Sickness 
Impact Profile-8 (SIP-8).23 The SIP-8 measures functional disability in eight different 
domains of functioning: sleep and rest, homemaking, mobility, social interactions, 
ambulation, leisure activities, alertness behavior, and work limitations. The eight subscale 
scores are added to provide one weighted score of disability (SIP-8 total score). Higher 
scores indicate more disabilities. Diabetes control will be determined with two diabetes- 
specific clinical measurements: HbA1c values and blood glucose variability. HbA1c values 
are routinely assessed at the diabetes outpatient clinics every three months. Whenever 
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possible, assessment of HbA1c for the study and the routine assessment will be combined. 
Blood glucose variability will be derived from 7-point blood glucose profiles, measured for 
two consecutive days. The standard deviation of the mean glucose level is used as an 
indicator of blood glucose variability.33
Questionnaires that will help to decide which modules of the Dia-Fit intervention should 
be used are described in the section “intervention”. Based on the model of fatigue in T1DM, 
several fatigue- and diabetes-related cognitions and behaviors are assessed. Questionnaires 
and measurement points are listed in Table 2.
Assessments
The baseline assessment (T0) consists of two appointments at the ECCF. During both test 
sessions patients will complete questionnaires (Table 2). In the two weeks between the 
two sessions, patients will wear an actometer to measure physical activity.27 Patients will 
also record their symptoms and activities in a diary. In addition, blood glucose variability 
and HbA1c will be assessed. After the baseline assessment, patients will be randomized to 
either the Dia-Fit intervention group or the waiting list group. After five months, the 
second assessment will be done (T1), consisting of the same measures as at baseline 
assessment. After T1, the waiting list group will start with Dia-Fit. The waiting list group will 
receive an extra assessment after therapy (T2). All patients will be assessed six months after 
finishing Dia-Fit (T3). T2 and T3 will consist of a limited number of measures (Table 2). 
Adverse events
Adverse events (AE) will be assessed at T1. Patients will be asked to fill in a questionnaire 
regarding the development of new symptoms during the therapy or waiting period. All 
AE’s that are spontaneously reported by patients or observed by the investigator will be 
recorded and reported to the ethical committee. The investigator will also record and 
report serious adverse events (SAEs) to the ethical committee. Previous research has 
shown that CBT for fatigue is a safe treatment.34
Treatment adherence 
Treatment adherence will be determined in two ways. First, therapists will be asked to rate 
the degree of adherence to the Dia-Fit intervention by the patient on a scale of 0 to 10 at 
the end of the therapy. Second, patients will be asked to rate the degree to which they 
adhered to the different modules of the Dia-Fit treatment at the end of the therapy. Both 
scores will be correlated with the change score (pre-treatment versus post-treatment) on 
the primary outcome measure. 
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Table 2   Time points of all measures 
Measurements T0 T1 T2 T3
Main outcome measures
Fatigue severity Checklist Individual Strength  
(CIS, subscale fatigue)19
X X X X
Secondary outcome measures
Limitations in daily functioning Sickness Impact Profile-8  
(SIP-8, total score)23
X X X X
Diabetes regulation HbA1c, Blood glucose variability33 X X X X
Indicators for modules
Sleep problems Sickness Impact Profile-8  
(SIP-8, subscale sleep)23
X X
Dysfunctional cognitions with  
respect to fatigue
Self-efficacy Scale (SES)24 X X
Fatigue Catastrophising Scale (FCS)25 X X
Illness Management Questionnaire (IMQ)26 X X
Level of physical activity Actometer27 X X
Pain severity and impact of pain SF36 Questionnaire (subscale pain)28 X X
Pain Catastrophising Scale (PCS)29 X X
Cognitions with respect to social 
support and social interactions
Sonderen Social Support Inventory (SSI)30 X X
Diabetes-related distress Problem Areas In Diabetes (PAID)31 X X
Other measures
Depression Beck Depression Inventory (BDI)20 X X
Psychological distress SCL9021 X
Cognitions regarding fatigue Fatigue Quality List (FQL)39 X X 
Cognitions with respect to activity Tampa Scale for Kinesiophobia 2 (TSK2)40 X X 
Affective quality of pain McGill Pain Questionnaire (MPQ)41 X X
Causal attributions CAL diabetes42 X X
Diabetes quality of life Diabetes Quality of Life Brief Clinical 
Inventory (DQOL_BCI)43
X X
Cognitions regarding symptoms  
of chronic illness
Illness Cognition Questionnaire (ICQ)44 X X
Cognitive and Behavioural Responses to 
Symptoms Questionnaire (CBRSQ)45
X X
Self-efficacy regarding diabetes- 
self-care
Confidence in Diabetes Self-Care Scale 
(CIDS)46
X X
Physical activity International Physical Activity Questionnaire 
(IPAQ)47
X X
Note. T0=baseline assessment; T1=second assessment; T2=post treatment assessment for patients of the waiting 
list; T3=follow-up assessment.
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Sample size 
Sample size calculation was based on the guidelines of Borm and colleagues35 and 
Van Breukelen36 for analysis of covariance (ANCOVA) in randomized controlled trials. 
On the primary outcome parameter, the CIS fatigue severity, we assumed a clinically 
relevant difference in post-treatment scores of 6 between the Dia-Fit and the waiting list 
condition.37 With a power of .90, a two-sided alpha of .05, and a standard deviation of 
8.6, a minimum number of 45 patients would be needed per condition when using a 
t-test. According to Borm and colleagues,35 this number of patients can be multiplied by 
a “design factor” when ANCOVA is used. This factor is one minus the squared correlation 
coefficient between baseline and second assessment of fatigue severity. As we have no 
data on which to base this correction, we used a conservative estimate of 1 as a factor 
which corresponds to a relatively low correlation between baseline and second assessment 
of about r=.20 (1-.202=.96≈1). Assuming a drop-out rate of 25%, 60 patients per condition 
need to be randomized (n=120 in total).
Randomization 
Patients will be randomized in an equal ratio (1:1) to one of the two groups: 1) intervention 
group or 2) waiting list group. A computer randomization program that is created by an 
independent statistical expert will be used for randomization. Block randomization is 
used with blocks of 6. Patients will be stratified into two groups: 1) patients recruited from 
hospitals and 2) patients recruited via media. A test assistant who is not involved in the 
study will do the random allocation in the presence of the patient after the baseline 
assessment. The researcher (JM) will also be present to plan appointments with the 
therapist and for the second assessment. The researcher is not blinded for treatment 
allocation. A researcher blinded for treatment allocation will do the statistical analysis. 
Statistical analyses 
To test if there is a difference between the intervention group and the waiting list condition 
on the primary outcome measure at second assessment (T1), ANCOVA will be used with 
the score on the second assessment as dependent variable, the baseline score on the 
dependent measure as covariate, and condition as fixed factor.36 Analysis of the data will 
be based on intention to treat. Missing values will be replaced with multiple imputation 
with fully conditional specification with at least five imputations. When statistical 
significant differences are found, a sensitivity analysis will be performed on the basis of 
different assumptions about the values of missing data. For the secondary outcome 
measures, limitations of daily functioning and diabetes control, the same analyses will be 
used. To determine if the expected positive result of CBT will be sustained at follow-up, 
scores at follow-up (T3) of patients treated with CBT directly or after the waiting period will 
be compared with the scores at post-treatment (T1 or T2) using paired t-tests.
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Finally, we will test with multiple mediation which changes in the proposed fatigue 
maintaining cognitions and behaviors mediate the expected effect of the intervention on 
the primary outcome parameter fatigue severity. The proposed mediators are factors 
that are thought to maintain fatigue severity. The mediation analysis will be conducted 
according to the approach of Preacher and Hayes.38 Significance of the mediation effects 
will be determined using a non-parametric bootstrap approach which increases the 
power to detect significant effects even in small, non-normally distributed samples.38
DISCUSSION
To our knowledge, this study is the first randomized controlled trial testing the efficacy of 
a web-based cognitive behavioral intervention for chronic fatigue in patients with T1DM. 
Chronic fatigue is highly prevalent in T1DM and is experienced by patients as one of 
the most disabling symptom of the illness. An effective treatment focusing on fatigue in 
patients with T1DM is not yet available. 
The blended care character of Dia-Fit—consisting of web-based information, assignments 
and e-mail contact supported by face-to-face sessions—is a promising approach for both 
patients and therapists. The tailored approach of Dia-Fit makes it possible to concentrate 
on fatigue maintaining factors that are relevant for each individual patient.
In conclusion, the results of the described study will provide information about the 
efficacy of CBT for severe fatigue in patients with T1DM and, one hopes, will contribute to 
the treatment of fatigue in T1DM. 
Trial status
Recruitment of the Dia-Fit study is ongoing. The recruitment started in January 2014 and 
is expected to end in February 2016.
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ABSTRACT
Background: Fatigue in type 1 diabetes is prevalent and persistent, but so far, no evidence- 
based treatments are available. We aimed to investigate the efficacy of cognitive behavioral 
therapy (CBT) in reducing fatigue severity in patients with type 1 diabetes.
Methods: We did a multicenter randomized controlled trial at one university medical 
centre and four large teaching hospitals in the Netherlands. Eligible patients were aged 
18-70 years and had type 1 diabetes for at least 1 year and chronic fatigue for at least 
6 months. We randomly assigned patients (1:1) to CBT or waiting list using computer- 
generated blocked randomization, stratified by type of enrolment. The CBT intervention 
(Dia-Fit) was given for 5 months in blended form, consisting of face-to-face and web-based 
sessions. The primary outcome was fatigue severity assessed 5 months after randomization, 
directly after the intervention or waiting list period, with the Checklist Individual Strength 
fatigue severity subscale. Secondary outcomes were functional impairment (assessed 
with the total score of the Sickness Impact Profile-8), glycemic control (HbA1c), and glucose 
variability. Analyses were done by intention to treat. This trial is registered with the 
Nederlands Trial Register, number NTR4312.
Findings: Between Feb 6, 2014, and March 24, 2016, we randomly assigned 120 eligible 
patients to either CBT (n=60) or waiting list (n=60), all of whom were included in the 
 intention-to-treat analyses. Compared with patients in the waiting list group, those in 
the CBT group had significantly lower fatigue severity scores (mean difference 13.8, 95% 
CI 10.0-17.5; p<.0001) and significantly lower scores for functional impairment (mean 
difference 513, 95% CI 340-686; p<.0001) after 5 months. HbA1c and glucose variability did 
not change after treatment and there was no difference between groups. Five patients in 
the CBT group and seven in the waiting list group reported adverse events; none were 
deemed to be related to the study intervention.
Interpretation: Although our findings need to be confirmed in larger and longer-term 
studies, they suggest that CBT can effectively reduce fatigue severity and functional 
impairment in type 1 diabetes.
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INTRODUCTION
Chronic fatigue, defined as severe fatigue that is present for at least 6 months and has a 
substantial effect on daily functioning, is a prevalent and burdensome complaint of 
patients with type 1 diabetes, according to findings from the few studies done so far.1 
In these studies, up to 40% of patients with type 1 diabetes are reported to have chronic 
fatigue and have significantly higher scores on fatigue scales than people from the general 
population.2,3 Patients have reported that fatigue is one of the most burdensome symptoms 
of their disease,2 and fatigue is persistent in three of four severely fatigued patients with 
type 1 diabetes.4 Although an association between fatigue in type 1 diabetes and glycemic 
control seems plausible, several studies2,4,5 could not clearly confirm an association.
To our knowledge, no intervention studies to investigate the management of fatigue in 
patients with type 1 diabetes have been reported before now. Randomized controlled 
trials in other chronic diseases and conditions characterized by severe and disabling 
fatigue have shown that cognitive behavioral therapy (CBT) can significantly reduce 
fatigue.6-8 CBT is based on a cognitive-behavioral model of fatigue, assuming that disease- 
specific elements trigger the fatigue, whereas the fatigue is maintained by cognitive- 
behavioral factors.9 Applied to type 1 diabetes, the primary disease—specifically hyper-
glycemia, diabetes-related complications, or somatic co-morbidities—seems likely to trigger 
fatigue,10 whereas several cognitive-behavioral factors such as self-efficacy concerning 
fatigue, pain, sleep disturbances, and physical inactivity perpetuate fatigue.2,4 On the basis 
of this construct, we developed a CBT intervention for chronic fatigue in type 1 diabetes, 
which is delivered in blended form as a combination of face-to-face sessions and web- 
based modules.10
In the present study, we investigated the efficacy of this CBT approach in reducing severe 
fatigue after 5 months of treatment. Additionally, we studied the effects of CBT on functional 
impairment, glycemic control (HbA1c), and glucose variability, because we speculated that 
reduced fatigue might enable patients to improve diabetes self-management. Furthermore, 
in an explorative uncontrolled analysis, we investigated whether the expected positive effects 
of treatment were sustained at follow-up, 6 months after the post-treatment assessment.
METHODS
Study design and participants
For this multicenter randomized controlled trial, we recruited patients from one university 
medical centre and four large teaching hospitals in the southeast of the Netherlands, and 
by placing advertisements on social media and sending flyers to other hospitals in the 
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area. Eligible patients were aged 18-70 years; had been diagnosed with type 1 diabetes for 
at least 1 year; were able to speak, read, and write Dutch; had a score of 35 or higher on the 
fatigue severity subscale of the Checklist Individual Strength, reflecting a score higher 
than the mean and at least two SDs above the score of a healthy population;11 and had 
a duration of fatigue of 6 months or longer, as indicated by the patient. Exclusion criteria 
were moderate-to-severe renal failure (estimated glomerular filtration rate ≤45 mL/min 
per 1.73 m²), blindness or severe visual impairment, medical history of congestive heart 
failure, medical history of a stroke in the past 5 years, BMI of 40 kg/m² or higher, wheelchair- 
dependence, and other concurrent psychiatric or medical co-morbidity that could 
account for the fatigue.
Patients were screened by their treating consultant for the first three inclusion criteria (age, 
type of diabetes and time since diabetes diagnosis, and ability to speak, read, and write 
Dutch) and all exclusion criteria. Eligible patients received an invitation letter for the study 
with a screening questionnaire for chronic fatigue attached to it (fatigue severity and 
duration were assessed with the Checklist Individual Strength fatigue severity subscale 
and a question regarding the duration of fatigue). A consultant from the Radboud 
University Medical Centre, Nijmegen, Netherlands, screened patients who enrolled for 
the study via self-referral for eligibility before inclusion.
The local medical ethical committees of all hospitals reviewed and approved the study 
(registration number 2013/165, NL43178.091.13). All participants received written and verbal 
information about the study, and provided written informed consent. A detailed description 
of the study protocol has been published.10
Randomization and masking
Patients were randomly assigned (1:1) to either the intervention group (CBT) or a waiting 
list control group. The waiting list control is representative of usual care because no 
evidence-based fatigue treatment for patients with type 1 diabetes is available.
The randomization was computer-generated with blocks of six, stratified by type of 
enrolment (referred from hospitals vs. self-referred via social media or flyers). A test assistant 
who was not involved in the trial did the randomization in the presence of the patient 
and the researcher (JM). Patients were unmasked because of the nature of  the study and 
the researcher was unmasked for practical reasons. The researcher who obtained the data (JM) 
was unmasked to the patients’ assignment condition. An independent researcher who 
was not involved in the study and was masked to treatment allocation did the statistical 
analyses.
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Procedures
The intervention was CBT for chronic fatigue in type 1 diabetes (named Dia-Fit), designed 
to address fatigue-perpetuating factors.10 Dia-Fit was given in blended form consisting of 
five to eight face-to-face sessions of 50 minutes with a therapist and web-based modules 
offered through an internet portal. Dia-Fit had a duration of 5 months and consisted of 
up to eight modules: goal setting, regulation of the sleep-wake pattern, formulation of 
helpful fatigue-related beliefs, activity regulation and graded activity, coping with pain, 
optimization of social support and interactions, reduction of diabetes-related distress, 
and step-by-step realization of goals. The intervention was tailored to the individual 
RESEARCH IN CONTEXT
Evidence before this study
Fatigue in patients with type 1 diabetes is 
 prevalent, associated with functional impair-
ment, and reported as one of the most 
 disabling symptoms of type 1 diabetes by 
 patients.  Additionally, it has been reported that 
fatigue in patients with type 1 diabetes is 
 persistent and perpetuated by cognitive 
 behavioral variables. We systematically 
searched Cochrane databases, PubMed, and 
PsycINFO for research articles (and protocols) of 
randomized controlled trials testing the 
 efficacy of cognitive behavioral interventions 
for fatigue in patients with type 1 diabetes from 
the databases’ inception until Jan 11, 2017. 
We used the search terms “type 1 diabetes 
 mellitus” or “insulin-dependent diabetes 
 mellitus” or “juvenile-onset diabetes mellitus”; 
and “fatigue” in MesH heading and free text 
words, and “cognitive behavioral therapy” or 
“cognitive therapy” or “psychotherapy”. We used 
no language restrictions in our search. Aside 
from the published protocol for the present 
trial, we did not identify any reports or  protocols 
of randomized controlled trials on cognitive 
behavioral interventions that address fatigue in 
patients with type 1 diabetes.
Added value of this study 
To our knowledge, the present randomized 
controlled trial is the first to provide evidence 
of a cognitive behavioral intervention on 
fatigue in patients with type 1 diabetes. 
Our results show that cognitive behavioral 
therapy (CBT) leads to a significant reduction 
of fatigue severity and functional impairment 
in chronically fatigued patients compared 
with a waiting list control group. HbA1c and 
glucose variability were not affected by the 
CBT intervention.
Implications of all the available evidence
Despite its high prevalence and associated 
disability, fatigue in type 1 diabetes remains 
an understudied symptom. The findings from 
the present study show that fatigue in type 1 
diabetes is significantly reduced after CBT 
compared with a waiting list control group. 
Although these findings need to be replicated, 
they suggest that fatigue in type 1 diabetes 
can be effectively treated and CBT can reduce 
the burden of fatigue for patients with type 1 
diabetes.
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pattern of perpetuating factors of patients. The criteria for the indication of the modules 
and their content is described in the appendix and in the trial protocol.10
Three clinical psychologists (licensed cognitive behavioral therapists from the Radboud 
University Medical Centre, Nijmegen, Netherlands) delivered the treatment. All therapists 
were experienced in the treatment of chronic fatigue and were trained in delivering the 
Dia-Fit intervention. During the trial, therapists received supervision every 2 weeks from a 
clinical psychologist (HK). The supervision was given in between the face-to-face sessions 
to discuss the treatment’s progress. Face-to-face sessions were audiotaped, and emails 
sent in the web-based portal were stored. Two independent evaluators rated a random 
sample of 5% of both face-to-face sessions and emails to determine treatment integrity. 
We calculated the proportion of intervention elements that was delivered in accordance 
with the treatment protocol, and the inter-rater agreement. We determined treatment 
adherence with two measures: a scale of 0 (not adherent at all) to 10 (fully adherent), filled 
in by the therapist at the end of treatment; and a scale of 1 (not adherent at all) to 5 (fully 
adherent), filled in by the patient for each module. The two measures were correlated with 
the change score of fatigue severity (pre-post score). We distinguished between non- 
starters (i.e., patients who completed not more than one face-to-face session), and study 
withdrawals (i.e., patients who completed at least two face-to-face sessions but stopped 
the treatment prematurely).
Patients assigned to the waiting list control group also received the intervention after a 5 
month waiting period, and were informed about this at randomization. Patients in the 
waiting list group were free to mention their complaints to health-care providers and 
could undergo additional tests for fatigue.
Outcomes
All outcome measures were assessed before randomization (baseline assessment), and 
5 months after randomization (at the end of the intervention or waiting period; second 
assessment). Additionally, outcome measures were assessed 6 months after treatment 
was finished (follow-up assessment) in the CBT group only. For ethical reasons, we decided 
to offer patients from the control group CBT after their participation in the waiting list 
study group. Therefore, the planned follow-up analysis to determine if the effect of CBT 
was sustained was uncontrolled.
The primary outcome was fatigue severity assessed at the end of the intervention or 
waiting list period (second assessment; 5 months after randomization) with the Checklist 
Individual Strength fatigue severity subscale.11 The eight questions of the fatigue severity 
subscale are scored with a Likert Scale ranging from 1 to 7. Total scores range from 8 to 56, 
with a score of 35 or higher indicating severe fatigue.11 The Checklist Individual Strength 
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has good psychometric properties.12 Cronbach’s α (a measure of internal consistency) in 
a sample of 214 patients with type 1 diabetes was high (α=.952).2
Secondary outcomes were functional impairment assessed with the Sickness Impact 
Profile-8 total score (SIP-8),13 HbA1c, and glucose variability, assessed by standardized 
laboratory methods. The SIP-8 measures functional impairment in eight categories: sleep 
and rest, homemaking, mobility, social interactions, ambulation, leisure activities, alertness 
behavior, and work, with higher scores indicating more severe impairment. Validity and 
reliability of the SIP-8 are high.13 HbA1c measurements were retrieved from medical records 
when possible (for baseline, when the measurement was made within 8 weeks before 
randomization and, for second and follow-up data, when the measurement was made 
within 4 weeks after the second and follow-up assessment). When these data were not 
available, HbA1c was measured for the study at the baseline, second assessment, and 
follow-up visits. In most patients, HbA1c was measured pairwise within the same hospital. 
The participating hospitals share similar reference ranges for HbA1c determination. Glucose 
variability was measured by the total SD of 14 glucose measures (i.e., seven measures 
throughout the day during 2 consecutive days [before and after breakfast, before and 
after lunch, before and after dinner, and bedtime]).14 Participants were asked to measure 
blood glucose values for the study immediately before randomization for baseline, after 
the 5 month intervention or waiting period for second assessment, and 6 months after 
the end of the intervention for follow-up assessment.
Questionnaires assessing fatigue severity and functional impairment were filled in online 
whenever possible. When this was not possible, patients received a paper and pencil 
version of the questionnaires at home.
Statistical analysis
With an assumed clinically meaningful difference of 6 points between the intervention 
and waiting list group on the Checklist Individual Strength fatigue severity subscale, and 
an SD of 8.6, we calculated that 120 participants (60 in each group) would be needed, 
assuming a power of 90%, a two-sided α of .05, a design factor of .96, and a 25% loss to 
second assessment.10,15 The assumed clinically meaningful difference of 6 points was 
based on findings from a study that determined the efficacy of CBT in patients with 
chronic fatigue syndrome.16
We used the independent sample t test and χ² tests to assess differences between patients 
who enrolled via self-referral and via hospitals. Analyses of outcomes were done according 
to intention to treat. We hypothesized that the CBT intervention would reduce fatigue 
severity and functional impairment, improve HbA1c, and reduce glucose variability, 
compared with the waiting list. For all outcomes, we used ANCOVA, with the second 
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assessment score as dependent variable, the baseline score as covariate, and the study 
group (CBT vs. waiting list group) as fixed factor. We repeated the analysis with an extra 
covariate (type of enrolment) to control for the possible effect of this variable on the effect 
of the intervention. Missing values were replaced with multiple imputation of 20 iterations 
under the assumption that data were missing at random.17 We did two sensitivity analyses 
to test the robustness of the results. In the first approach, we replaced missing values with 
the last observation of that variable (last observation carried forward). In the second 
approach, we used a modified worst case scenario, in which missing values in the CBT 
group were replaced by the highest score of the CBT group at baseline and missing values 
in the waiting list group were replaced by the lowest score of the waiting list group at 
baseline. Finally, we did a post-hoc, per-protocol analysis excluding all participants who 
did not adhere to the treatment protocol.
We calculated the effect size (Cohen’s d) for all significant outcome measures (i.e., by 
subtracting the mean scores of the CBT group and the waiting list group at second 
assessment divided by the pooled SD of both groups); this analysis was post hoc. An effect 
size was classified as small (d=0.2-0.49), medium (d=0.5-0.79), or large (d≥0.8).18
We did a post-hoc analysis to assess whether more patients in the CBT group than in the 
control reported a clinically significant improvement on the primary outcome measure. 
We defined clinically significant improvement as a statistically reliable change,19 plus a 
Checklist Individual Strength fatigue severity score of 34 or less. The statistically reliable 
change was calculated by a reliable change index with a normative group (n=110) of 
non-severely fatigued patients with type 1 diabetes.2 We analyzed the differences in the 
proportions of patients with clinically significant improvement between the CBT group 
and the waiting list group with χ² tests. Clinically significant improvement was visually 
displayed in a scatter plot.20 Because depressive symptoms and diabetes distress are 
prevalent in patients with type 1 diabetes, we also did a post-hoc analysis with depressive 
symptoms (assessed with the Beck Depression Inventory for Primary Care)21 and diabetes 
distress (assessed with the Problem Areas in Diabetes questionnaire22 at baseline) as 
covariates in the ANCOVA to control for the possible effects of these variables on the 
effect of the intervention.
We investigated the follow-up effects of the CBT group with paired t tests, comparing 
the scores at follow-up with the scores at second assessment for all outcome measures. 
When these scores differed significantly, we repeated t tests by comparing the scores at 
follow-up with the scores at baseline. The analysis was done by intention-to-treat. We also 
calculated the proportion of patients with clinically significant improvement at follow-up 
by post-hoc analysis.
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The presence of adverse events during the trial was assessed by recording any 
spontaneously adverse events reported by patients or noted by the researcher, and at 
second assessment by patients’ self-report. Adverse events were not assessed at follow-up 
assessment. Additionally, the investigator recorded serious adverse events during the 
study. There was no data monitoring committee, but the data entry was checked by an 
independent data manager. All statistical analyses were done with IBM SPSS Statistics, 
version 22.0.23 This study is registered with the Nederlands Trial Register, number NTR4312.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
RESULTS
Between Feb 6, 2014, and March 24, 2016, we screened 1816 patients with type 1 diabetes. 
1107 (61%) patients met the medical inclusion criteria and received an invitation letter with 
the screening questionnaire for chronic fatigue. Of these, 515 did not respond, 305 were 
not chronically and severely fatigued, and 33 were excluded because of medical reasons. 
Of the 254 remaining patients, 134 declined to participate, and 120 were randomly 
assigned (60 to CBT and 60 to waiting list; Figure 1). The main reasons for non-participation 
were time investment and travel distance to the treatment centre (data not shown). 
At baseline, we noted no major differences between the study groups with respect to 
demographic and outcome variables (Table 1). Of the 120 participants, 36 (30%) enrolled 
via social media (self-referral) and 84 (70%) via hospitals. Patients who enrolled via self- 
referral were significantly more often female, had lower numbers of diabetes complications 
(especially retinopathy), used less antihypertensive drugs, and reported more functional 
impairments than patients who enrolled via hospitals (Appendix).
Among the 120 participants, the numbers with missing values at second assessment were 
0 for fatigue severity, two (2%) for functional impairment, four (3%) for HbA1c, and eight 
(7%) for glucose variability. Two patients at baseline and five patients at second assessment 
refused a new HbA1c test for the study, and, for these patients, HbA1c values from medical 
records that were closest to the assessments were used. In 116 participants, HbA1c was 
assessed pairwise at the same hospital (at baseline and second assessment). In four 
participants, HbA1c was not assessed pairwise. These patients were self-referrals who were 
seen at the Radboud University Medical Center at baseline, but HbA1c determination at 
second assessment was done in their own hospitals. Four patients filled in a paper and 
pencil version of the questionnaires due to internet problems. Four (7%) of 60 patients 
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Figure 1   Trial profile
1107 sent invitation letter and 
screening questionnaire   
709 did not meet inclusion criteria*  
60 reached second assessment 
 
11 did not complete treatment
 4 non-starters
  1 therapy took too much time
  1 problems with internet portal
  1 did not believe therapy would help
  1 unknown
 7 discontinued treatment
  2 therapy took too much time
  2 did not believe therapy would help
  3 unknown 
 
 
 
 
 
 
 
 
60 assigned to CBT
1 erroneously included (CIS fatigue=34 at baseline)        
120 randomly assigned 
987 excluded
 515 never responded
 305 not severely and chronically fatigued
 167 severely and chronically fatigued
   14 had depression detected with the MINI
   3 had other psychiatric disorder detected with the MINI
   16 excluded for medical reasons**
   134 declined to participate       
60 reached second assessment  
60 assigned to waiting list
1 erroneously included (type 2 diabetes)       
1816 assessed for eligibility
 1711 from medical record review by clinician
   105 self-referred    
 
59 reached follow-up assessment 
Intervention period (5 m
onths)  
Follow
-up period (6 m
onths) 
60 included in intention-to-treat analysis
(second assessment and follow-up)  
Follow-up data were not available for
waiting list group  
 
60 included in intention-to-treat analysis
(second assessment; 0 included in follow-up analysis)
1 lost to follow-up 
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who received CBT did not start treatment (i.e., had no more than one session). Seven (12%) 
patients who received CBT withdrew from the CBT intervention: four after the second 
face-to-face session and three after the third session. Mean time between randomization 
and second assessment was 153 days (SD 18) in the CBT group, and 154 days (SD 10) in 
the waiting list group. No patients reported any adverse events spontaneously during 
the study, and the investigator did not record any serious adverse events during the trial. 
12 patients reported adverse events at second assessment (five in the CBT group and 
seven in the waiting list group); these adverse events were deemed to be unrelated to the 
CBT and waiting list group (Appendix). Data for adverse events at second assessment were 
missing for nine patients, all in the waiting list group.
Compared with patients in the waiting list group, patients in the CBT group reported 
significantly lower fatigue severity scores (mean difference 13.8, 95% CI 10.0-17.5; p<.0001) 
after 5 months. The decrease in fatigue severity and functional impairment was significantly 
greater in the CBT group than in the waiting list group, with a large effect size for both 
fatigue severity (d=1.3, 95% CI 0.9-1.7) and functional impairment (d=0.8, 0.4-1.1; Table 2). 
We identified no significant differences in HbA1c and glucose variability between the 
groups (Table 2). Sensitivity analyses showed similar results (Appendix). Type of enrolment 
had no significant effect on fatigue severity (data not shown). The proportion of 
participants with clinically significant improvement in fatigue severity in the CBT group 
(46 [77%] of 60; 95% CI 66-87) was significantly higher than in the waiting list group 
(15 [25%] of 60; 14-36; χ²=32; p<.0001; Figure 2).
For the per-protocol analysis, we excluded 11 patients: four who did not start CBT 
treatment and seven who withdrew from the CBT treatment prematurely. The per-protocol 
analysis showed similar results to the intention-to-treat analysis (Appendix). Two patients 
were included erroneously (one had type 2 diabetes and one had a Checklist Individual 
Strength fatigue severity score of 34; Figure 1); we repeated the analysis without these 
patients, but this did not affect the results (data not shown).
Note. MINI=Mini International Neuropsychiatric Interview; CBT=cognitive behavioral therapy; CIS fatigue=Checklist 
Individual Strength, subscale fatigue severity. 
*Inclusion criteria assessed by the treating medical consultant. 
**Medical reasons were prespecified exclusion criteria that were not detected by the consultant at the first step 
of screening (sleep apnoea [n=2]), fibromyalgia [n=3], rheumatoid arthritis [n=3], sarcoidosis [n=1], uncontrolled 
severe Graves’ disease [n=1], congestive heart failure [n=2], estimated glomerular filtration rate ≤45 mL/min per 
1.73m2 [n=1], BMI ≥40 kg/ m2 [n=1], and no type 1 diabetes [n=2]).
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Table 1   Baseline characteristics  
CBT (n=60) Waiting list (n=60)
Age (years)  44.4 (12.1) 42.9 (12.5)
Women 37 (62%) 37 (62%)
Education level*
Low 11 (18%) 7 (12%)
Medium 30 (50%) 31 (52%)
High 19 (32%) 22 (37%)
Diabetes duration (years) 24.2 (13.3) 24.1 (13.9)
HbA1c (mmol/mol) 65 (11) 64 (11)
HbA1c (%) 8.1 (1.0) 8.0 (1.0)
Glucose variability (mmol/L) 3.5 (1.1) 3.6 (1.1)
Mean number of diabetes complications 0.6 (1.1) 0.6 (1.1)
Diabetes complications
Retinopathy 13 (22%) 14 (23%)
Nephropathy 3 (5%) 3 (5%)
Neuropathy 12 (20%) 11 (18%)
Numbness in the feet 5 (8%) 5 (8%)
Cardiovascular disease 3 (5%) 3 (5%)
Myocardial infarction 1 (2%) 0 (0%)
Stroke 0 (0%) 1 (2%)
Insulin therapy 
Multiple daily injections 22 (37%) 15 (25%)
CSII 38 (63%) 45 (75%)
CGM 7 (12%) 12 (20%)
Drugs
Antihypertensives 15 (25%) 18 (30%)
Cholesterol-lowering therapy 17 (28%) 16 (27%)
Anticoagulants 3 (5%) 2 (3%)
Psychopharmacological drugs 5 (8%) 5 (8%)
Analgesics 7 (12%) 6 (10%)
BMI (kg/m2) 26.2 (4.8) 26.0 (4.0)
Fatigue severity (CIS fatigue) 45.9 (5.9) 46.0 (5.8)
Functional impairment (SIP-8) 929 (635) 855 (543)
Depressive symptoms (BDI-PC) 3.5 (2.7) 3.3 (2.1)
Diabetes distress (PAID) 26.1 (18.3) 26.9 (17.0)
Note. Data are mean (SD), n (%), unless otherwise indicated. CBT=cognitive behavioural therapy; CSII=continuous 
subcutaneous insulin infusion; CGM=continuous glucose monitoring; CIS fatigue=Checklist Individual Strength, 
subscale fatigue severity; SIP-8=Sickness Impact Profile-8; BDI-PC=Beck Depression Inventory for Primary Care; 
PAID=Problem Areas in Diabetes questionnaire. 
*Education level classified as low (4 years of secondary education), medium (5 years of secondary education), or 
high (6 or more years of secondary education). 
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At follow-up (6 months after intervention period; CBT group only), one (2%) of 60 participants 
had missing values for fatigue severity, three (5%) of 60 had missing values for functional 
impairment, three (5%) had missing values for HbA1c, and nine (15%) had missing values for 
glucose variability. The intention-to-treat analysis of the follow-up effects showed that the 
fatigue severity score at follow-up increased compared with the fatigue severity score at 
second assessment (30.2 [SD 11.4] vs. 26.5 [SD 11.6]; mean difference 3.7; p=.0067). However, 
fatigue severity was still significantly lower at follow-up than at baseline (30.2 [SD 11.4] 
vs. 45.9 [SD 5.9]; mean difference 15.7; p<.0001). 36 (61%) of 59 patients reported a clinically 
significant improvement at follow-up. The analysis of the scores on functional impairment 
showed that the positive effects at second assessment were sustained at follow-up (326 
[SD 417] vs. 353 [SD 433]; mean difference 27.2; p=.5541; Appendix). HbA1c and glucose 
variability scores at follow-up did not differ significantly from scores at second assessment. 
Post-hoc analysis with depressive symptoms (p=.6458) and diabetes distress (p=.1562) 
as covariates and fatigue severity as a dependent variable showed that both were not 
significant covariates.
Table 2   Effect of treatment (ITT) on primary and secondary outcome measures 
CBT
(n=60)
Waiting list 
(n=60)
Treatment  
effect 
(95% CI)
p-value Effect size  
cohen’s d 
(95% CI)*
Fatigue severity (CIS fatigue) 26.5 (11.6) 40.4 (10.4) 13.8 (10.0-17.5) <.001 1.3 (0.9-1.7)
Functional impairment (SIP-8) 326 (417) 792 (744) 513 (340-686) <.001 0.8 (0.4-1.1)
HbA1c (mmol/mol) 64 (11) 63 (11) 0.2 (-2.2-2.6) .889 N/A
Glucose variability (mmol/L) 3.1 (1.1) 3.3 (1.2) 0.1 (-0.5-0.3) .537 N/A
Note. Scores are means (SD) at second assessment, unless otherwise indicated. Two HbA1c values at baseline 
could not be retrieved within 8 weeks before randomization, so we used values from the medical records that 
were the closest to randomization; one was determined 1 month too early (waiting list [n=1]), and one was 
determined 4 months too early (CBT [n=1]). These patients refused a new HbA1c test at the study’s baseline 
assessment. Five HbA1c values at second assessment could not be retrieved within 4 weeks after second 
assessment measurement; three were determined 1 month too late (waiting list [n=2], CBT [n=1]), and two were 
determined 1 month too early (CBT [n=2]). These patients refused a new HbA1c test at the study’s second 
assessment. CBT=cognitive behavioral therapy; CIS fatigue=Checklist Individual Strength, subscale fatigue 
severity; SIP-8=Sickness Impact Profile-8; NA=not applicable. 
*Effect sizes could be classified as small (d=0.2-0.49), medium (d=0.5-0.79), or large (d≥0.8).
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Figure 2   Change in fatigue severity scores between baseline and second assessment 
for CBT (A) and waiting list (B) groups
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In the CBT group, the mean number of face-to-face sessions given during treatment was 
5.4 (SD 1.5) and the mean number of emails sent by the therapists was 3.6 (SD 2.3). Mean 
time of website usage was 5 h 33 min, with a range of 21 min to 22 h 48 min. Treatment 
integrity was high for both face-to-face sessions (92%) and emails (93%). Inter-rater 
agreement was 96% for face-to-face sessions and 95% for emails. Therapists rated the 
participants’ level of adherence with a mean score of 7.4 (SD 1.4; range 0-10). The mean 
adherence of all modules rated by patients was 3.4 (SD 0.8; range 1-5). The change score 
of fatigue severity was significantly correlated with the mean adherence score rated by 
patients (r=0.329, p=.0272), but not with the adherence score rated by therapists (r=0.213, 
p=.1424).
DISCUSSION
The CBT-based Dia-Fit intervention significantly decreased fatigue severity in patients with 
type 1 diabetes compared with the waiting list control. CBT also significantly decreased 
functional impairment and showed large effect sizes for both fatigue severity and 
functional impairment. The proportion of patients who improved to a clinically significant 
extent with respect to fatigue was significantly higher in the CBT group (77%) than in the 
waiting list group (25%). HbA1c and glucose variability did not seem to be affected by 
the CBT intervention.
Our findings in patients with type 1 diabetes and fatigue confirm that CBT is a safe 
treatment, as has been previously shown in other populations.24 Adverse events reported 
in the study were not related to the intervention and were not more prevalent in the CBT 
group than in the waiting list group. The treatment integrity in our study was high and 
it seems reasonable that CBT in patients with type 1 diabetes can be easily done by 
therapists, if they receive adequate training. Our treatment was delivered by web-based 
modules in combination with face-to-face sessions. Nonetheless, the most frequently 
mentioned reasons for non-participation in our study were time investment and travel 
time to the treatment centre. These barriers could be overcome by a fully web-based 
treatment, since this form is probably more time-efficient both for patients and therapists, 
and is easily accessible for most patients.25
Note. CBT=cognitive behavioural therapy; CIS fatigue=Checklist Individual Strength, subscale fatigue severity. 
The diagonal line represents no baseline-second assessment change, the dashed upper and lower lines represent 
the bounds of the 95% CI of the Reliable Change Index, and the horizontal and vertical lines represent the CIS 
fatigue cut-off score of 35. Clinical significant improvement is defined as a second assessment score of less than 
35 in combination with the criterion for reliable change. The points with the superscript “2” are double as two 
participants had the same scores.
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Patients who enrolled via self-referral were more often female, were more functionally 
impaired, and had fewer diabetes-related complications than patients who were referred 
via hospitals. Previous evidence suggests that women are more likely to gather online 
information about health problems than men,26 which could account for the first of these 
findings. The significantly higher scores on functional impairment could suggest that 
self-referral patients have more problems in daily functioning as a consequence of fatigue 
than patients referred via the hospitals, which could have been the reason that they 
enrolled in the study. This discrepancy between enrolment types and the high level of 
motivation for treatment could have led to a selection bias. However, we did not identify 
differences between these two groups with respect to treatment effects, but the skewed 
distribution of self-referrals (30%) and hospital-referrals (70%) might have limited statistical 
power to detect a possible difference. In most cases, the study participation was offered 
through the treating physicians who screened patients for eligibility. In clinical practice, 
the treatment would probably be offered to patients in the same way, so any selection 
bias would be unlikely to affect the generalizability of our findings to clinical practice. 
The treatment adherence measured by patient self-report was correlated with the fatigue 
severity change score. Therefore, further optimization of adherence in future treatments 
is likely to be important to ensure positive outcomes for patients.
We identified a substantial improvement on fatigue in the CBT group, but patients in the 
waiting list group also improved with respect to fatigue (albeit only one in four patients). 
This improvement seems in line with natural fluctuations in severe fatigue as shown by 
a recent study in which 19 (24%) of 78 patients with type 1 diabetes and severe fatigue 
improved over time without treatment.
We did not identify an effect of CBT on glycemic control (HbA1c) or glucose variability. In a 
recent meta-analysis27 investigating the effects of CBT for patients with diabetes on 
psychological outcomes and glycemic control, Uchendu and Blake reported that CBT has 
beneficial effects on short-term and medium-term glycemic control, but not on long-term 
glycemic control. However, none of the studies included in the meta-analysis investigated 
CBT for chronic fatigue, which makes it impossible to generalize these findings to our 
study population. Our findings regarding glycemic control are in line with existing 
evidence that fatigue in type 1 diabetes is not related to HbA1c or glucose variability.2,5 
However, these findings should be interpreted with caution because we did not base our 
power calculation on these secondary outcomes, although based on our results we believe 
that a larger study sample would be unlikely to produce different findings.
We have not scored the number of hypoglycemic events or the occurrence of severe 
hypoglycemia. As far as we know, none of the participants had severe hypoglycemia 
during the trial. Nevertheless, several patients who participated in the trial were very well 
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controlled (often treated by pump and sensor) and some of these patients had hypo- 
glycemic events, impaired awareness of hypoglycemia, or a history of severe hypoglycemia. 
In an earlier study,2 we did not find an association between glucose variability, as measured 
by continuous glucose monitoring, and fatigue, and found no association with time spent in 
the hypoglycemic range; in fact, this time was a little less in the fatigued group. The underlying 
mechanism between diabetes control and chronic fatigue might be attributable to a 
U-shaped association: patients who do not pay much attention to their diabetes will have 
poor control with high glucose variability, which might contribute to fatigue, as might 
concerns about potential complications. Patients who put a lot of effort into their diabetes 
control will have better, less variable glycemic control, but at the same time will have a 
substantially increased burden associated with treatment, which in turn will also drain 
energy.
Depression and diabetes-related distress are common psychosocial problems in diabetes.28 
We excluded patients with a depressive disorder from our study. A post-hoc analysis with 
depressive symptoms and diabetes distress as covariates showed that CBT significantly 
reduced fatigue independent of the level of depressive symptoms or diabetes distress at 
baseline. Depressive symptoms or diabetes distress might be reduced after CBT; as such, 
future studies (e.g., using mediation analysis) should investigate the relation between these 
possible effects and the decrease in fatigue. We think that changes in the perpetuating factors 
of fatigue addressed in the CBT modules (e.g., sleep disturbances or self-efficacy concerning 
fatigue) probably mediate the positive effects of CBT on fatigue. Research in other chronic 
disorders has shown that changes in these perpetuating factors can mediate the effects of 
CBT on fatigue.29 Researchers should investigate the mechanisms of change of CBT in type 
1 diabetes, because this knowledge could help to improve the effectiveness and efficiency 
of this intervention.
Chronic fatigue is an understudied symptom in patients with type 1 diabetes;1 what 
contributes to fatigue in type 1 diabetes is not fully understood. A recently published 
systematic review1 showed that most studies on fatigue in patients with type 1 diabetes 
are of low quality, suggesting that additional high-quality research on fatigue in type 1 
diabetes is needed.
Our study might have clinical implications. As reported, severe fatigue in type 1 diabetes 
is persistent in three of four severely fatigued patients, meaning an effective treatment 
intervention would be welcome. The results of our trial show that CBT is indeed effective 
in reducing fatigue and improving functional impairment. The explorative analysis of the 
follow-up assessment in the CBT group showed that the mean fatigue severity at follow-up 
was increased compared with the fatigue severity directly after treatment, but the scores 
were still significantly lower than at baseline. At follow-up, most patients in the CBT group 
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still had a clinically significant improvement in fatigue (61%; compared with 77% directly 
after treatment), which suggests that the treatment effects are maintained over time. 
However, these findings should be interpreted with caution because the follow-up assessment 
was uncontrolled.10 Additional future research investigating the long-term effectiveness 
of CBT for fatigue in type 1 diabetes is needed.
The present study has limitations. First, we used a waiting list control group as a comparator, 
rather than an active control intervention. The design of an active control group in 
psychosocial intervention studies is challenging,30 and this is the first study to test the 
efficacy of an intervention for fatigue in type 1 diabetes so it is difficult to determine what 
would be an appropriate active control without a specific effect on fatigue. The use of a 
waiting list group could have provoked nocebo effects (i.e., patients’ negative expectations 
about the effects on fatigue of having to wait). However, the course of fatigue in our 
waiting list group was similar to the natural course of fatigue without any intervention,4 
which suggests that a nocebo effect is unlikely to have occurred in the study. Second, 
because of the type of intervention and for practical reasons, we were unable to mask 
participants or the researcher to the treatment allocation. To reduce potential bias, an 
independent researcher, masked to the treatment allocation, did the analyses and almost 
all participants filled in questionnaires online at home to keep contact with the unmasked 
researcher (JM) to a minimum. Third, the sample size was fairly small and we recruited a 
selected sample of patients without severe complications or co-morbidities. Whether 
patients with severe complications or co-morbidities would also benefit from CBT for 
fatigue is unclear. Finally, an objective measurement of adherence and of the time patients 
spent on each treatments’ web-based module (rather than just total time logged in to the 
portal) would have improved validity; however, this approach was not possible because 
of the technical limitations of the web portal software.
In summary, this study shows beneficial effects of CBT on fatigue severity and functional 
impairment, with large effect sizes and a large proportion of patients with clinically 
significant improvement in the CBT group compared with the waiting list control group. 
Glycemic control and glucose variability did not improve after CBT.
Acknowledgments
The study was funded by the Dutch Diabetes Research Foundation (Diabetes Fonds, 
grant number 2012.00.1483). We thank all patients for participating. Additionally, we thank 
all internists and nurses of the participating hospitals for referring patients (Radboud 
University Medical Centre, Nijmegen; Canisius Wilhelmina Hospital, Nijmegen; Rijnstate 
Hospital, Arnhem; VieCuri Medical Center, Venlo & Venray; Jeroen Bosch Hospital, ‘s-Hertogen-
bosch), and Petra Kruiswijk, Margreet Worm-Smeitink, and Sacha Bouman for delivering 
the treatment. We thank Harriët Abrahams for doing the masked statistical analysis.
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 89
89
5
CBT FOR CHRONIC FATIGUE IN TYPE 1 DIABETES: EFFECT STUDY
REFERENCES
1. Jensen Ø, Bernklev T, Jelsness-Jørgensen LP. Fatigue in type 1 diabetes: a systematic review of observational 
studies. Diabetes Res Clin Pract. 2017;123:63-74.
2. Goedendorp MM, Tack CJ, Steggink E, Bloot L, Bazelmans E, Knoop H. Chronic fatigue in type 1 diabetes: 
highly prevalent but not explained by hyperglycaemia or glucose variability. Diabetes Care. 2014;37:73-80.
3. Segerstedt J, Lundqvist R, Eliasson M. Patients with type 1 diabetes in Sweden experience more fatigue than 
the general population. J Clin Transl Endocrinol. 2015;2:105-109.
4. Menting J, Nikolaus S, Van der Veld WM, Goedendorp MM, Tack CJ, Knoop H. Severe fatigue in type 1 diabetes: 
exploring its course, predictors and relationship with HbA1c in a prospective study. Diabetes Res Clin Pr. 
2016;121:127-134.
5. Lasselin J, Layé S, Barreau JB, Rivet A, Dulucg MJ, Gin H, Capuron L. Fatigue and cognitive symptoms in patients 
with diabetes: relationship with disease phenotype and insulin treatment. Psychoneuroendocrino. 2012;37: 
1468-1478.
6. Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behaviour therapy in severely fatigued 
disease-free cancer patients compared with patients waiting for cognitive behaviour therapy: a randomised 
controlled trial. J Clin Oncol. 2006;4882-4887.
7. Van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A randomised controlled trial 
of cognitive behaviour therapy for multiple sclerosis fatigue. Psychosom Med. 2008;70:205-213.
8. Voet N, Bleijenberg G, Hendriks J, De Groot I, Padberg G, Van Engelen B, Geurts A. Both aerobic exercise and 
cognitive-behavioural therapy reduce chronic fatigue in FSHD: an RCT. Neurology. 2014; 83:1914-1922.
9. Kalkman JS, Schillings ML, Zwarts MJ, Van Engelen BGM, Bleijenberg G. The development of a model of fatigue 
in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007;62:571-579.
10. Menting J, Nikolaus S, Wiborg JF, Bazelmans E, Goedendorp MM, Van Bon AC, Van den Bergh JP, Mol MJ, Tack 
CJ, Knoop H. A web-based cognitive behaviour therapy for chronic fatigue in type 1 diabetes (Dia-Fit): study 
protocol for a randomised controlled trial. Trials. 2015;16:262.
11. Vercoulen JHMM, Alberts M, Bleijenberg G. De checklist individual strength (CIS). Gedragstherapie, Houten: 
Bohn Stafleu Van Loghum; 1999 [Dutch]. 
12. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, Van der Meer JW, Bleijenberg G. Dimensional assessment of 
chronic fatigue syndrome. J Psychosom Res. 1994;38:383-392.
13. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a 
health status measure. Med Care. 1981;19:787-805.
14. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev. 2010;31:171-182.
15. Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in randomised 
clinical trials. J Clin Epidemiol. 2007;60:1234-1238.
16. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, De Boo TM, Severens JL, Van der Wilt GJ, Spinhoven P, Van der 
Meer JW. Cognitive behaviour therapy for chronic fatigue: a multicentre randomised controlled trial. Lancet. 
2001;17:841-847.
17. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications 
of multiple imputation theory. Prev Sci. 2007;8:206-213.
18. Cohen J. Statistical power analysis for the behavioural sciences. Hillside, NJ: Lawrence Earlbaum Associates; 1988.
19. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy 
research. J Consult Clin Psych. 1991;59:12-19.
20. Morley S, Dowzer CN. Manual for the Leeds Reliable Change Indicator: simple Excel applications for the 
analysis of individual patient and group data. Leeds: University of Leeds; 2014.
21. Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck 
Depression Inventory for Primary Care. Behav Res Ther. 1997;35:785-791.
22. Snoek FJ, Pouwer F, Welch GW, Polonsky WH. Diabetes-related emotional distress in Dutch and US diabetic 
patients. Diabetes Care. 2000;23:1305-1309.
23. IBM Corp. IBM SPSS statistics for Windows, version 22.0. Armonk, NY: IBM Corp; 2013.
24. Heins MJ, Knoop H, Prins JB, Stulemeijer M, Van der Meer JW, Bleijenberg G. Possible detrimental effects of 
cognitive behaviour therapy for chronic fatigue syndrome. Psychother Psychosom. 2010;249-256.
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 90
90
CHAPTER 5
25. Andersson G, Titov N. Advantages and limitations of Internet-based interventions for common mental 
disorders. World Psychiatry. 2014;13:4-11.
26. Fox S, Duggan M. Health online 2013. Pew Research Center; 2013. Retrieved from http://pewinternet.org/
Reports/2013/Health-online.aspx.
27. Uchendu C, Blake H. Effectiveness of cognitive-behavioural therapy on glycaemic control and psychological 
outcomes in adults with diabetes mellitus: a systematic review and meta-analysis of randomised controlled 
trials. Diabet Med. 2016;34:328-339.
28. Snoek FJ, Skinner TC, eds. Psychology in diabetes care, 2nd edn. Chichester: John Wiley & Sons; 2005.
29. Heins MJ, Knoop H, Burk WJ, Bleijenberg G. The process of cognitive behaviour therapy for chronic fatigue 
syndrome: which changes in perpetuating cognitions and behaviour are related to a reduction in fatigue? 
J Psychosom Res. 2013;75:235-241.
30. Hart T, Fann JR, Novack TA. The dilemma of the control condition in experience-based cognitive and 
behavioural treatment research. Neuropsychol Rehabil. 2008;18:1-21.
APPENDIX
Participating institutions / hospitals  
Radboud University Medical Center, Nijmegen, The Netherlands
Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
Rijnstate Hospital, Arnhem, The Netherlands
VieCuri Medical Center, Venlo & Venray, The Netherlands
Jeroen Bosch Hospital, ’s-Hertogenbosch, The Netherlands
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Appendix table 1   Differences between self-referral and referral via the hospital
Hospital 
(n=84)
Self-referral 
(n=36)
Difference 
p-value
Age (years) 44.6 (12.3) 41.4 (12.1) .1865
Women 44 (52%) 30 (83%) .0014
Education level* .6501
Low 14 (17%) 4 (11%)
Medium 43 (51%) 18 (50%)
High 27 (32%) 14 (39%)
Diabetes duration (years) 25.7 (13.1) 20.6 (14.0) .0579
HbA1c (mmol/mol) 65 (11) 63 (10) .4626
HbA1c (%) 8.1 (1.0) 7.9 (0.9) .4626
Glucose variability (mmol/L) 3.7 (1.0) 3.3 (1.1) .0825
Mean number of diabetes complications 0.7 (1.2) 0.3 (0.8) .0302
Diabetes complications
Retinopathy 24 (29%) 3 (8%) .0150
Nephropathy 5 (6%) 1 (3%) .4647
Neuropathy 18 (21%) 5 (14%) .3363
Numbness in the feet 9 (11%) 1 (3%) .1494
Cardiovascular disease 4 (5%) 2 (6%) .8550
Myocardial infarction 1 (1%) 0 (0%) .5109
Stroke 1 (1%) 0 (0%) .5109
Insulin therapy
Multiple daily injections 27 (32%) 10 (28%) .6351
CSII 57 (68%) 26 (72%)
CGM 14 (17%) 5 (14%) .7025
Drugs
Antihypertensives 28 (33%) 5 (14%) .0288
Cholesterol-lowering therapy 27 (32%) 6 (17%) .0819
Anticoagulants 4 (5%) 1 (3%) .6182
Psychopharmacological drugs 6 (7%) 4 (11%) .4711
Analgesics 10 (12%) 3 (8%) .5640
BMI (kg/m2) 26.1 (4.6) 26.2 (3.8) .9025
Fatigue severity (CIS fatigue) 45.3 (6.0) 47.5 (5.4) .0559
Functional impairment (SIP-8) 798 (496) 1111 (727) .0073
Note. Data are mean (SD), n (%), unless otherwise indicated. SD=Standard deviation. CSII=Continuous subcutaneous 
insulin infusion. CGM=Continuous glucose monitoring. BDI=Body-mass Index. CIS fatigue=Checklist Individual 
Strength, subscale fatigue severity. SIP-8=Sickness Impact Profile-8. Differences are significant at p<.05.
*Education level: low (4 years of secondary education), medium (5 years of secondary education), high (6 or more 
years of secondary education). 
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 92
92
CHAPTER 5
Appendix table 2   Adverse events based on patients’ self-report (n=12)
CBT (n=5) Waiting list (n=7)
Tinnitus (n=1) Thyroid disease (n=2)
Tietze syndrome (n=1) “too much muscle strain” (n=1)
Broken toe (n=1) Polymyalgia rheumatic (n=1)
Shingles (n=1) Epilepsy (n=1)
Dupuytren’s contracture (n=1) Fibromyalgia (n=1)
Vitamin B12 deficiency (n=1)
Note. CBT=cognitive behavioral therapy.
Appendix table 3   Sensitivity analysis
CBT  
(n=60)
Waiting 
list 
(n=60)
Treatment 
effect 
(95% CI)
p-value Effect size 
cohen’s d 
(95% CI)
LOCF
Functional impairment 
(SIP-8)
320 (408) 788 (736) 514 (346-682) <.0001 0.8 (0.4 to 1.2)
Modified worst case scenario
Functional impairment 
(SIP-8)
372 (587) 772 (741) 445 (239-651) <.0001 0.6 (0.2 to 1.0)
Note. Scores are means (SD) at second assessment, unless otherwise indicated. CBT=cognitive behavioral 
therapy; LOCF=last observation carried forward; SIP-8=Sickness Impact Profile-8.
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Appendix table 4   Per protocol analyses (n=109)
CBT  
(n=49)
Waiting 
list  
(n=60)
Treatment 
effect 
(95% CI)
p-value Effect size 
cohen’s d  
(95% CI)
Fatigue severity (CIS fatigue) 24.6 (10.5) 40.4 (10.4) 15.9 (12.1 to 19.7) <.0001 1.5 (1.1-1.9)
Functional impairment (SIP-8) 302 (401) 784 (742) 551 (369 to 733) <.0001 0.8 (0.4-1.2)
HbA1c (mmol/mol) 64 (11) 63 (11) 0.5 (-1.9 to 2.9) .6769 N/A
Glucose variability (mmol/L) 3.2 (1.2) 3.3 (1.2) 0.0 (-0.4 to 0.5) .8813 N/A
Note. Scores are means (SD) at second assessment, unless otherwise indicated. CBT=Cognitive behavioral therapy; 
CIS fatigue=Checklist Individual Strength, subscale fatigue severity; SIP-8=Sickness Impact Profile-8. 
Missing values for functional impairment, HbA1c and glucose variability are not replaced (functional impairment: 
n=1 missing, HbA1c: n=4 missing, glucose variability: n=6 missing). Two HbA1c values at baseline could not be 
retrieved within 8 weeks before randomization, so we used values from the medical records that were the closest 
to randomization [one was determined 1 month too early (n=1 waiting list), and one was determined 4 months 
too early (n=1 CBT)]. These patients refused a new HbA1c test at the study’s baseline assessment. Five HbA1c 
values at second assessment could not be retrieved within 4 weeks after the second assessment measurement 
[three were determined 1 month too late (n=2 waiting list, n=1 CBT), and two were determined 1 month too early 
(n=2 CBT)]. These patients refused a new HbA1c test at the study’s second assessment.
Appendix table 5   Subgroup analysis (ITT) of the follow-up effects of  
the intervention group (n=60)
Baseline Second 
assessment
Follow-up Second assessment – follow-up
Mean  
difference
(95% CI)
p-value
Fatigue severity  
(CIS fatigue)
45.9 (5.9) 26.5 (11.6) 30.2 (11.4) 3.7 (1.0 to 6.3) .0067
Functional impairment 
(SIP-8)
929 (635) 326 (417) 353 (433) 27.2 (-117 to 62.9) .5541
HbA1c  
(mmol/mol)
65 (11) 64 (11) 64 (13) 0 (-3 to 4) .7743
Glucose variability 
(mmol/L)
3.5 (1.1) 3.1 (1.1) 3.0 (0.9) 0.1 (-0.2 to 0.5) .4755
Note. Scores are means (SD), unless otherwise indicated. CBT=Cognitive behavioral therapy; CIS fatigue=Checklist 
Individual Strength, subscale fatigue severity; SIP-8=Sickness Impact Profile-8.
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 94
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 95
Potential mechanisms involved in 
the effect of cognitive behavioral therapy 
on fatigue severity in type 1 diabetes  
Juliane Menting
Cees J. Tack
Rogier Donders 
Hans Knoop
In revision
6
514794-L-bw-menting
Processed on: 26-10-2017 PDF page: 96
96
CHAPTER 6
ABSTRACT
Objective: To identify mediators of the beneficial effect of cognitive behavioral therapy 
(CBT) on fatigue severity in chronically fatigued patients with type 1 diabetes. 
Methods: We performed additional analyses of data of a randomized controlled trial 
testing the efficacy of CBT by comparing patients allocated to the treatment (n=60) with 
patients on a waiting list (n=60). Primary outcome measure was fatigue severity assessed 
with the Checklist Individual Strength, subscale fatigue severity. We used multiple mediation 
analysis to determine potential mediators of the treatment effect. Proposed mediators, 
assessed with questionnaires, were the following fatigue-perpetuating factors: symptom 
focusing, self-efficacy concerning fatigue and pain, perceived activity, sleep disturbances, 
confidence in diabetes self-care, diabetes distress and discrepancy regarding social support. 
Additionally, actigraphy was used to assess the level of physical activity. The mediation 
analysis was repeated with changes in depressive symptoms brought on by CBT to test 
to what extent the mediation model changed. 
Results: The effect of CBT on fatigue severity was partly mediated by a change in 
symptom focusing (-1.39, 95% CI=-3.32 to -0.19), fear avoidance (-1.10, 95% CI=-2.49 to 
-0.22), self-efficacy concerning fatigue (-1.95, 95% CI=-4.51 to -0.40), and perceived physical 
activity (-2.44, -4.53 to -1.07). Depressive symptoms were also a mediator (-1.22, 95% 
CI=-2.56 to -0.38), but the aforementioned fatigue-perpetuating factors still explained 
part of the treatment effect.  
Conclusions: Changes in specific cognitions about fatigue and activity, and a change in 
depressive symptoms partly mediated the treatment effect of cognitive behavioral therapy 
on fatigue severity in type 1 diabetes. 
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INTRODUCTION
Fatigue in type 1 diabetes is a common and troublesome symptom. Approximately 40% 
of patients with type 1 diabetes report chronic fatigue, and in three out of four severely 
fatigued patients fatigue persists over time.1,2 The severe fatigue has an adverse impact 
on daily functioning, and is seen by patients as one of the most burdensome diabetes 
symptoms.1 While it is widely assumed that fatigue is associated with suboptimal glycemic 
control, a study of our own research group did not find a clear relationship between 
fatigue severity and HbA1c or glucose variability.1 Research has shown that cognitions and 
behaviors associated with fatigue play an important role in the perpetuation of fatigue in 
type 1 diabetes.1,2
We composed a cognitive-behavioral model for fatigue in type 1 diabetes suggesting 
that the disease, particularly diabetes-specific complications or hyperglycemia, triggers 
the fatigue, while cognitive and behavioral factors perpetuate it.3 According to this model, 
fatigue and illness-related cognitions, e.g., a low self-efficacy concerning fatigue and 
diabetes, perpetuate fatigue severity in type 1 diabetes.3 Fatigue-related maintaining 
behaviors are sleep disturbances and physical inactivity.1,2 Pain and diabetes distress are 
common symptoms in diabetes and can also maintain fatigue.1,4 Finally, lack of social 
support has been found to be an important associated factor of fatigue in for example 
cancer survivors,5 as it may be experienced similarly by patients with type 1 diabetes.3 
On the basis of our model of fatigue in type 1 diabetes, we developed a web-based 
cognitive behavioral therapy (CBT) aimed at cognitions and behaviors thought to maintain 
fatigue. The efficacy of this intervention was tested in a randomized controlled trial3 and 
showed that fatigue severity and functional impairment significantly decreased following 
CBT, as compared to a waiting list.6 The CBT consisted of six modules, each aimed at one 
of the aforementioned fatigue maintaining factors. In the first treatment module, patients 
learned how to develop a regular sleep-wake pattern. The second module focused on 
changing unhelpful beliefs about fatigue. The third module addressed balancing and 
increasing activities and consisted of a graded activity program. In the three remaining 
modules, patients learned how to cope with pain symptoms, to communicate more 
effectively with significant others about their fatigue, and how to cope with diabetes- 
related distress. The intervention was a tailored treatment, i.e., patients only received 
modules that were relevant to them based on a baseline assessment.3 
The mechanisms underlying the decrease in fatigue in patients with type 1 diabetes are 
unknown. The present study attempts to determine the mediators of the treatment 
response using multiple mediation analysis, a strategy that can determine which variables 
mediate the relationship between treatment and outcome.7 If we know more about the 
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mechanisms of change of CBT for fatigue, we can develop more effective and efficient 
interventions. Multiple mediation analysis makes it possible to test several potential 
mediators simultaneously. Based on the cognitive-behavioral model of fatigue in type 1 
diabetes, we assumed that a change in the fatigue maintaining factors during CBT 
mediated the reduction of fatigue. We selected potential mediators reflecting aspects 
that are addressed by the six different CBT modules. To assess the role of fatigue-related 
cognitions, we included measures of symptom focusing and self-efficacy concerning 
fatigue.8 Graded activity is an important element of the intervention and we therefore 
used measures to assess changes in the level of perceived and objective physical activity, 
as well as measures assessing changes in the perceived relationship between symptoms 
and activity as potential mediators.9,10 Changes in sleep disturbances, self-efficacy concerning 
pain, confidence in diabetes self-care, diabetes distress and discrepancy regarding social 
support were assessed to determine to what extent these factors addressed in the remaining 
treatment modules mediated the reduction of fatigue.
Although not part of the model for fatigue, it has been found that depressive symptoms 
are common in type 1 diabetes11 and related to fatigue.1,2 Depressive symptoms were not 
specifically addressed in the intervention; however, it is likely that depressive symptoms 
decrease during CBT. This could have a positive effect on fatigue levels. We therefore 
added depressive symptoms in a second step to the mediation model to test if a change 
in depressive symptoms is a mediator of the treatment response and if this variable 
changed the results on the role of the proposed mediators based on our model.
METHODS
Patients and procedure 
Participants were recruited for a randomized controlled trial testing the efficacy of 
web-based CBT, blended with face-to-face sessions, for fatigue in type 1 diabetes. The trial 
protocol and treatment effect have been described in detail elsewhere.3,6 In short, 
chronically fatigued patients, defined by a score of ≥35 on the Checklist Individual 
Strength (CIS), subscale fatigue severity12 and a ≥6 months duration of fatigue, were 
included. Additionally, patients had type 1 diabetes for at least 1 year and were excluded 
if they experienced any medical or psychological co-morbidity that could explain the 
presence of fatigue. In total, 120 patients were randomly assigned to either CBT (n=60) or 
a waiting list control group (n=60). The mean age of participants was 43.6 years (SD=12.4) 
and mean time since diabetes diagnosis was 24 years (SD=13.5). Assessment took place 
before randomization (baseline) and after 5 months (second assessment), i.e., after 
treatment or waiting period. CBT significantly reduced fatigue severity and functional 
impairment, compared to the waiting list with large effects sizes of Cohen’s d=1.3 and 
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Cohen’s d=0.8, respectively. Three quarters of patients in the CBT group reported a 
clinically significant improvement in fatigue severity.6
All patients gave written informed consent. The study was approved by the medical 
ethical committee of the Radboud university medical center (registration number 
2013/165, NL43178.091.13), and was registered at the Dutch Trial Register (trial number 
NTR4312).
Intervention
CBT was offered through a combination of web-based modules and 5 to 8 face-to-face 
sessions with a therapist. Each patient started with the formulation of personal goals for 
the treatment. The intervention contained of up to six modules: regulation of a healthy 
sleep-wake pattern, changing unhelpful beliefs about fatigue, activity regulation and 
increasing the level of physical activity, coping with pain, the role of social support and 
interactions, and coping with diabetes-related distress. Before the start of the treatment at 
baseline assessment, each patient was screened by questionnaire on the presence of 
problems regarding these topics. Patients received only the modules that were relevant to 
them. The intervention’s duration was 5 months. 
Percentage of treatment’s modules indicated
As the intervention was tailored, not each patient received all treatment’s modules. 
We calculated the percentage of patients receiving each module in two ways: (1) modules 
indicated by questionnaires’ cut-off scores at baseline assessment and (2) self-report by 
patients at second assessment. 
Instruments
 Fatigue severity was assessed using the CIS, subscale fatigue severity,12 which measures 
the severity of fatigue over the last two weeks. The CIS fatigue severity consists of 8 items, 
each scored on a 7-item Likert Scale. The scores range from 8 to 56, whereas a score of ≥35 
is indicated as severe fatigue. Cronbach’s alpha of the CIS subscale fatigue severity in a 
subgroup of patients with type 1 diabetes is .95.12
Potential mediators 
 Symptom focusing was measured using the Illness Management Questionnaire, 
subscale focusing on symptoms (IMQ).13 The IMQ consists of 9 items, e.g., “My symptoms 
are always at the back of my mind”. Each item is scored on a 6-point Likert Scale from 1 
“never” to 6 “always”; scores range from 9 to 54. Higher scores indicate more symptom 
focusing. Internal consistency of the IMQ is .88.13 
 Self-efficacy concerning fatigue was assessed using the Self-Efficacy Scale for fatigue (SES 
fatigue).14 The scale consists of 7 items, each scored on a 4-point Likert Scale. The scores 
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range from 7 to 28, higher scores indicating more sense of control over fatigue. Internal 
consistency of the SES fatigue ranges between .68 and .77.14,15 
 The Checklist Individual Strength, subscale activity was used to assess perceived 
activity.8 The CIS activity measures the perceived level of activity and consists of 3 items, 
each scored on a 7-point Likert Scale. Scores range from 3 to 21 with higher scores 
indicating a lower level of perceived activity. Internal consistency of the scale is .81.8 
 Objective physical activity was assessed with actigraphy using the actometer (©Actilog 
V3.0), a small motion-sensing device, which assesses physical activity using a piezoelectric 
sensor measuring physical activity in 5-minute intervals.16 Patients wore the actometer 
around their ankle for twelve consecutive days; a mean activity score over the twelve days 
was calculated with higher scores indicating higher physical activity. Accelerometers such 
as actometers have been shown to be reliable and valid instruments in measuring physical 
activity.17 
 Fear avoidance was assessed using the Cognitive and Behavioral Responses to 
Symptoms Questionnaire (CBSQ), subscale fear avoidance.18 The subscale measures the 
fear that activity or exercise will make symptoms worse. The subscale contains of 6 items 
(e.g, “I should avoid exercise when I have symptoms”). Each item is scored on a 5-point 
Likert scale ranging from 1 “strongly disagree” to 5 “strongly agree”; higher scores indicate 
more unhelpful responses. The internal consistency of the subscale fear avoidance was 
good in the present study (α=.85). 
 Sleep disturbances were measured with the Sickness Impact Profile-8, subscale sleep 
and rest (SIP-8).19 It measures the functional impairment in the daily life regarding sleep 
and rest, and consists of 7 items, e.g., “I sleep or nap during the day”. The SIP-8 has good 
validity and reliability; higher scores indicate more impairment. Additionally, we assessed 
the variation of waking and bedtime at baseline and second assessment in hours. Patients 
were asked to fill in a diary reporting these times during twelve consecutive days. The 
variation of waking and bedtime was calculated by the standard deviation of these two 
times over the twelve days. 
 Self-efficacy concerning pain was measured with an adjusted version of the SES fatigue 
questionnaire.14 The word “fatigue” was replaced by the word “pain”. The SES pain 
questionnaire consists of 7 items and each item is scored on a 4-point Likert Scale. 
Scores range from 7 to 28 with higher scores indicating more sense of control over pain. 
The internal consistency is .85 in the present study. 
 Confidence in diabetes self-care was assessed with the Confidence in Diabetes Self-Care 
Scale (CIDS),20 a 20-item questionnaire that measures the patients’ confidence in the 
ability to carry out diabetes management. All items are scored on a 5-point Likert Scale; 
scores range from 0 to 100 with higher scores reflecting more confidence in diabetes 
self-care. The psychometric properties of the CIDS are good.20 
 Diabetes distress was assessed with the Problem Areas in Diabetes Scale (PAID),21 
which measures emotional distress with respect to living with diabetes. The questionnaire 
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consists of 20 items (e.g., “feeling scared when you think about living with diabetes”), each 
scored on a 6-point Likert score ranging from 1 “not a problem” to 6 “a serious problem”. 
The psychometric properties of the PAID are good.21  
 Discrepancy regarding social support was assessed with the Sonderen Social Support 
Inventory Discrepancy, total score (SSL-D)22 which measures the discrepancy between 
actual social support and the need of patients’ social support. The questionnaire consists 
of 34 items. Each item is scored on a 4-point Likert Scale, higher scores indicate a perceived 
lack of social support. The internal consistency of the SSI-D total score is good, ranging 
from .83 to .96.22
 Depressive symptoms were assessed with the Beck Depression Inventory for Primary 
Care (BDI-PC),23 a 7-item, 4-point Likert questionnaire. Higher scores indicate more 
depressive symptoms (range 0 to 21). The internal consistency of the BDI-PC is .86.23  
Mechanisms of change according to patients
At second assessment, patients were asked to rate to what extent they experienced the 
treatment’s modules as helpful. They rated to what extent they thought the most 
important elements of each module contributed to the positive effects of CBT. Each 
component could be rated on a scale from 1 “very much” to 4 “not at all”. For each element, 
the mean score was calculated; controlling for the indicated modules. 
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics Version 22.0.24 We conducted 
an ANCOVA25 to test for differences between the treatment group and the waiting list 
group with respect to all potential mediating variables. The second assessment score 
was used as the dependent variable, the baseline score as the covariate, and condition 
(treatment vs. waiting list) as the fixed factor. Effect sizes were calculated for each potential 
mediator with Cohen’s d.26 An effect size of d=0.2 is small, d=0.5 medium and d=0.8 large. 
We entered only the variables that were significantly different between treatment and 
waiting list group in the mediation analysis. P-values were regarded to be statistically 
significant at <.05.  
Preacher and Hayes’ macro expansion for IBM SPSS, PROCESS, was used to perform the 
mediation analysis.27 We tested a parallel multiple mediation model, which examines 
multiple mediators at the same time by testing direct and indirect values for each 
mediation path while accounting for other mediation paths. The model is illustrated in 
Figure 1. In Figure 1a, changes in fatigue severity are explained by receiving CBT (path c). 
In Figure 1b, the effect of CBT on changes in fatigue is partly mediated by the change in 
the potential mediators, which are responsible for the reduction in fatigue severity. 
All paths (a, b, c, and c’) were tested with regression analysis. For each mediator, changes 
in the mediator were regressed on treatment, i.e., CBT vs. waiting list (path a). Changes in 
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fatigue severity were regressed on changes in the the proposed mediators (path b). Path c 
was examined by regressing changes in fatigue severity on treatment, and in the case of 
path c’, this relationship was corrected by changes in the proposed mediators. A complete 
mediation is met when all paths, except path c’, are significant. In the case of a significant 
path c’, there is partial mediation. We tested the proposed mediators that were significantly 
different between the two conditions (CBT vs. waiting list) by the ANCOVA. In a second 
step, we added changes in depressive symptoms to the model to determine if this changed 
the results of the other proposed mediators. 
Statistical significance of the mediation analysis was tested using a non-parametric 
bootstrap approach with 10,000 datasets that are created by resampling subjects from 
the original data set.27 Bootstrapping is a recommended technique to determine indirect 
effects as it increases power in small, non-normally distributed samples.28 The mean of 
the mediation effects, together with its 95% confidence intervals (CI’s) was reported. 
The null hypothesis was rejected when the 95% CI did not include zero. 
Figure 1   The effect of cognitive behavioral therapy on fatigue, (A) without and (B)  
with the proposed mediators
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RESULTS
A total of 112 (93%) patients filled in all questionnaires assessing the potential mediating 
factors at second assessment. Data from 5 (4%) patients in the CBT condition and 3 (3%) 
patients in the waiting list condition was not complete and they were excluded from 
further analysis. 
Percentage of treatment’s modules indicated
The majority of patients received the modules regulation of sleep-wake pattern, activity 
regulation and changing unhelpful beliefs about fatigue, both according to the indication 
by baseline assessment scores and patients’ self-report (Table 1). Less than half of patients 
received the other three modules (coping with pain, improving social support, and coping 
with diabetes distress). 
 
Differences of the potential mediators between the CBT and waiting  
list group
ANCOVA showed that patients in the CBT group focused less on symptoms, reported a 
higher level of perceived activity, less fear avoidance, less sleep disturbances, and less 
diabetes distress and depressive symptoms on the second assessment than patients on 
the waiting list. Additionally, they scored higher on self-efficacy concerning fatigue and 
pain, and confidence in diabetes self-care, compared to patients in the waiting list group. 
All these variables were entered in the mediation analysis. The change in objective 
physical activity assessed with the actometer, variation in waking and bedtime assessed 
by diary, and discrepancy regarding social support did not differ significantly between the 
two groups at second assessment (Table 2).  
Multiple mediation analysis of the potential mediators 
The results of the regression analysis testing which variables mediated the reduction in 
fatigue are shown in Table 3 (regression coefficients) and Table 4 (mediation effect and its 
95% CI). The multiple mediation analysis demonstrated that a change in symptom focusing 
and self-efficacy concerning fatigue mediated the changes in fatigue severity by CBT. 
A change in perceived activity and fear avoidance were also mediators. When testing the 
effect of treatment on the changes of fatigue severity by controlling for the potential 
mediators (path c’), the effect remained significant. 
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The role of change in depressive symptoms on the effect of CBT on fatigue
When adding changes in depressive symptoms to the multiple mediation model, the 
fatigue- and activity-related cognitions were still significant mediators of the change in 
fatigue severity (Table 3 and 4). A change in depressive symptoms was an additional 
mediator with a mean mediation effect of -1.22 (95% CI -2.56, -0.38).
Mechanisms of change according to patients
Patients rated the behavioral elements such as the regulation of the sleep-wake pattern 
or the spreading of activities more evenly as most helpful, followed by the elements 
addressed in the module changing unhelpful beliefs about fatigue (Table 1).
Table 3   Testing path b, c, and c’ as depicted in Figure 1
Model 1 Model 2
β coefficient p β coefficient p
Path b
∆ Symptom focusing (IMQ) 0.29 .018 0.26 .028
∆ Self-efficacy fatigue (SES fatigue) -0.74 .007 -0.68 .011
∆ Perceived physical activity (CIS activity) 0.63 .001 0.62 .001
∆ Fear avoidance (CBRQ) 0.40 .036 0.41 .026
∆ Sleep disturbances (SIP-8) 0.01 .44 0.00 .71
∆ Self-efficacy pain (SES pain) -0.07 .77 -0.08 .73
∆ Confidence in diabetes self-care (CIDS) -0.04 .70 -0.00 .99
∆ Diabetes distress (PAID) 0.02 .74 0.00 .95
∆ Depressive symptoms (BDI-PC) 0.74 .020
Path c -14.93 <.001 -14.93 <.001
Path c’ -6.84 <.001 -6.44 <.001
Note. CBT=Cognitive behavioral therapy; IMQ=Illness Management Questionnaire, subscale symptom focusing; 
SES fatigue=Self-Efficacy Scale concerning fatigue; CIS activity=Checklist Individual Strength, subscale physical 
activity; CBRQ=Cognitive and Behavioral Responses to Symptoms Questionnaire, subscale fear avoidance; 
SIP-8=Sickness Impact Profile-8, subscale sleep disturbances; SES pain=Self-Efficacy Scale concerning pain; 
CIDS=Confidence in Diabetes Self-Care questionnaire; PAID=Problem Areas in Diabetes Questionnaire; BDI-PC= 
Beck Depression Inventory for Primary Care. Path a is not displayed as the change scores of the potential mediators 
are already shown in Table 1.
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DISCUSSION
The positive effect of CBT on fatigue severity in patients with type 1 diabetes was partly 
mediated by a change in cognitions concerning fatigue and activity. More specifically, an 
increase in self-efficacy concerning fatigue and a reduction of focusing on symptoms 
were the fatigue-related cognitions that were related to a reduction of fatigue severity. 
Increased perceived activity and less negative beliefs about the relationship between 
symptoms and activity were also associated with the reduction of fatigue severity through 
CBT. These mediators remained significant when the change of depressive symptoms was 
taken into account. A reduction of depressive symptoms contributed to the reduction of 
fatigue severity. Although sleep, self-efficacy concerning pain, confidence in diabetes 
self-care, and diabetes distress improved significantly following CBT, they did not 
contribute to the positive effect of the intervention on fatigue severity. 
CBT for chronic fatigue has also been applied successfully in other conditions, such as 
multiple sclerosis (MS),29 FSHD,30 chronic fatigue syndrome (CFS),31 and cancer survivors.32 
Similar to CBT for chronic fatigue in type 1 diabetes, these interventions address cognitive- 
Table 4   Testing the mediation effect of the proposed mediators using  
the bootstrap approach 
Model 1 Model 2
Mean 
mediation 
effect
95% CI Mean 
mediation 
effect
95% CI
∆ Symptom focusing (IMQ) -1.52 -3.46 to -0.35 -1.39 -3.32 to -0.19
∆ Self-efficacy fatigue (SES fatigue) -2.12 -4.71 to -0.53 -1.95 -4.51 to -0.40
∆ Perceived physical activity (CIS activity) -2.48 -4.53 to -1.09 -2.44 -4.53 to -1.07
∆ Fear avoidance (CBRQ) -1.06 -2.39 to -0.19 -1.10 -2.49 to -0.22
∆ Sleep disturbances (SIP-8) -0.50 -1.88 to 0.63 -0.24 -1.54 to 1.00
∆ Self-efficacy pain (SES pain) -0.10 -1.03 to 0.70 -0.12 -1.13 to 0.66
∆ Confidence in diabetes self-care (CIDS) -0.17 -1.17 to 0.74 -0.00 -0.87 to 0.96
∆ Diabetes distress (PAID) -0.13 -1.20 to 0.58 -0.03 -0.95 to 0.80
∆ Depressive symptoms (BDI-PC) -1.22 -2.56 to -0.38
Note. CBT=Cognitive behavioral therapy; IMQ=Illness Management Questionnaire, subscale symptom focusing; 
SES fatigue=Self-Efficacy Scale concerning fatigue; CIS activity=Checklist Individual Strength, subscale physical 
activity; CBRQ=Cognitive and Behavioral Responses to Symptoms Questionnaire, subscale fear avoidance; SIP-8= 
Sickness Impact Profile-8, subscale sleep disturbances; SES pain=Self-Efficacy Scale concerning pain; CIDS= 
Confidence in Diabetes Self-Care questionnaire; PAID=Problem Areas in Diabetes Questionnaire; BDI-PC=Beck 
Depression Inventory for Primary Care.
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behavioral factors thought to maintain fatigue in the specific conditions. The interventions 
consist of generic elements that are the same across conditions, for example the regulation 
of sleep-wake pattern or increasing the level of physical activity, and disease-specific elements 
such as fear of disease recurrence in cancer survivors. Several studies have investigated 
the mechanisms of change of CBT in these chronic conditions. The finding of the present 
study that changes in beliefs about fatigue and activity mediate the effect of CBT on 
fatigue is in line with those mediators found to explain the mechanism of CBT in patients 
with MS33 or CFS.8,34 More specifically, reductions in symptom focusing and self-efficacy 
concerning fatigue have been found to contribute to the positive effects of CBT on fatigue 
in both MS and CFS.8,33,35 
A change in perceived activity was found to be an important mediator of CBT in type 1 
diabetes, as was confirmed by recent research in CFS.8,34 The decrease in fear avoidance 
beliefs, i.e., beliefs about the relationship between symptoms and activity, was found to 
be importantly related to the decrease in fatigue severity through CBT. This finding is in 
accordance with a large study investigating the mechanisms of change in CBT and graded 
exercise therapy for CFS,10 as with two other mediation studies.35,36 
Surprisingly, a change in the level of physical activity assessed with the actometer did not 
mediate the effects of CBT on fatigue, neither did the level of physical activity significantly 
change after CBT. This is in line with two previous mediation analyses that did not find 
objectively assessed physical activity to be a mediating factor of CBT in cancer survivors37 
and patients with CFS.38 During CBT, patients set treatment goals and learn to achieve 
these goals gradually. They start to apply this step-by-step principle by increasing the 
level of physical activity, but learn to extend the principle to other activities, not related to 
physical activity. It seems that rather the perception of being able to carry out and increase 
various activities than the actual level of physical activity contributes to the decrease in 
fatigue severity through CBT.
Depressive disorders are prevalent in type 1 diabetes11 and may also explain the presence 
of fatigue. We therefore excluded patients with a clinical depressive disorder from the 
study. However, patients could still suffer from depressive symptoms, and we found that 
the change in depressive symptoms following CBT was one of the mediators of the 
change in fatigue severity. We decided to add depressive symptoms separately to the 
mediation model to control whether the other potential mediators would still contribute 
to the effects of CBT; this was indeed the case. These findings indicate that the effects of 
CBT are, at least partly, explained by changes in the factors thought to maintain chronic 
fatigue, and not only by changes in depressive symptoms. 
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Our CBT intervention was tailored and we identified the number of patients receiving 
each treatment’s module. This number slightly varied between the percentage calculated 
by scores of the baseline assessment and patients’ self-report. Less than half of patients 
received the modules coping with pain, improving social support, and coping with 
diabetes distress. Due to the limited number of patients who received those modules, 
it might be possible that the mediation analysis was underpowered for the factors addressed 
in these modules. As some of the modules were indicated for only a minority of patients, 
it seems important to match the patients’ needs with the treatment’s content. A tailored 
and personalized treatment approach seems the most promising for the future.
 
When asking patients about the most helpful component of treatment, behavioral elements 
such as the regulation of sleep-wake pattern and spreading activities more evenly, were 
rated as most helpful. These behavioral elements were not found to be significant mediators. 
However, sleep disturbances assessed with self-report were importantly decreased after 
treatment. It is possible that behavioral elements have an indirect effect on the outcomes 
through CBT. It may be that a decrease in sleep disturbances affected other variables, for 
example cognitions, which then significantly affected the decrease in fatigue. 
We found evidence of a partial mediation, indicating that other mediators—not assessed 
in our model—contributed to the treatment effects of CBT. It may be that other cognitions, 
e.g., damaging or embarrassment avoidance beliefs39 that arise due to fears or uncertainly 
about the future, could have influenced the treatment effects of CBT. Recent research in 
the field of CFS has investigated cognitive processing biases with experimental methods,40 
as well as is investigating the potential neurobiological mechanisms of change through 
CBT on fatigue severity such as cortisol.41 These factors, not assessed with self-report, 
could also be important mediators in the explanation of the effects of CBT in type 1 
diabetes and should be investigated in future studies. 
The present study has limitations. First, we measured the potential mediators at two time 
points, which made it hard to demonstrate a cause-and-effect relationship. Had we measured 
the mediators more frequently during treatment, it would have been possible to look 
more closely at possible reciprocal relationships between the different mediators. More 
specifically, we could have investigated whether potential mediators changed temporarily 
or when changes in the cognitions and behaviors took place. Second, we used multiple 
mediation analysis, which has the advantage that it can explore multiple variables at the 
same time, but can also lead to the suppression of the mediation effects of other variables in 
the model. Third, as reported before, it was not possible to carry out the mediation analysis 
in a tailored way for each module. It might be that some factors did not significantly 
contribute to the effects of CBT due to the limited number of patients that received those 
modules. Future studies with even larger study samples could address this limitation.
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In conclusion, the key mechanisms of change on fatigue severity in type 1 diabetes 
brought on by CBT seem most likely to be changes in the beliefs about fatigue and 
activity. Although more research investigating the mechanisms of change on fatigue 
severity in type 1 diabetes is necessary, we have gained information about the possible 
explanation of the effect of CBT. The findings can help in the development of more 
effective and efficient interventions for fatigue in type 1 diabetes. 
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ABSTRACT
Objective: Severe fatigue is highly prevalent in various chronic diseases. Disease-specific 
fatigue models have been developed, but it is possible that fatigue-related factors in these 
models are similar across diseases. The purpose of the current study was to determine the 
amount of variance in fatigue severity explained by: (1) the specific disease, (2) factors 
associated with fatigue across different chronic diseases (transdiagnostic factors) and (3) 
the interactions between these factors and specific diseases. 
Methods: Data from 15 studies that included 1696 patients with common chronic diseases 
and disorders that cause long-term disabilities were analyzed. Linear regression analysis 
with the generalized least-squares technique was used to determine fatigue-related factors 
associated with fatigue severity, i.e., demographic variables, health-related symptoms and 
psychosocial variables.    
Results: Type of chronic disease explained 11% of the variance noted in fatigue severity. 
The explained variance increased to 55% when the transdiagnostic factors were added to 
the model. These factors were female sex, age, motivational and concentration problems, 
pain, sleep disturbances, physical functioning, reduced activity and lower self-efficacy 
concerning fatigue. The predicted variance increased to 61% when interaction terms were 
added. Analysis of the interactions revealed that the relationship between fatigue severity 
and relevant predictors mainly differed in strength, not in direction. 
Conclusions: Fatigue severity can largely be explained by transdiagnostic factors; the 
associations vary between chronic diseases in strength and significance. This suggests 
that severely fatigued patients with different chronic diseases can probably benefit from 
a transdiagnostic fatigue-approach which focuses on individual patient needs rather than 
a specific disease. 
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INTRODUCTION
Severe fatigue is highly prevalent in patients with chronic diseases and medical conditions 
that cause long-term disabilities, with prevalence rates varying from 40% to 74%.1-5 Several 
studies have shown that severely fatigued patients report more limitations in physical, 
social and mental functioning than those without severe fatigue as well as describing 
fatigue as one of the most debilitating symptoms of their disease.3,5-7
It has been suggested that fatigue in chronic disorders is a disease-specific symptom, with 
disease-specific somatic underlying processes. Hence, terms such as “post-stroke fatigue”, 
“multiple sclerosis fatigue”, or “rheumatoid arthritis fatigue” have been introduced. 
However, the relationship between fatigue and somatic processes associated with a 
specific disease, such as inflammation in rheumatoid arthritis4 or glycemic control in 
diabetes8 is often absent or weak. Studies of fatigue at the individual patient level have 
been more successful, investigating not only the fatigue’s relationship with somatic 
abnormalities, but also with patients’ behavior and other symptoms. This has led to several 
cognitive-behavioral—but still disease-specific—models of fatigue.9-11 Most models 
differentiate between factors that trigger fatigue, which is frequently a somatic process 
that is part of the disease, and factors that maintain or are associated with fatigue. It has 
been demonstrated that several factors such as demographic variables, health-related 
symptoms, psychosocial factors and aspects of patients’ daily functioning, are linked with 
or maintain fatigue. For example, age and sex are correlated with fatigue in patients with 
type 1 diabetes and neuromuscular diseases;3,5 depressive symptoms, sleep disturbances 
and pain have been found to be related to fatigue in patients with narcolepsy and 
rheumatoid arthritis;4,7 social and physical functioning are associated with fatigue in 
patients with Ehlers-Danlos syndrome;12 and concentration problems, reduced motivation 
and activity along with a low self-efficacy concerning fatigue are related to fatigue in 
patients with rheumatoid arthritis, narcolepsy and neuromuscular disorders.3,4,7,12
To date, studies have investigated fatigue and the factors associated with it in different 
chronic diseases, mostly treating both fatigue and such factors as disease-specific. 
However, it is potentially likely that factors linked with fatigue are generic and thus similar 
across diseases. Perhaps the prevalence of these factors varies between diseases, like 
depression, but the relationship with fatigue is most likely not dependent on the specific 
disease. If this is true, there are implications for both assessment and management of this 
highly prevalent and burdensome symptom. Thus far, most research has focused on the 
development of disease-specific fatigue treatments, such as cognitive behavioral therapy 
for patients with multiple sclerosis13 or aerobic exercise therapy for those with neuro- 
muscular disorders.14 However, if fatigue-related factors are the same across chronic 
diseases, it might be possible to generalize findings from one chronic disease to another. 
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Consequently, a transdiagnostic treatment for fatigue could be developed, defined as 
an approach where processes and factors are common across disorders,15 and hence 
interventions targeting these factors are similar across diseases. It would also imply that 
the pathophysiology of fatigue is not disease-specific, but that the (neuro)biological 
mechanisms underlying the perception of fatigue are a generic response to illness in a 
substantial subgroup of patients. 
To our knowledge, it has not been empirically tested to what extent fatigue severity in 
chronic diseases and disorders that cause long-term disabilities can be explained by  trans- 
diagnostic factors that are the same across various chronic diseases or whether fatigue is 
a unique or disease-specific symptom. As studies evaluating fatigue in chronic diseases so 
far have found a number of overlapping fatigue-related factors, we hypothesize that more 
variance in fatigue severity will be accounted for by transdiagnostic, non- disease- specific 
factors, such as sleep disturbances or self-efficacy concerning fatigue. The purpose of the 
present, explorative study was to re-analyze data of patients suffering from 15 common 
chronic diseases and disorders that cause long-term disabilities. We sought to demonstrate the 
extent to which variance in fatigue severity can be explained by: 1) the specific chronic 
disease; 2) non-disease-specific factors related to fatigue, irrespective of the specific chronic 
disease; and 3) interactions between non-disease-specific factors and type of illness. 
A significant interaction would indicate a variable strength and/or direction of the 
relationship between non-disease-specific factors and fatigue severity for one or more 
chronic diseases. A different direction of the effect in particular would suggest a disease- 
specific effect of the factor and therefore indicate that the studied factor does not have 
a transdiagnostic association with fatigue. The non-disease-specific factors studied were 
demographic variables, current health-related symptoms, aspects of daily functioning and 
cognitive-behavioral factors. 
METHODS
Study design, participants and selection of studies
Data from 15 cross-sectional studies involving patients with the following chronic diseases 
or medical disorders causing long-term disabilities were re-analyzed: 1) neuralgic amyo - 
trophy (NA);16 2) cerebrovascular accident (CVA);2 3) Ehlers-Danlos syndrome (EDS);12 
4) immunoglobulin deficiency (ID);17 5) narcolepsy type 1 (NC);7 6) chronic kidney disease 
(CKD); 7) renal transplantation (RT);18 8) chronic pancreatitis (CP); 9) primary Sjögren’s 
syndrome (pSS); 10) facioscapulohumeral muscular dystrophy (FSHD);3 11) adult-onset 
myotonic dystrophy (MD);3 12) hereditary motor and sensory neuropathy type 1 (HMSN-I);3 
13) multiple sclerosis (MS);1,19 14) rheumatoid arthritis (RA);4 and 15) type 1 diabetes mellitus 
(T1DM).5 
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In selecting the individual studies, we contacted as many authors as possible of which we 
knew had studied fatigue in chronic diseases with the Checklist Individual Strength (CIS) 
questionnaire.20 We chose only studies that assessed fatigue severity with the CIS and 
evaluated at least the following potential determinants: sex, age, concentration problems, 
reduced motivation and reduced activity. 
Of the 15 study cohorts, data from 11 studies was published. The data on CKD, CP, and pSS 
were collected, but was not previously published. The data on ID is also not yet published. 
A total of 1696 patients were included for the statistical analysis. The number of patients 
per study is listed in Table 1. For each study, patients were recruited from different universities 
and general hospitals in the Netherlands between 1999 and 2015. 
The medical ethical committee gave approval for each of the published studies or decided 
that the study did not fall under the remit of the Medical Research Involving Human 
Subjects policy. The same was true for the four unpublished studies—the study of 
Strik-Albers and colleagues (ID) was approved by the medical ethical committee; the 
studies of Goedendorp and colleagues (CKD) along with Bleijenberg and co-workers (CP 
and pSS) were remitted of judgment. The medical ethical committee also reviewed the 
present study and decided that no further judgment was necessary according to Dutch 
law, specifically the Medical Research Involving Human Subjects Act.  
Instruments
Demographic variables
Demographic variables were sex and age assessed by patient self-reporting.  
Fatigue severity
Fatigue severity was measured using the CIS questionnaire, in particular the fatigue 
severity subscale.20 The subscale consists of eight items, e.g., “I am feeling tired”. Each item 
is scored on a seven-point Likert scale ranging from one (“Yes, that is true”) to seven 
(“No, that is not true”). Scores on the questionnaire range from eight to 56, with higher 
scores indicating more fatigue severity. A score of 35 is used as a cut-off for severe fatigue. 
The CIS has been demonstrated to be a valid and reliable instrument.20
Concentration problems
Concentration problems were evaluated with the concentration subscale  of the CIS.20 
The scale is comprised of five items, e.g., “It takes a lot of effort to concentrate on things”; 
each item is scored on a Likert scale ranging from one (“Yes, that is true”) to seven (“No, 
that is not true”). Higher scores on this subscale indicate more concentration problems. 
The psychometric properties of the CIS subscale are robust.20
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Reduced motivation
Reduced motivation was assessed using the motivation subscale of the CIS,20 which 
consists of four items (e.g., “I do not feel like doing anything”) scored on a seven-point 
Likert scale ranging from one (“Yes, that is true”) to seven (“No, that is not true”). The 
validity and reliability of the CIS subscale are regarded as strong.20
Reduced activity
Reduced activity was determined using the activity subscale of the CIS.20 This subscale 
features of three items (e.g., “I think I do very little in a day”); each item is scored on a 
seven-point Likert scale ranging from one (“Yes, that is true”) to seven (“No, that is not 
true”). Once again, the CIS is considered a valid and reliable instrument.20 
Depressive symptoms
Depressive symptoms were established with the Beck Depression Inventory for Primary 
Care (BDI-PC)21 in 14 studies, and one study employed the Symptom Checklist (SCL-90), 
depression subscale.22 The BDI-PC is a widely used self-reporting questionnaire with 
robust psychometric properties.21 The questionnaire is comprised of seven items; each 
item is scored on a four-point Likert scale ranging from zero to three. The seven items deal 
with the symptoms of sadness, loss of pleasure, pessimism, past failure, self-dislike, self- 
criticalness and suicidal thoughts and wishes. Scores range from zero to 21 with scores of 
four and higher indicating clinically relevant depressive symptoms.21 Meanwhile, the 
SCL-90 is a multidimensional symptom checklist measuring psychological and physical 
symptoms. The depression subscale of the SCL-90 consists of 16 items (e.g., the symptom, 
“lack of motivation”), which are scored on a five-point scale from zero (“Not at all”) to four 
(“Extremely”) to reflect the extent to which the symptoms have been manifested. The 
scores range from 16 to 80. Higher scores suggest more severe depressive symptoms. 
A cut-off score of 29—the mean score plus one standard deviation from the normal 
population22—was utilized to indicate clinically relevant depressive symptoms. The SCL-90 has 
strong psychometric properties.22 To determine whether depressive symptoms predicted 
severe fatigue, the score of the BDI-PC and the depression subscale of the SCL-90 were 
transformed into a dichotomous variable to indicate the presence of depressive symptoms 
using the aforementioned cut-off scores (zero=no, one=yes). 
Sleep disturbances and disrupted sleep-wake pattern
Sleep disturbances and disrupted sleep-wake patterns were gauged using the Sickness 
Impact Profile-8 (SIP-8), specifically the sleep and rest subscale.23 The SIP-8 measures 
limitations in daily functioning across eight domains: sleep and rest, homemaking, 
mobility, social interactions, ambulation, leisure activities, alertness behavior and work 
limitations. The sleep and rest subscale consists of seven items (e.g., “I sleep or nap during 
the day”). The subject is asked to check only those items that are applicable to their health. 
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The checked items are added to a score ranging from zero to 499; a higher score indicates 
more sleep disturbances. As with the other scoring procedures in this study, the SIP-8 has 
high reliability and validity.23  
Pain
Pain and pain symptoms were evaluated by the Health Survey Short Form-36 (SF-36) 
questionnaire, in particular the bodily pain subscale.24 The SF-36 measures the health 
status across eight domains: vitality, physical functioning, bodily pain, general health 
perceptions, role limitations based on physical health problems, role limitations owing to 
emotional problems, social functioning and general mental health. The raw scale scores 
of the bodily pain subscale are transformed into one score ranging from zero to 100; a 
higher score indicates better functioning and accordingly less pain. The psychometric 
properties of the SF-36 are highly reliable.24 
Social functioning
Social functioning was assessed with the SF-36 questionnaire, specifically the social 
functioning subscale.24 The SF-36 evaluates the health status across eight domains, 
including social functioning. Scores on the social functioning subscale range from zero to 
100; a greater score on this subscale is demonstrative of better social functioning. The 
social functioning subscale of the SF-36 has documented validity and reliability.24 
Physical functioning 
Physical functioning was measured via the SF-36 questionnaire, physical functioning 
subscale.24 Scores from the physical functioning subscale range from zero to 100 with 
higher scores suggestive of a better physical functioning. As per the other subscales 
employed herein, the physical functioning subscale of the SF-36 has high validity and 
reliability.24
Self-efficacy concerning fatigue
Self-efficacy concerning fatigue relates to the patients’ confidence in coping with fatigue 
and was evaluated with the Self-Efficacy Scale (SES) for fatigue.25 The SES for fatigue is a 
seven-item questionnaire (e.g., “Do you think you can influence your fatigue?”); each item 
is scored on a four-point scale ranging from one (“No, I do not think so”) to four (“Yes, I do 
think so”). Scores ranged from seven to 28 with higher scores indicating more self-efficacy 
concerning fatigue. 
Assessment of risk of bias in the included studies
We rated the risk of bias for three biases that we thought to be the most important and 
common in cross-sectional studies: the selection of participants, the accuracy of the 
medical diagnosis and the sample size. Each potential bias was classified into a low risk, an 
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unclear risk and a high risk of bias. The potential risks were systematically gauged by two 
raters (JM, HK); agreement was reached through discussion. 
Selection of participants
In cross-sectional studies, potential selection biases can arise based on the procedure of 
selecting participants. We defined the risks of this bias as follows:
- Low risk: participants were selected by picking a random sample from a pool of eligible 
participants; all forms of systematically selecting participants;
- Unclear risk: insufficient information about the sample selection; and 
- High risk: the sample for the study was picked by convenience. 
Accuracy of medical diagnosis
The present paper included studies with patients that suffered from a medical condition. 
It may be possible that potential bias could have been present because of how the 
patients were included in these studies. 
- Low risk: a medical practitioner selected the participants; participants were chosen from an 
outpatient pool of a hospital; the medical diagnosis was tested by a medical practitioner;
- Unclear risk: insufficient information on how the patients were selected; and
- High risk: self-report scale; patients were selected from a patient organization. 
Sample size 
A small sample size could be cause of a potential bias. We defined the risk of this bias as 
follows:
- Low risk: >100 participants;
- Unclear risk: 50-99 participants; and
- High risk: <50 participants. 
Statistical analysis
Statistical analysis was performed using IBM’s Statistical Package for the Social Sciences 
(SPSS) Version 22.0.26 Descriptive statistics with means and their standard deviations or 
frequencies and percentages were reported. Linear regression analysis with the generalized 
least-squares (GLS) technique with fatigue severity as the dependent variable was employed 
to test which factors were significantly related to fatigue severity. As fixed effects, the 
following independent variables were entered: chronic disease (1=NA, 2=CVA, 3=EDS, 
4=ID, 5=NC, 6=CKD, 7=RT, 8=CP, 9=pSS, 10=FSHD, 11=MD, 12=HMSN-I, 13=MS, 14=RA, 
15=T1DM), age, sex, concentration problems, reduced motivation, reduced activity, 
depressive symptoms, pain, sleep disturbances, social functioning, physical functioning 
and self-efficacy concerning fatigue, and the interactions between these variables and 
each chronic disease. Missing values were not replaced. A stepwise procedure was used 
to analyze the explained variance (R2) of fatigue severity explained by: (1) the main effect 
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of chronic disease; (2) the main effects of the chronic disease and other independent 
variables; and (3) the main effects plus the interaction effects between the chronic disease 
and the independent variables. Significant main effects indicated an overall effect of the 
independent variables on fatigue severity across all chronic diseases. Significant interaction 
effects suggested that the relationship between fatigue severity and the independent 
variables differed between chronic diseases. To interpret significant interactions, the size 
and direction of the estimates and their 95% confidence intervals (CI) for each chronic 
disease were calculated and plotted. Plots were visually inspected to aid interpretation. 
As not all studies assessed all potential fatigue-related factors, the stepwise procedure 
was executed for five different fatigue models: model one (15 chronic diseases and seven 
independent variables), model two (13 chronic diseases and eight independent variables), 
model three (11 chronic diseases and eight independent variables), model four (11 chronic 
diseases and 10 independent variables) and model five (nine chronic diseases and nine 
independent variables). A detailed overview of the fatigue-related factors assessed in 
each study is provided in Table 1. P-values were considered to be significant at p<0.05. 
As this study had an explorative character, correcting the p-level for multiple testing was 
purposely refrained from.  
RESULTS
Demographic characteristics and prevalence of severe fatigue
The mean age of the sample was 48.3 years (SD=13.7) and 947 patients (56%) were female. 
More than half of the patients (57%) reported fatigue scores above the cut-off for severe 
fatigue. Prevalence rates of severe fatigue varied between chronic diseases from 39% to 
77%. Table 1 presents an overview of the age, sex, mean fatigue severity score and the 
number of severely fatigued patients for each chronic disease.  
Effect of chronic fatigue and potential fatigue-related factors on  
fatigue severity 
In the first step of the fatigue model with the largest number of cases, chronic disease 
[F(14,126.82)=15.61, p<0.001] was found as a significant predictor of fatigue severity (Table 2). 
The explained variance was 11%. The effect and explained variance of chronic fatigue in 
the other fatigue models was similar and can be reviewed in Tables 1.1 to 1.4 in the 
Appendix. When adding the other potential fatigue-related factors in a second step to 
the fatigue model,  the explained variance rose to 55%. Chronic disease still significantly 
predicted fatigue severity [F(14,154.39)=13.68, p<0.001], however the impact of chronic 
disease was less strong compared to step 1 as can be inferred from Figure 1. In Figure 1, 
the mean value of fatigue severity and its 95% CIs for each chronic disease is displayed for 
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Table 1   Overview of the 15 included cohorts (n=1696)
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Van Alfen  
et al. 
neuralgic 
amyotrophy (NA)
87 patients with the diagnosis of 
NA were included. Patients were 
recruited from the outpatient clinic 
of one university medical center.
The objective of this study was to 
investigate the prevalence of fatigue 
and pain, and to describe the 
severity of psychological symptoms, 
the functional status and quality of 
life in patients with NA.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
· Depressive symptoms (yes/no)
· Pain
· Social functioning
· Physical functioning
33 (38%) 44.7 (13.8) 29.6 (14.2) 40 (30 to 51)
Van der Werf  
et al. 
cerebrovascular 
accident (CVA)
74 patients with the diagnosis of a 
CVA one year before the start of the 
study were included. The patients 
were recruited from a stroke 
database of one teaching hospital.
The purpose of this study was to 
investigate the prevalence of severe 
fatigue after a CVA had occurred. In 
addition, the relationship between 
fatigue and levels of physical 
impairment and depression was 
studied. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Sleep disturbances
20 (27%) 61.5 (8.8) 35.2 (14.7) 58 (47 to 70)
Voermans  
et al. 
Ehlers-Danlos 
syndrom (EDS)
273 patients with EDS were 
included. Patients were recruited 
from a Dutch EDS patient 
organization and the outpatient 
clinic from one university medical 
center. 
The objective of this study was 
to investigate the prevalence of 
fatigue in EDS, as well as its clinical 
relevance and association with 
potential variables.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
244 (89%),  
2 missing
40.7 (12.7) 41.7 (11.3) 77 (73 to 82)
Strik-Albers  
et al.* 
immunoglobulin 
deficiency (ID)
43 patients with ID were included. 
Patients were recruited from the 
Expert Center for Immunodeficiency 
and Autoinflammation from one 
university medical center. 
The objective of this study was to 
investigate the prevalence and 
associated factors of fatigue in 
patients with ID.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
18 (42%) 45.1 (15.3) 32.3 (12.0) 51 (38 to 70),  
2 missing
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Table 1   Overview of the 15 included cohorts (n=1696)
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Van Alfen  
et al. 
neuralgic 
amyotrophy (NA)
87 patients with the diagnosis of 
NA were included. Patients were 
recruited from the outpatient clinic 
of one university medical center.
The objective of this study was to 
investigate the prevalence of fatigue 
and pain, and to describe the 
severity of psychological symptoms, 
the functional status and quality of 
life in patients with NA.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
· Depressive symptoms (yes/no)
· Pain
· Social functioning
· Physical functioning
33 (38%) 44.7 (13.8) 29.6 (14.2) 40 (30 to 51)
Van der Werf  
et al. 
cerebrovascular 
accident (CVA)
74 patients with the diagnosis of a 
CVA one year before the start of the 
study were included. The patients 
were recruited from a stroke 
database of one teaching hospital.
The purpose of this study was to 
investigate the prevalence of severe 
fatigue after a CVA had occurred. In 
addition, the relationship between 
fatigue and levels of physical 
impairment and depression was 
studied. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Sleep disturbances
20 (27%) 61.5 (8.8) 35.2 (14.7) 58 (47 to 70)
Voermans  
et al. 
Ehlers-Danlos 
syndrom (EDS)
273 patients with EDS were 
included. Patients were recruited 
from a Dutch EDS patient 
organization and the outpatient 
clinic from one university medical 
center. 
The objective of this study was 
to investigate the prevalence of 
fatigue in EDS, as well as its clinical 
relevance and association with 
potential variables.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
244 (89%),  
2 missing
40.7 (12.7) 41.7 (11.3) 77 (73 to 82)
Strik-Albers  
et al.* 
immunoglobulin 
deficiency (ID)
43 patients with ID were included. 
Patients were recruited from the 
Expert Center for Immunodeficiency 
and Autoinflammation from one 
university medical center. 
The objective of this study was to 
investigate the prevalence and 
associated factors of fatigue in 
patients with ID.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
18 (42%) 45.1 (15.3) 32.3 (12.0) 51 (38 to 70),  
2 missing
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Table 1   Continued
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Droogleever 
Fortuyn et al. 
narcolepsy type 
1 (NC)
80 patients under active treatment 
for NC were included. The patients 
were recruited from one university 
medical center.  
The objective of this study was 
to determine the prevalence of 
severe fatigue in patients with NC, 
as well as to study its association 
with excessive daytime sleepiness, 
psychological distress, functional 
impairment and quality of life. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
46 (58%) 48.3 (14.7) 38.9 (11.6) 63 (52 to 73)
Goedendorp 
et al.* 
chronic kidney 
disease (CKD)
137 patients with the diagnosis 
CKD were included. The patients 
were recruited from one university 
medical center. 
The purpose of this study was to 
investigate the prevalence of severe 
fatigue in patients with CKD, as 
well as the impact of severe fatigue 
on daily functioning. In addition, 
potential associations of severe 
fatigue were studied.  
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
57 (42%) 54.3 (11.6) 37.4 (13.4) 61 (53 to 70),  
2 missing
Goedendorp 
et al. 
renal 
transplantation 
(RT)
180 patients who underwent  
a renal transplantation were 
included. The patients were 
recruited from one university 
medical center.
The objective of this study was 
to determine the prevalence, 
impact and associated  factors 
of severe fatigue in patients with 
a RT. The latter were specific 
transplantation-related factors and 
nonspecific somatic, behavioral and 
psychosocial factors.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
61 (34%) 54.1 (12.4) 28.8 (14.8) 39 (32 to 46),  
1 missing
Bleijenberg 
et al.*
chronic 
pancreatitis (CP)
61 patients with CP were included. 
The patients were recruited from a 
Dutch CP patient organization.
The objective of this study was to 
investigate the prevalence and 
potential associated factors of 
severe fatigue in CP. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
29 (48%) 51.5 (11.0) 40.3 (12.6) 72 (62 to 85),  
1 missing
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Table 1   Continued
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Droogleever 
Fortuyn et al. 
narcolepsy type 
1 (NC)
80 patients under active treatment 
for NC were included. The patients 
were recruited from one university 
medical center.  
The objective of this study was 
to determine the prevalence of 
severe fatigue in patients with NC, 
as well as to study its association 
with excessive daytime sleepiness, 
psychological distress, functional 
impairment and quality of life. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
46 (58%) 48.3 (14.7) 38.9 (11.6) 63 (52 to 73)
Goedendorp 
et al.* 
chronic kidney 
disease (CKD)
137 patients with the diagnosis 
CKD were included. The patients 
were recruited from one university 
medical center. 
The purpose of this study was to 
investigate the prevalence of severe 
fatigue in patients with CKD, as 
well as the impact of severe fatigue 
on daily functioning. In addition, 
potential associations of severe 
fatigue were studied.  
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
57 (42%) 54.3 (11.6) 37.4 (13.4) 61 (53 to 70),  
2 missing
Goedendorp 
et al. 
renal 
transplantation 
(RT)
180 patients who underwent  
a renal transplantation were 
included. The patients were 
recruited from one university 
medical center.
The objective of this study was 
to determine the prevalence, 
impact and associated  factors 
of severe fatigue in patients with 
a RT. The latter were specific 
transplantation-related factors and 
nonspecific somatic, behavioral and 
psychosocial factors.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
61 (34%) 54.1 (12.4) 28.8 (14.8) 39 (32 to 46),  
1 missing
Bleijenberg 
et al.*
chronic 
pancreatitis (CP)
61 patients with CP were included. 
The patients were recruited from a 
Dutch CP patient organization.
The objective of this study was to 
investigate the prevalence and 
potential associated factors of 
severe fatigue in CP. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
29 (48%) 51.5 (11.0) 40.3 (12.6) 72 (62 to 85),  
1 missing
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Table 1   Continued
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Bleijenberg  
et al.*
primary Sjögren’s 
syndrome (pSS)
31 patients with the diagnosis 
pSS were included. The patients 
were recruited from one university 
medical center. 
The objective of this study was to 
gain more knowledge about the 
characteristics of severely fatigued 
patients with pSS. In addition, 
potential psychosocial factors 
associated with fatigue were 
studied. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Self-efficacy concerning fatigue
28 (90%) 50.5 (15.8) 38.1 (12.8) 68 (50 to 85)
Kalkman  
et al. 
facioscapulo - 
humeral muscular 
dystrophy (FSHD)
65 patients with the diagnosis 
of FSHD were included. The 
patients were recruited from 
the Neuromuscular Center of 
one university medical center. In 
addition, patients were recruited 
from a Dutch Neuromuscular 
Diseases Association.
The objective of this study was to 
investigate the prevalence and 
impact on functional impairment in 
daily life in patients with relatively 
common types of neuromuscular 
disorders. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
27 (42%) 43.1 (10.3) 36.1 (11.9) 62 (49 to 74)
Kalkman  
et al. 
adult-onset 
myotonic 
dystrophy (MD)
79 patients with the diagnosis 
of MD were included. The 
patients were recruited from 
the Neuromuscular Center of 
one university medical center. In 
addition, patients were recruited 
from a Dutch Neuromuscular 
Diseases Association.
The objective of this study was to 
investigate the prevalence and 
impact on functional impairment in 
daily life in patients with relatively 
common types of neuromuscular 
disorders.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
35 (44%) 41.0 (9.9) 38.7 (11.2) 66 (55 to 77)
Kalkman  
et al. 
hereditary motor 
and sensory 
neuropathy type 1 
(HMSN-I)
73 patients with the diagnosis 
of HMSN-I were included. The 
patients were recruited from 
the Neuromuscular Center of 
one university medical center. In 
addition, patients were recruited 
from a Dutch Neuromuscular 
Diseases Association.
The objective of this study was to 
investigate the prevalence and 
impact on functional impairment in 
daily life in patients with relatively 
common types of neuromuscular 
disorders.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
43 (59%) 42.4 (9.8) 38.1 (11.9) 66 (55 to 77)
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Table 1   Continued
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Bleijenberg  
et al.*
primary Sjögren’s 
syndrome (pSS)
31 patients with the diagnosis 
pSS were included. The patients 
were recruited from one university 
medical center. 
The objective of this study was to 
gain more knowledge about the 
characteristics of severely fatigued 
patients with pSS. In addition, 
potential psychosocial factors 
associated with fatigue were 
studied. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Self-efficacy concerning fatigue
28 (90%) 50.5 (15.8) 38.1 (12.8) 68 (50 to 85)
Kalkman  
et al. 
facioscapulo - 
humeral muscular 
dystrophy (FSHD)
65 patients with the diagnosis 
of FSHD were included. The 
patients were recruited from 
the Neuromuscular Center of 
one university medical center. In 
addition, patients were recruited 
from a Dutch Neuromuscular 
Diseases Association.
The objective of this study was to 
investigate the prevalence and 
impact on functional impairment in 
daily life in patients with relatively 
common types of neuromuscular 
disorders. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
27 (42%) 43.1 (10.3) 36.1 (11.9) 62 (49 to 74)
Kalkman  
et al. 
adult-onset 
myotonic 
dystrophy (MD)
79 patients with the diagnosis 
of MD were included. The 
patients were recruited from 
the Neuromuscular Center of 
one university medical center. In 
addition, patients were recruited 
from a Dutch Neuromuscular 
Diseases Association.
The objective of this study was to 
investigate the prevalence and 
impact on functional impairment in 
daily life in patients with relatively 
common types of neuromuscular 
disorders.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
35 (44%) 41.0 (9.9) 38.7 (11.2) 66 (55 to 77)
Kalkman  
et al. 
hereditary motor 
and sensory 
neuropathy type 1 
(HMSN-I)
73 patients with the diagnosis 
of HMSN-I were included. The 
patients were recruited from 
the Neuromuscular Center of 
one university medical center. In 
addition, patients were recruited 
from a Dutch Neuromuscular 
Diseases Association.
The objective of this study was to 
investigate the prevalence and 
impact on functional impairment in 
daily life in patients with relatively 
common types of neuromuscular 
disorders.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Sleep disturbances
· Self-efficacy concerning fatigue
43 (59%) 42.4 (9.8) 38.1 (11.9) 66 (55 to 77)
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Table 1   Continued
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Van der Werf  
et al. & 
Vercoulen  
et al. 
multiple sclerosis 
(MS)
71 patients with the diagnosis MS 
were included. For the present 
study, data from two studies were 
combined that both studied fatigue 
in MS. The patients were recruited 
from one university medical center. 
· The objective of the study of Van 
der Werf and colleagues was to 
investigate the potential cerebral 
abnormalities in fatigued patients 
with MS.
· The objective of the study of 
Vercoulen and colleagues was to 
investigate the multidimensional 
character of fatigue in patients  
with MS.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Sleep disturbances
48 (68%) 36.7 (8.7) 40.8 (12.2) 73 (63 to 84)
Van Hoogmoed 
et al. 
rheumatoid 
arthritis (RA)
228 patients with the diagnosis 
of RA were included. The patients 
were recruited from the outpatient 
rheumatology clinic of one 
university medical center.
The objective of this study was 
to determine the prevalence of 
severe fatigue in patients with RA. 
In addition, the patients’ perception 
of fatigue and potential associated 
factors of fatigue were determined.
· Sex
· Age
· Concentration problems
· Reduced motivation
·  Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Self-efficacy concerning fatigue
144 (63%) 55.9 (10.8) 31.5 (12.8) 42 (36 to 49)
Goedendorp 
et al. 
type 1 diabetes 
(T1DM)
214 patients with the diagnosis 
of type 1 diabetes were included. 
The patients were recruited from 
a diabetes clinic of one university 
medical center.
The objective of this study was to 
investigate the prevalence and 
impact of severe fatigue in patients 
with type 1 diabetes. In addition, 
potential determinants of fatigue 
were studied. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Sleep disturbances
· Self-efficacy concerning fatigue
114 (53%) 48.0 (13.0) 30.9 (14.4) 44 (38 to 51)
Note.*not (yet) published; sd=standard deviation. 
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Table 1   Continued
Author Chronic disease Study population & setting Objective of the study Potential associated factors Female sex 
(%)
Mean age 
(SD)
Mean CIS 
 fatigue severity 
(SD)
Percentage of 
severely fatigued 
patients (95% CI)
Van der Werf  
et al. & 
Vercoulen  
et al. 
multiple sclerosis 
(MS)
71 patients with the diagnosis MS 
were included. For the present 
study, data from two studies were 
combined that both studied fatigue 
in MS. The patients were recruited 
from one university medical center. 
· The objective of the study of Van 
der Werf and colleagues was to 
investigate the potential cerebral 
abnormalities in fatigued patients 
with MS.
· The objective of the study of 
Vercoulen and colleagues was to 
investigate the multidimensional 
character of fatigue in patients  
with MS.
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Sleep disturbances
48 (68%) 36.7 (8.7) 40.8 (12.2) 73 (63 to 84)
Van Hoogmoed 
et al. 
rheumatoid 
arthritis (RA)
228 patients with the diagnosis 
of RA were included. The patients 
were recruited from the outpatient 
rheumatology clinic of one 
university medical center.
The objective of this study was 
to determine the prevalence of 
severe fatigue in patients with RA. 
In addition, the patients’ perception 
of fatigue and potential associated 
factors of fatigue were determined.
· Sex
· Age
· Concentration problems
· Reduced motivation
·  Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Social functioning
· Physical functioning
· Self-efficacy concerning fatigue
144 (63%) 55.9 (10.8) 31.5 (12.8) 42 (36 to 49)
Goedendorp 
et al. 
type 1 diabetes 
(T1DM)
214 patients with the diagnosis 
of type 1 diabetes were included. 
The patients were recruited from 
a diabetes clinic of one university 
medical center.
The objective of this study was to 
investigate the prevalence and 
impact of severe fatigue in patients 
with type 1 diabetes. In addition, 
potential determinants of fatigue 
were studied. 
· Sex
· Age
· Concentration problems
· Reduced motivation
· Reduced activity
·  Depressive symptoms 
(continuous variable)
· Pain
· Sleep disturbances
· Self-efficacy concerning fatigue
114 (53%) 48.0 (13.0) 30.9 (14.4) 44 (38 to 51)
Note.*not (yet) published; sd=standard deviation. 
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step 1 and step 2. In step 2, the value is adjusted for chronic disease and the other fatigue- 
related factors. It is apparent that the mean values of fatigue severity are more similar for 
the chronic diseases and their 95% CIs are decreased in the second step. This suggests 
that the effect of chronic disease becomes smaller when adding transdiagnostic factors 
to the model. 
We report the potential transdiagnostic factors that are significantly related to fatigue 
severity and thus are similar across all chronic diseases. When the effects were significant 
in multiple fatigue-models, the effect of the model with the highest number of cases is 
reported. The effects of fatigue model one can be found in Table 2 and the effects of 
models two to five are located in Tables 1.1 to 1.4 in the Appendix. Concentration problems 
[F(1,1542.01)=105.63, p<0.001], motivational problems [F(1,1509.38)=180.25, p<0.001] and 
reduced activity [F(1,1554.97)=269.19, p<0.001] were observed as significant predictors 
Figure 1   Adjusted mean scores and their 95% CIs for fatigue severity for each  
chronic diseases in step one and step two of the fatigue model
Note. Step one: only chronic disease as independent variable; step two: chronic disease and transdiagnostic 
factors as independent variables. NA=neuralgic amyotrophy, CVA=cerebrovascular accident, EDS=Ehlers-Danlos 
syndrome, ID=immunoglobulin deficiency, NC=narcolepsy type 1, CKD=chronic kidney disease, RT=renal trans-
plantation, CP=chronic pancreatitis, pSS=primary Sjögren’s syndrome, FSHD=facioscapulohumeral muscular 
dystrophy, MD=adult-onset myotonic dystrophy, HMSN=hereditary motor and sensory neuropathy type 1, 
MS=multiple sclerosis, RA=rheumatoid arthritis, T1DM=type 1 diabetes mellitus.
Adjusted mean scores and their 95% CIs for fatigue severity 
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Figure 2   Standardized estimates and 95% CIs of the significant interaction effects  
for each predictor
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Figure 2   Continued
Note. NA=neuralgic amyotrophy, CVA=cerebrovascular accident, EDS=Ehlers-Danlos syndrome, ID=immuno-
globulin deficiency, NC=narcolepsy type 1, CKD=chronic kidney disease, RT=renal transplantation, CP=chronic 
pancreatitis, pSS=primary Sjögren’s syndrome, FSHD=facioscapulohumeral muscular dystrophy, MD=adult-onset 
myotonic dystrophy, HMSN=hereditary motor and sensory neuropathy type 1, MS=multiple sclerosis, RA=rheumatoid 
arthritis, T1DM=type 1 diabetes mellitus.
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of fatigue severity. Both pain [F(1,1385.90)=182.76, p<0.001] and sleep disturbances 
[F(1,1074.85)=77.32, p<0.001] predicted fatigue severity. For each of these factors, a more 
problematic score was associated with more fatigue severity. Also social functioning 
[F(1,1101.74)=7.52, p=0.006], physical functioning [F(1,1153.72)=51.05, p<0.001] and self- 
efficacy concerning fatigue [F(1,911.63)=90.34, p<0.001] predicted fatigue severity. Here, 
lower social functioning, physical functioning and self-efficacy concerning fatigue were 
related to a higher fatigue severity. Being younger [F(1,1371.46)=23.40, p<0.001] was 
associated with higher fatigue severity, and in most models, female sex [F(1,1384.02)=17.27, 
p<0.001] was associated with being more severely fatigued. Depressive symptoms 
evaluated with the dichotomous variable (“yes/no”) predicted fatigue severity in model 
one [F(1,1402.69)=7.14, p=0.008], but not in model two. Depressive symptoms assessed via 
the BDI-PC questionnaire predicted fatigue severity in model five [F(1,191.06)=5.00, 
p=0.027], but not in models three or four. 
Effect of significant interaction effects between chronic diseases and 
fatigue-related factors on fatigue severity 
By adding the interaction effects between chronic diseases and fatigue-related factors in 
the third step of the model, the explained variance increased slightly to 61%. In eight out 
of the 12 potential fatigue-related factors, an interaction effect was found, which indicated 
differences in the predictive value of these variables on fatigue severity between chronic 
diseases. Figure 2 depicts the estimates and their 95% CIs of the significant interaction 
effects. It is clear that associations of sex and age with fatigue severity were significant for 
less than half of the chronic diseases. Sex was related to fatigue severity in patients with 
FSHD, T1DM and pSS. With these three diseases, being female was associated with being 
more fatigued. In five out of 15 diseases, being younger was associated with greater 
severity of fatigue. These associations were determined in patients with RT, T1DM, RA, 
CP and ID. In the majority of diseases, pain was significantly related to fatigue severity. 
There was a clear trend indicating that more pain was associated with more severe fatigue. 
The same was true for concentration problems with the majority of diseases. In half of the 
chronic diseases, lower levels of physical functioning as well as reduced physical activity 
were associated with fatigue severity. In all of these chronic diseases, reduced activity was 
associated with being more fatigued. In approximately half of the diseases, both sleep 
disturbances and self-efficacy concerning fatigue were related to fatigue severity. More 
sleep disturbances were associated with being more severely fatigued in patients with 
MS, HMSN-I, EDS, T1DM, RT and CKD. Lower self-efficacy concerning fatigue was connected 
with more severe fatigue in patients with EDS, RA, T1DM and HMSN-I.
Risk of bias in included studies
Table 2 in the Appendix outlines the risk of the three biases for each individual study.  
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Selection of participants
Two studies were rated to be of low risk; they systematically selected a random pool of 
potential participants for their study. Twelve studies determined to have an unclear bias 
risk as it was not apparent whether the selection of participants was random or not. 
One study established to have a high bias risk. In this study, a select group of participants 
of a Dutch patient organization was chosen. 
Accuracy of medical diagnosis
Ten studies were rated to be of low risk as they featured patients from an outpatient clinic 
datapool and/or medical practitioners had screened patients based on medical diagnosis. 
Three studies were rated to be of unclear bias risk and two studies were rated to be of 
high risk. The latter included patients from a patient organization that had not verified 
the medical diagnoses. 
Sample size 
Five studies included more than 100 patients and were rated as having a low risk of bias. 
Eight studies were rated to feature an unclear risk of bias as they included between 55 and 
99 participants. Two studies were rated to have a high risk of bias; they included 43 and 31 
patients.  
DISCUSSION
To our knowledge, the present study of 15 common chronic diseases and disorders that 
cause long-term disabilities is one of the first to determine to what extent the variance in 
terms of fatigue severity can be explained by a chronic disease, transdiagnostic factors 
across different diseases and interactions between the chronic disease and those factors. 
We determined that the type of chronic disease accounted for only 11% of the variance 
with respect to fatigue severity, while this variance increased to 55% when accounting 
for transdiagnostic factors, such as reduced motivation, pain, limitations in physical 
functioning, concentration problems, lower levels of activity, sleep disturbances and self- 
efficacy concerning fatigue. Analysis of the interaction effects between transdiagnostic 
factors and the particular chronic disease revealed that the explained variance increased 
slightly (6%), and the direction of the relationship between these factors and fatigue 
severity was the same for nearly all chronic diseases. The fact that in certain chronic diseases, 
these relationships failed to reach significance, is probably at least partly attributable to 
the limited sample size of certain studies. However, the significant interaction effects 
reflect that future studies should also investigate disease-specific and patient-specific 
factors concerning fatigue.   
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Our findings might have implications for both the understanding and management of 
fatigue. It is possible that the study of fatigue in chronic diseases does not require disease- 
specific approaches, such as those suggested in the recent literature,9-11 but rather a 
 transdiagnostic approach focusing on the identification of relevant fatigue-related factors. 
The identification of these transdiagnostic fatigue-related factors could assist in the 
development of interventions for severe fatigue. The work we have presented here has 
identified several of these factors, though future studies are necessary to discern more 
factors and generalize findings to other chronic diseases. 
Pain severity was found to be positively associated with fatigue severity in all but three 
chronic diseases. The studies in our analysis were cross-sectional, which does not allow us 
to draw any firm conclusions about the causal relationship between pain and fatigue. 
However, recent literature has found pain to be a perpetuating factor of fatigue in chronic 
diseases,27,28 and a randomized controlled trial for patients with RA was effective in 
reducing pain and fatigue.29 This suggests that the management of pain as a perpetuating 
factor of fatigue could have positive impacts on the reduction of fatigue severity. More 
concentration problems along with reduced activity and physical functioning were 
significantly positively associated with fatigue severity in more than half of the chronic 
diseases of this study. With this, previous work has demonstrated the pertinence of these 
factors to the management of fatigue. For example, lower levels of physical activity have 
been observed as a perpetuating factor of fatigue severity in neuromuscular disorders.28 
The present study also showed that sleep disturbances and self-efficacy concerning 
fatigue were correlated to fatigue severity in about half of the chronic diseases reviewed. 
A more disturbed sleep was linked with more severe fatigue with remarkably large effects 
in patients with MS. This is in accordance with findings of MS-fatigue models that have 
uncovered sleep disturbances as the largest contributor to fatigue severity in MS.30 
The significant relationship between self-efficacy and fatigue severity was negative with 
lower self-efficacy scores related to higher fatigue severity scores. The role of a low 
self-efficacy, or “the sense of control over symptoms”, as a predictor of fatigue has been 
found in previous prospective studies in patients with chronic fatigue syndrome and 
MS,31-33 which suggests that patients can benefit from fatigue interventions that address 
self-efficacy concerning fatigue.   
There were also factors that were not or inconsistently associated with fatigue severity. 
Depressive symptoms were significantly related to fatigue in only half of the tested fatigue 
models. This is surprising, because most previous research in chronic diseases has 
established a positive association between fatigue and depressive symptoms, for example 
in patients with T1DM5 or RA.4 A potential explanation for these inconsistent findings in our 
study could be that, in the context of other variables that were added to the models, 
depressive symptoms did not remain significant in the fatigue models. Additionally, the 
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mean prevalence of patients with clinically relevant levels of depression is relatively low in 
our group with 15% (ranging 14% to 17%), which could have made it difficult to determine 
significant connections with fatigue severity. 
Female sex was associated with fatigue severity in only three chronic diseases: T1DM, 
FSHD and pSS. While in the case of pSS this could be explained by the high number of 
female patients in the study (90%), this is not true for T1DM and FSHD, where there is no 
clear explanation for this relationship. As most chronic diseases are progressive and with 
the number of co-morbidities or complications tending to rise with age,34 one might 
expect older age to be associated with fatigue severity, but, in fact, we found the opposite. 
Younger age was correlated with fatigue severity in four chronic diseases. One reason 
could be that younger people face more challenges in daily life with regards to careers or 
families.35 More research investigating the relationship between age and fatigue is 
required. 
Except for demographic factors, the aforementioned factors associated with fatigue 
severity can be addressed in behavioral interventions. Several studies have explored the 
effectiveness of such interventions in specific chronic diseases13,14,29,36,37 observing that 
cognitive behavioral therapy or exercise therapy that addressed factors such as sleep 
disturbances, physical inactivity or self-efficacy were effective in reducing fatigue. As our 
findings intimate, a large amount of fatigue severity can be understood through similar 
fatigue-related factors, and interventions aimed at reducing fatigue might be transdiag-
nostic. This could encourage the formulation of a generic fatigue model as a starting 
point for the development of fatigue interventions across various chronic diseases. It 
would also imply that results of fatigue research in one chronic disease could be transferred 
or generalized to other chronic diseases more easily.  
The factors established in our study differed in terms of the significance and strength of 
their relationship with fatigue. Therefore, interventions would probably benefit when 
tailoring them to patients’ needs, and it might be the case that tailored interventions are 
indeed effective. Recent studies with tailored interventions in patients with T1DM36 and 
cancer survivors38,39 proven them to be efficacious. In line with the findings of the present 
study, it seems that fatigue models and, consequently, treatments should focus on the 
transdiagnostic factors of fatigue, but also on the individual needs of patients; additional 
future research is needed to confirm this. 
The overall risk of bias of the included studies, especially with respect to the selection of 
participants bias, was rated as an unclear risk. The possibility of bias in the included studies 
should be recognized when interpreting our results. It should also be noted that we did 
not perform a systematic selection of the studies, but chose studies because we knew of 
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authors that investigated fatigue in chronic diseases with the same fatigue questionnaire, 
the CIS. In addition, we only included studies that addressed at least five potential trans-
diagnostic factors in order to perform a meaningful data analysis. In conclusion, the risk 
of convenience sampling might be present and should be taken into account in the 
interpretation of the findings we have presented herein. 
As a consequence of the exploratory character of the present study, it was only possible 
to include variables and instruments that were overlapping between the 15 cross-sectional 
studies. As such, the present study focused on a limited number of fatigue-related factors; 
other potentially relevant factors, e.g., fear of disease progression40 or illness acceptance41 
were not included. In future work, it would be interesting to look at the role of other potential 
covariates, like, for example demographic variables like the marital status or ethnicity, 
or the level of disabilities, as well as to conduct more specific analyses to unravel the 
potentially mediating associations between those factors and fatigue. The limited number 
of overlapping measures was also the reason why we decided to create a dichotomous 
measure of depression using the cut-off scores of two measures—the BDI-PC and SCL-90. 
This procedure has been followed previous,42 but should be interpreted with caution as 
no validity or reliability measures are available. In a future study, it would be important to 
demonstrate the psychometric properties of this technique when measuring depression. 
The small sample size of certain included studies—the sample sizes varied from 31 to 273 
patients—introduced a risk of bias and is another limitation of our study as it could have 
influenced the range and interpretability of the estimates and their CIs. Therefore, we cannot 
rule out that factors were not significantly different in a number of chronic diseases based 
on the lack of power. To exclude this possibility, it would be beneficial to replicate the present 
analysis with larger sample sizes. Based on the heterogeneity of the dataset, one should 
be careful in generalizing the findings from our work; however, the wide range of chronic 
diseases included in the present analysis strengthens our conclusion that fatigue seems 
to be a symptom with congruous characteristics as the transdiagnostic factors exhibited 
large overlap between chronic diseases. Another important issue to consider is the use of 
the CIS questionnaire in assessing three fatigue-related factors: concentration problems, 
reduced motivation and reduced activity. It could be that the subscales of the CIS are 
correlated with each other and fatigue severity, which may have affected the significance 
of other tested fatigue-related factors. Based on the use of the fatigue severity subscale of 
the CIS as a dependent variable, we were unable to study the potential differences between 
chronic diseases with respect to other dimensions of fatigue, e.g., post-exertional or mental 
fatigue. It seems critical that future studies take into account these different fatigue aspects 
regarding differences between chronic diseases. 
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Although the present study has limitations, it is one of the first studies to combine fatigue 
data from a large number of common chronic diseases to evaluate whether there are 
variables that are related to fatigue severity across diseases. The results showed that 
fatigue severity can largely be explained by transdiagnostic factors. Our findings suggest 
that future studies investigating fatigue models and management approaches should 
focus on transdiagnostic fatigue-related factors, but also involve individual characteristics 
and patient needs. 
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SUMMARY
This thesis reports on chronic fatigue in type 1 diabetes, from its predictors and associated 
factors to its efficacy of treatment. Below, we present a summary of the main findings of 
the studies conducted for this thesis.
In a 2014 cross-sectional study, we showed that chronic fatigue is a prevalent and disabling 
symptom in type 1 diabetes. This finding was the starting point for the research presented 
in this thesis. Despite the high prevalence and disturbing character of chronic fatigue in 
type 1 diabetes, few (high-quality) studies have been conducted in this area. Chapter 1 
reviews the existing literature on chronic fatigue in type 1 diabetes, and provides an outline 
of this thesis.
First, in a prospective study, we explored the course and predictors of severe fatigue in a 
sample of patients with type 1 diabetes. We studied health-related and cognitive-behavioral 
factors as potential predictors, as well as was the relationship between HbA1c and severe 
fatigue over time in two sub-groups (i.e., patients with suboptimal and with optimal 
glycemic control) studied. In Chapter 2, we present the results of this study. We found that 
after a mean follow-up of 3.5 years, severe fatigue persisted in three out of four severely 
fatigued patients. Predictors of severe fatigue at follow-up were depressive symptoms, 
pain, sleep disturbances, a low self-efficacy concerning fatigue, low confidence in diabetes 
self-care, more severe fatigue at baseline, and more diabetes-related complications. HbA1c 
at baseline was positively associated with fatigue severity at follow-up in both sub-groups, 
but this relationship was weak and HbA1c was not found to be a predictor in the multivariate 
logistic regression analysis with severe fatigue as dependent variable. The main conclusion 
of this study is that chronic fatigue, if left untreated, is highly persistent over time. 
Pain has been found to be an important factor of fatigue in several chronic diseases and 
disorders that cause long-term disability. As pain might also be an important factor related 
to fatigue in type 1 diabetes, we investigated the prevalence and associated factors of 
pain in severely fatigued patients with type 1 diabetes. The results of this cross-sectional 
study are reported in Chapter 3. Pain was found to be a highly prevalent symptom: 
approximately three out of four fatigued patients reported pain. In about one out of four 
of those patients, the pain had a high impact. Muscle ache, joint pain, back pain, and 
headache were most common. Pain was associated with diabetes duration, number of 
diabetes-related complications, fatigue severity, depressive symptoms, and functional 
impairment. The level of physical activity was not associated with pain, neither was HbA1c. 
As pain and fatigue severity are correlated, and both independently contribute to 
functional impairment, it seems important that future fatigue interventions also address 
pain to reduce fatigue and limitations in daily functioning.
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To date, treatment for patients with type 1 diabetes who suffer from chronic fatigue has 
been lacking, but seems highly warranted, given the significance and persistence of 
fatigue. Based on the previous findings and established treatments for chronic fatigue in 
other chronic diseases, we developed a cognitive behavioral therapy (CBT) named Dia-Fit 
for chronic fatigue in type 1 diabetes. The efficacy of Dia-Fit was tested in a randomized 
controlled trial (RCT). Chapter 4 describes the rationale and design of the RCT. The Dia-Fit 
treatment is based on a model assuming that diabetes and potential somatic complications 
of diabetes trigger the fatigue, and that cognitive-behavioral factors maintain it. These 
maintaining factors are addressed in the therapy, which is delivered as a combination of 
web-based modules and face-to-face sessions with a therapist. Dia-Fit is a tailored 
treatment consisting of up to eight modules; the modules indicated for each individual 
patient are determined at baseline assessment. 
In Chapter 5, we report on the efficacy of the Dia-Fit treatment by comparing patients 
allocated to the Dia-Fit treatment (CBT group) with patients allocated to a waiting list. 
A total of 120 chronically fatigued patients with type 1 diabetes were included in this 
multicenter, randomized controlled trial. 70% enrolled via five hospitals in the Netherlands, 
and 30% enrolled via self-referral (recruited by social media and flyers). Primary outcome 
was fatigue severity assessed using the Checklist Individual Strength, subscale fatigue 
severity. Secondary outcomes were functional impairment assessed with the Sickenss 
Impact Profile-8, and HbA1c and glucose variability. For ethical reasons, patients on the 
waiting list also received treatment after a waiting period of 5 months. An uncontrolled 
follow-up assessment was performed 6 months after treatment. Assessment 5 months 
after CBT or waiting list period demonstrated that patients in the CBT group reported 
significantly lower scores on fatigue severity and functional impairment, compared to 
patients on the waiting list. Effect sizes for fatigue severity and functional impairment 
were large. Approximately three out of four patients in the CBT group showed a clinically 
significant improvement in fatigue, compared to one out of four patients in the waiting 
list group. HbA1c and glucose variability did not change after treatment. At follow-up (CBT 
group only), fatigue severity increased slightly compared to the assessment directly after 
treatment, but the majority of patients reported a persistent, clinically significant 
improvement in fatigue. 
To indicate which mechanisms of change explained the positive treatment effects of 
Dia-Fit, a secondary analysis of the RCT was conducted. The results of this mediation 
analysis—a strategy to detect factors that mediate the relationship between treatment 
and outcome—are reported in Chapter 6. Potential mediators were cognitive-behavioral 
factors addressed in the CBT. A change in symptom focusing, fear avoidance, self-efficacy 
concerning fatigue, and perceived activity partially mediated the treatment effects. 
To determine whether depressive symptoms—prevalent in type 1 diabetes and related 
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to fatigue severity—explained the positive treatment outcome, depressive symptoms 
were added to the mediation model as a second step. A change in depressive symptoms 
was also found to be a mediator, but the other mediators still explained part of the 
treatment effect. Patients experienced behavioral elements, such as activity regulation 
and establishment of an optimal sleep-wake pattern, as the most helpful elements of 
treatment. The results of this study suggest that cognitions with regard to fatigue and 
activity probably play an important role in the explanation of the mechanisms of change 
of CBT for fatigue in type 1 diabetes.
In Chapter 7, we determined whether fatigue is a generic or a disease-specific symptom 
across various chronic diseases and diseases causing long-term disability, including type 1 
diabetes. We analyzed cross-sectional data on fatigue from 15 studies including 1696 
patients, and investigated how much variance of fatigue severity was explained by (1) the 
specific disease, (2) factors associated with fatigue across different chronic diseases, i.e., 
transdiagnostic factors, and (3) the interactions between these factors and the disease. 
The majority of variance was explained by the transdiagnostic factors. More specifically, 
sex, age, motivational problems, pain, sleep disturbances, physical functioning, concentration 
problems, reduced activity, and lower self-efficacy concerning fatigue were associated 
with fatigue severity. Relationships between these factors and fatigue severity mainly 
differed in strength, but not in direction, suggesting that fatigue is a generic symptom 
associated with similar factors across chronic diseases. This conclusion implies that 
individually tailored transdiagnostic interventions would be welcome, as these could 
address the factors that are specific for each patient’s needs.
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Chronic fatigue is a prevalent and burdensome symptom for patients with type 1 diabetes, 
but remains understudied. The central purpose of this thesis was to investigate chronic 
fatigue in patients with type 1 diabetes, from its predictors and associated factors to its 
treatment. This final chapter discusses the main findings of the studies conducted for this 
thesis in the context of existing literature, and formulates implications for clinical practice. 
First, the relationship between fatigue and glycemic control (as reported in Chapter 2), 
and psychosocial and health-related factors (as described in Chapter 2 and 3) will be 
discussed. Second, we will consider methodological issues, clinical considerations, and 
future research in the context of the Dia-Fit study, the randomized controlled trial (RCT) 
testing the efficacy of cognitive behavioral therapy (CBT) for chronic fatigue in type 1 
diabetes (described in Chapters 4 to 6). Third, as Dia-Fit was developed under the 
assumption that fatigue in diabetes is a disease-specific symptom requiring a disease- 
specific intervention, we will discuss whether fatigue in medical conditions is a generic or 
disease-specific symptom (as addressed in Chapter 7). Finally, we will review implications 
of the results obtained in this thesis for clinical practice.
Fatigue and glycemic control in type 1 diabetes
Fatigue is one of the presenting symptoms of type 1 diabetes,1 and it is often suggested 
that fatigue can be explained by the patients’ (suboptimal) glycemic control. To date, 
the exact relationship between fatigue and glycemic control is not clear; moreover, 
to ascertain this relationship, it is important to differentiate between different types of 
fatigue. Fatigue can occur as an acute symptom of tiredness that fluctuates from day to 
day, or, can persist as severe fatigue over a long period, causing functional impairment. 
Some studies have investigated the relationship between glycemic control and acute 
fatigue, i.e., the symptom of tiredness. Warren and colleagues revealed tiredness to be one 
important symptom of hyperglycemia, suggesting a relationship between acute fatigue 
and glycemic control.2 This finding was not confirmed by our cross-sectional study, in which 
patients wearing continuous glucose monitors rated acute fatigue several times daily; 
neither time spent in hyperglycemia nor time spent in hypoglycemia were associated 
with acute fatigue.3 King and colleagues showed in an experimental setting that the 
presence of nocturnal hypoglycemia affected acute fatigue the next day, suggesting a 
relationship between the symptom of fatigue and glycemic control.4 
As acute fatigue and glycemic control may be related to each other—considering the 
inconclusive findings from the few studies conducted so far—studies investigating severe, 
long-lasting fatigue are unable to demonstrate a significant relationship with glycemic 
control. The relationship between glycemic control (i.e., HbA1c) and persistent, severe and/
or disabling fatigue failed to reach significance in several cross-sectional studies.5,6 Also, 
in our earlier work, neither HbA1c nor glucose variability were significantly related to 
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chronic fatigue; the latter was defined as a severe fatigue lasting for at least for six months.3 
Because these cross-sectional findings do not exclude a potential relationship between 
HbA1c and severe, long-lasting fatigue over time, we included HbA1c as a potential predictor in a 
multivariate regression analysis, and looked at a potential reciprocal relationship between 
HbA1c and fatigue severity in a cross-lagged panel model (as described in Chapter 2). 
In line with earlier findings, HbA1c was again not found to be a significant predictor of 
fatigue severity; however, in the cross-lagged model, HbA1c at baseline was significantly 
(but weakly) associated with fatigue severity 3.5 years later. Conversely, baseline fatigue 
was not associated with future HbA1c. This might imply that (suboptimal) glycemic control 
can contribute to (the development of) severe, long-lasting fatigue in the future. 
In type 2 diabetes, it has been suggested that severe, long-lasting fatigue and glycemic 
control are only related to each other in patients with suboptimal glycemic control.7 In our 
prospective study (Chapter 2), we separately investigated patients with suboptimal and 
optimal glycemic control, but could not find differences between the two groups. One 
may argue that severe, long-lasting fatigue and HbA1c can be related in a more complex 
way, for example in a U-shaped relationship where optimal glycemic control contributes 
to high fatigue scores due to all effort and energy invested to obtain “perfect diabetes 
control”, and/or poor glycemic control contributes to high fatigue scores. It is also possible 
that severe, long-lasting fatigue is triggered by an interaction between glycemic control 
and fatigue-related factors. In his comment on the effects of the Dia-Fit study, Pouwer 
suggests that the presence of nocturnal hypoglycemia could influence sleep quality and 
therefore affect fatigue levels.8 More studies—preferably with many participants and 
several measurements over time—are necessary to investigate the exact role of (nocturnal) 
hypoglycemia and the development of severe, long-lasting fatigue in type 1 diabetes.
The results of the RCT conducted to test the efficacy of Dia-Fit (Chapter 5) showed that 
CBT for severe and chronic fatigue did neither affect HbA1c nor glucose variability. 
Meta-analyses investigating the effects of CBT for several psychosocial problems on 
glycemic control show mixed results. One meta-analysis including studies with patients 
with mental or behavioral disorders such as depression did not find any impact of CBT on 
glycemic control.9 Another meta-analysis found that CBT is effective in reducing short-term 
and medium-term glycemic control, but not long-term control.10 This meta-analysis 
included studies of patients with diabetes-related distress, anxiety, depression, and 
reduced quality of life, and some of the included studies have enrolled patients with poor 
glycemic control, which could explain why CBT affects glycemic control. In our RCT 
(Chapter 5), we did not screen or include patients based on their HbA1c value. Due to the 
weak association between chronic fatigue and glycemic control, it is unlikely that the 
results of our RCT with regard to glycemic control had been different when selecting 
patients with poor glycemic control. Future RCTs are needed to confirm our results, 
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but currently, available evidence suggests that CBT for chronic fatigue cannot influence 
patients’ glycemic control. 
Psychosocial and health-related factors associated with fatigue in 
type 1 diabetes
Fatigue in type 1 diabetes is associated with several cognitive-behavioral factors, such as 
a low self-efficacy concerning fatigue, sleep disturbances and physical inactivity.3 Our 
prospective study (Chapter 2) demonstrates that cognitive-behavioral factors are indeed 
predictors of severe fatigue in type 1 diabetes. These factors include sleep disturbances, a 
low self-efficacy concerning fatigue, and diabetes-related cognitions, such as confidence 
in diabetes self-care. Our findings imply that addressing cognitions and behaviors related 
to fatigue could theoretically reduce fatigue severity.
Clinicians often do not perceive pain as a prevalent symptom of type 1 diabetes, and, if 
existing, mostly associate it with chronic painful peripheral neuropathy, which occurs in 
approximately 11% to 20% of patients.11 However, pain might also be relevant for patients 
without diabetes-specific complications, as it was found that about 60% of patients with 
diabetes report moderate to severe pain.12 Moreover, pain seems to be associated with 
fatigue in type 1 diabetes. We show that three out of four severely fatigued patients with 
type 1 diabetes experience pain, from which one in four reports pain to be of high impact 
(Chapter 3). Pain is not only associated with fatigue in type 1 diabetes—as shown in this 
thesis—it is also related to fatigue in other chronic diseases, such as neuromuscular 
disorders,13 rheumatoid arthritis,14 or neuralgic amyotrophy.15 To date, the exact relationship 
between pain and chronic fatigue is unclear. It is possible that pain is mainly attributable 
to the chronic disease and its disease-specific complications and/or co-morbidities. It may 
also be argued that pain is an accompanying symptom of chronic fatigue, as seen in 
patients with chronic fatigue syndrome where the majority of patients experience muscle 
pain, joint pain, or headache without a medical somatic explanation.16 In our group of 
severely fatigued patients with type 1 diabetes, pain was most frequently present in the 
head and lower back; muscle and joint pain were also common (Chapter 3). The latter 
two could be explained by the presence of typical entrapment neuropathies prevalent in 
diabetes,17 but headache and back pain are not diabetes-specific pain symptoms. It would 
be interesting to further investigate pain in fatigued patients with diabetes by differentiat-
ing between patients whose pain was triggered by typical diabetes-related complications, 
and patients without complications. However, it seems important to address pain in 
fatigue interventions due to its high prevalence in this group and its associations with 
fatigue and disability. 
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As fatigue can be a presenting symptom of clinical depression,18 it is important to 
distinguish between chronic fatigue and clinical depression. This is particularly true for 
people with diabetes, because research has shown that the prevalence of depression in 
people with diabetes is almost twice as high than in the population at large.19 Effective 
interventions for depression in diabetes have been developed: web-based CBT seems to 
be effective in reducing depressive symptoms in patients with type 1 and type 2 diabetes 
with a co-morbid depression.20 People with diabetes and fatigue should be carefully 
screened for the presence of depression to ensure that they receive the correct treatment. 
In our RCT, we screened and excluded patients with clinical depression (Chapter 5). 
Still, depressive symptoms seem to be importantly associated with fatigue.3 In this thesis, 
we showed that depressive symptoms are an important predictor of fatigue severity 
(Chapter 2). The positive effects of our RCT for fatigue may be explained by a reduction 
of depressive symptoms and/or non-specific effects of CBT by techniques that are also 
used in CBT for depressive symptoms. To evaluate this possibility, we used mediation 
analysis and tested the potential mediators of change of our fatigue treatment (Chapter 6). 
A change in depressive symptoms was indeed found as mediator of the change of fatigue 
severity through CBT; patients allocated to the CBT reported a significant decrease of 
depressive symptoms, compared to patients allocated to the waiting list. However, the 
change in fatigue severity through CBT was not only explained by a change in depressive 
symptoms, but also by a change in several cognitive fatigue-related factors, such as an 
increase in self-efficacy concerning fatigue. This suggests that CBT for fatigue in type 1 
diabetes should address cognitions and behaviors related to fatigue, but also account for 
depressive symptoms in a sub-group of patients. In future research, it would be interesting to 
investigate the interplay between cognitive fatigue-specific factors and depressive symptoms 
and beliefs. Does an increase in self-efficacy concerning fatigue lead to a reduction in 
depressive symptoms? Or does a change in depressive beliefs have an effect on self- 
efficacy concerning fatigue, and hence on the reduction of fatigue? Ideally, potential 
mediators of change are measured several times during treatment to explain when specific 
changes take place. Taken together, depressive symptoms are importantly related to severe 
fatigue in type 1 diabetes, and it is essential to adequately screen patients for the presence 
of depressive symptoms to determine the correct treatment for this subgroup of patients.
Treatment for fatigue in type 1 diabetes: the Dia-Fit study
In this thesis we show that severe fatigue in type 1 diabetes has a persistent character if 
left untreated. Therefore, a treatment for chronic fatigue in this patient group was urgently 
needed. We developed Dia-Fit, a blended CBT for chronically fatigued patients with type 1 
diabetes, and evaluated its efficacy in a multicenter randomized controlled trial. We found 
that after treatment, patients reported significantly lower scores on fatigue severity and 
functional impairment, compared to a waiting list group (Chapter 5). Effect sizes for 
fatigue severity and functional impairment were large, and the number of patients with 
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clinically significant improvement was high (77%). The positive effects of CBT for chronic 
fatigue in type 1 diabetes match those of fatigue interventions for other chronic diseases. 
For chronic fatigue in patients with multiple sclerosis21 or facioscapulohumeral muscular 
dystrophy (FSHD)—a progressive neuromuscular disorder22— and for patients with 
cancer-related fatigue23 or chronic fatigue syndrome,24-26 CBT has been proven effective 
in reducing fatigue severity and disability. Below, we discuss several methodological 
aspects and future directions of the Dia-Fit trial. 
Tailored intervention
The Dia-Fit treatment was a tailored intervention; patients received only the treatment 
modules that were relevant for them. In recent years, several fatigue interventions have 
been developed that use tailoring, among them CBT for cancer-survivors;27 for patients 
with incurable cancer;28 or for patients with multiple sclerosis.29 Tailored interventions 
have several advantages, as they match the patients’ needs, and patients do not receive 
information that is not relevant to them.30 Tailoring is a system feature that can improve 
the attractiveness and simplicity of an intervention,31 and can be used as a persuasive 
technology, as it is known that patients pay more attention to information that is tailored 
to them.30 It has even been shown that tailored information is more effective in changing 
attitude and behaviors, compared with generic information.32 However, despite the 
advantages of tailored treatment, the tailored approach of our Dia-Fit interventions 
created variability between patients in delivering the treatment’s content. Ideally, we 
would have analyzed which different combinations of modules explained the effect of 
the intervention by investigating different subgroups of patients, but the sample size of 
our trial (n=120) was insufficient for such an analysis.
We determined the percentage of treatment modules that was indicated in our intervention 
(Chapter 6) and used two different scorings: (1) the questionnaires’ cut-off scores at 
baseline assessment, and (2) self-report after 5 months treatment by patients. We also 
chose to report the modules indicated by patients’ self-reports, as patients were free to 
access all potential treatment modules via the web-based system during treatment. 
We found several discrepancies between the two types of scorings. For example, based 
on the baseline assessment, it was apparent that 73% of patients received the module 
“Regulation of Sleep-wake pattern,” whereas this was 83% by patients’ self-reports. 
Research has shown that users of web-based interventions apply a large amount of 
self-tailoring as they select the content that suits their personal needs.33 This could explain 
the discrepancy between modules indicated by baseline assessment and patients’ 
self-reports. In future research, it would be interesting to gather more log-data of the 
web-based portal, and to investigate whether some modules of the Dia-Fit intervention 
are more effective than others. To investigate the latter question, one could use sub-group 
analysis with larger study samples. 
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Web-based treatment 
The internet is quickly evolving; according to the internet usage statistics of 2017, 
approximately 95% of the Dutch population uses the internet.34 With this penetration of 
the Internet, the development of eHealth care services and web-based interventions has 
also increased. According to Barak and colleagues,35 a web-based intervention can be 
defined as “a primarily self-guided intervention program that is executed by means of a 
prescriptive online program operated through a website and used by consumers seeking 
health- and mental-health related assistance”. Web-based interventions overcome several 
limitations of regular face-to-face interventions as they reduce travel time to the treatment 
center, are time efficient both for patients and therapists and are easily accessible for a 
broad group of patients.36 In addition, they may be cost-effective, compared to non- 
web-based control groups.37 
In recent years, web-based interventions for patients with diabetes have been developed 
to focus on different aspects of diabetes management, such as improving blood-glucose 
monitoring,38,39 as well as interventions focusing on psychosocial aspects of diabetes, 
such as depression20 or general psychosocial well-being.40 These interventions permit 
following treatment from home; a considerable advantage for patients with type 1 
diabetes, as they already need to visit their health care provider for regular diabetes 
control. In our RCT (Chapter 5), 134 out of 254 eligible patients declined to participate in 
the study. The main reasons for non-participation were time investment and travel 
distance to the treatment centre. The latter could be overcome by using a fully web-based 
treatment, which could be accessed by patients via internet at home in their own time. 
Despite the advantages of web-based treatment, patients in our trial reported that they 
appreciated the personal contact with the therapist during the treatment; an advantage 
of a blended care approach. To further decrease travel time for patients, but to preserve 
the personal contact with a therapist, it is possible to supplement future web-based 
treatments with video-conferencing where patients and therapists have contact via a 
secured video consultation system. Video-conferencing has already been adopted in 
ongoing studies that test the efficacy of CBT for cancer-related fatigue.27,41
The use of waiting list as a comparator 
As noted in Chapter 5, we compared the CBT group to a waiting list group, rather than 
using an active control group. Choosing a psychological placebo or attention control 
group is challenging in psychosocial interventions,42 and was not feasible in our study; 
there was no good data available on the content of active elements in a potential fatigue 
intervention for type 1 diabetes. The use of a waiting list in RCTs controls for effects of time 
and regression to the mean, but can also have disadvantages.42 A meta-analysis of RCTs 
which tested the effects of CBT for depression suggested that the type of control condition 
(psychological placebo, treatment as usual, no treatment, or waiting list) leads to different 
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outcome effect sizes estimates.43 The no-treatment control group showed greater effect 
sizes than the waiting list group, assuming that the use of a waiting list control group 
could lead to nocebo effects—the negative psychological expectations of “waiting for 
the desired treatment”.43 Theoretically, this could have occurred in our RCT, but we 
thought this to be unlikely as the number of patients who improved in fatigue in the 
waiting list group (one in four) matched the natural course of severe fatigue in type 1 
diabetes in our prospective study (Chapter 2). To overcome potential risks of waiting list 
groups, future RCTs for fatigue in type 1 diabetes might use active control conditions to 
control for potential nocebo and placebo effects and the effects of being involved in 
research. A reasonable active control condition could be a group that receives psycho- 
educational material about fatigue in type 1 diabetes several times during the trial 
–e.g., via email or a website–according to the approach of Postel and colleagues.44
External validity 
A lack of external validity–often referred to as the generalizability to routine practice–is a 
major concern of RCTs,45 and is one reason why evidence-based treatments are often not 
used in routine practice.46,47 In our RCT, we excluded patients with severe diabetes- 
related complications and/or co-morbidity. These were approximately 40% of the 
patients who were screened for the trial. Due to the strict in- and exclusion criteria, several 
patients with diabetes were unable to participate in our trial. As for the fact that most 
patients with type 1 diabetes develop macrovascular and microvascular complications 
after several years,48 it is possible that our intervention for chronic fatigue will show 
different results when generalizing it to all patients with type 1 diabetes. It would be 
interesting to investigate the effects of CBT for fatigue and type 1 diabetes in patients with 
complications as well. By recruiting patients from five different hospitals—one university 
medical center and four large teaching hospitals—and selecting patients from all over the 
country by spreading flyers and advertising on social media (self-referral), we included 
patients from various settings. A total of 45 patients (37.5%) were included from the 
university medical center, 39 patients (32.5%) from the teaching hospitals and 36 patients 
(30%) by self-referral. 
Another barrier of generalizability is the fact that RCTs are often conducted under careful 
control, and the treatment is delivered by highly trained therapists who receive supervision 
during the trial.45 This was also true for our study. To successfully treat patients with chronic 
fatigue, the training and supervision of therapists who perform the CBT is also necessary 
in clinical practice. While we cannot rule out that the effects of the Dia-Fit intervention 
may be different in clinical practice, it has been shown that CBT for chronic fatigue in 
patients with chronic fatigue syndrome can successfully be implemented in clinical 
practice, and that therapists who have no experience with this particular treatment 
protocol can learn the CBT approach for chronic fatigue easily by training and supervision.49
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Fatigue and its treatment in type 2 diabetes
Our CBT intervention aimed at reducing severe fatigue in patients with type 1 diabetes. 
Research suggests that fatigue is also prevalent in patients with type 2 diabetes.6,50-52 
Type 1 and type 2 diabetes differ in their pathophysiology as type 1 diabetes is an auto- 
immune disease requiring permanent insulin treatment and type 2 diabetes is strongly 
related to obesity and physical inactivity resulting in insulin resistance.53 It is quite possible 
that the factors associated with fatigue in type 2 diabetes are different from those found 
to maintain fatigue in type 1 diabetes, and as such, other treatment modules would be 
necessary. For example, physical inactivity is importantly related to type 2 diabetes; and 
exercise interventions can have beneficial effect on the patient’s glycemic control.54 It is 
possible that the increase of physical activity through a graded activity program is a much 
more important factor in reducing fatigue in type 2 than in type 1 diabetes. Overweight 
and obesity are other important factors prevalent in type 2 diabetes. Research has shown 
that a high body mass index is significantly associated to fatigue in both people from the 
general population55 and patients with type 2 diabetes.6 Therefore, it is possible that 
weight control is an important factor that should be addressed in fatigue treatment for 
type 2 diabetes. Based on these considerations, we cannot generalize the findings from 
the recent randomized controlled study (Dia-Fit) to fatigue in type 2 diabetes. Future 
studies should investigate the potential maintaining factors of fatigue as well as the effects 
of CBT for fatigue in patients with type 2 diabetes.
Which factors contribute to the treatment effect?
We investigated what contributed to the positive treatment effect of the Dia-Fit intervention 
with mediation analysis, an approach that can detect potential factors explaining the 
effects between treatment and outcome56 (Chapter 6). Mediation analysis has been 
applied in several studies investigating the positive effects of CBT on reducing fatigue 
severity in patients with multiple sclerosis,57 cancer survivors,58 or chronic fatigue syndrome.59 
These studies looked for potential cognitive and behavioral factors that were addressed 
during treatment. As a graded activity program is part of the CBT for chronic fatigue, it is 
often assumed that the increase of the level of physical activity explains the treatment 
effects. However, none of the previous mediation analyses confirmed this hypothesis. 
A reduction in fatigue severity could not be explained by a change in the level of physical 
activity, neither in CBT for fatigue in cancer survivors58 nor in patients with chronic fatigue 
syndrome.60 The level of physical activity was also not found to be a mediator of the 
treatment effect of CBT in type 1 diabetes (Chapter 6), neither did the level of physical 
activity change after CBT. Another behavioral factor that is addressed in CBT for chronic 
fatigue are sleep disturbances. Although CBT reduced sleep disturbances, again this 
behavioral factor did not mediate the changes in fatigue severity after treatment in the 
Dia-Fit trial. As this suggests that addressing behavioral factors do not significantly 
contribute to the treatment effect of CBT, it does not exclude such an effect. After 
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treatment, we asked patients to rate which treatment’s elements they experienced as the 
most helpful. Surprisingly, we found that patients rated the behavioral elements of the 
treatment such as the regulation of sleep-wake pattern or the activity regulation as most 
helpful. Heins and colleagues61 showed that the level of physical activity temporarily 
increased during treatment. It is possible that an increase in physical activity and/or a 
reduction of sleep disturbances influences other change processes, for example an 
increase in self-efficacy concerning fatigue. This could be a potential explanation why 
behavioral factors were not found as mediators in the treatment response for type 1 
diabetes. Another explanation could be that the role of physical activity may be an 
important mediator in a specific subgroup of patients. In research and clinical practice, we 
differentiate between different activity patterns: patients with a low active, relatively 
active and pervasively active activity pattern.62 It is likely that the level of physical activity 
explained part of the treatment effects in only patients who had a low activity pattern. 
As our group of patients with a low activity level was relatively small (9%), future studies 
with larger samples and sub-analysis should investigate the effects of the specific activity 
pattern on the change in fatigue severity through CBT. 
Several studies have shown the important role of cognitions in changing fatigue severity 
through CBT. For example, it has been found that a change in self-efficacy concerning 
fatigue and focusing on symptoms of patients with chronic fatigue syndrome explains 
the changes in fatigue severity through CBT.59,61 These two cognitions were also found 
to mediate the positive effects of CBT on fatigue severity in type 1 diabetes (Chapter 6). 
During treatment, therapists should encourage patients in developing more self-efficacy 
concerning fatigue and to direct the attention away from fatigue as this seems important 
for the change in fatigue severity. In addition to the cognitions regarding fatigue, 
cognitions with regard to physical activity seem to importantly contribute to treatment 
effects of CBT in fatigue. Changes in perceived activity and fear avoidance–i.e., negative 
beliefs about the relationship between symptoms and activity–contribute to the reduction 
in fatigue severity through CBT. This was also found in mediation analyses in chronic 
fatigue syndrome.61,63 It seems that a change in the perception of being able to carry out 
different activities and not the change in objective level of physical activity is an important 
mechanism of change. The reduction of fatigue brought on by CBT seems to be mediated 
by changes of specific fatigue-related cognitions and this mechanism is found in treatment 
studies in different diseases.    
Future directions of CBT for chronic fatigue in type 1 diabetes
There is a need for future research in the context of the Dia-Fit study. Remaining questions 
include: “to what extent are CBT effects sustained over time?” and “for whom is the 
treatment effective and for whom is it not?” Mainly for ethical reasons, patients allocated 
to the waiting list in our RCT also received the CBT treatment after waiting time, which 
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made it impossible to conduct a controlled follow-up assessment. We did collect 
(uncontrolled) data on fatigue severity, functional impairment, HbA1c and glucose 
variability 6 months after treatment in both groups. This allowed us to investigate whether 
the effects of the Dia-Fit treatment persisted over short-time. Initial results suggest that 
scores on fatigue severity after the 6 month follow-up increase slightly, compared to 
scores directly after treatment. Nevertheless, the majority of patients showed a sustained 
clinical significant improvement at follow-up (61% at follow-up vs. 77% directly after 
treatment). Type 1 diabetes is a chronic condition that requires intensive self-management 
and frequent therapy adjustments. This disease burden—including the onset of new dia-
betes-related complications—can have an important impact on the psychosocial state of 
the patient, including fatigue. Booster sessions after treatment could help to reinforce the 
skills learned during CBT and/or to prevent relapse after end of the treatment. 
Further to initial analyses to explain the treatment effects of CBT by mediation analysis 
(Chapter 6), more research is necessary to determine why and for whom the treatment 
works best. Moderation analysis is an approach that can detect variables that affect the 
direction and/or the strength of the relation between treatment and outcome, and can 
test for whom the treatment works best.56 Research investigating CBT for chronic fatigue 
has investigated the effects of age and depressive symptoms on treatment response.64 
It would be interesting to investigate which group of patients with type 1 diabetes 
benefits most from the treatment. Potential factors that could be studied are age, 
health-related factors such as the presence/number of diabetes-related complications, 
pain, or depressive symptoms. In addition, future studies should establish qualitative 
research. For example, interviews can provide important insights into the patients’ 
opinions about the treatment, and can reveal which parts of the treatment need 
improvement according to patients. The use of web-based therapy can have considerable 
advantages as a large amount of log-data can be stored during a treatment. Log-data can 
provide us with important information, for example, the frequency of logins, the total 
duration spent on one functionality/module of the treatment, or in what order the func-
tionalities/modules are used.33,65 This would allow us to answer research questions such 
as “are high-rate users more adherent?” or “which treatment modules are most frequently 
used?” and “is the usage of a given treatment module associated with the treatment 
response?” 
Is fatigue in type 1 diabetes a disease-specific symptom?
It is often assumed that fatigue is a disease-specific symptom; terms such as multiple-scle-
rosis fatigue66 or post-stroke fatigue67 have been introduced, and several treatments for 
chronic fatigue have been developed for these conditions. Also in psychological disorders, 
disorder-focused approaches that focus on the etiology and treatment of each disorder 
separately are common.68 In this thesis, we show that several associated factors of fatigue 
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are the same across different chronic conditions and that the chronic disease itself did not 
explain much variance of fatigue severity (Chapter 7). These results seem to support 
earlier studies which have been repeatedly unable to find a significant relationship 
between fatigue and disease-specific parameters such as glycemic control in diabetes4 or 
inflammation in rheumatoid arthritis.14 The findings of our study described in Chapter 7 
would therefore rather support a transdiagnostic approach where fatigue-related factors 
are similar across different chronic disorders than a disorder-focused approach where fatigue is 
a specific symptom in each chronic disease. According to Harvey and colleagues,68 
a transdiagnostic perspective emerges when “the perspective is shifted away from a ‘disorder- 
focus’ towards an ‘across disorder’, or transdiagnostic perspective”. A transdiagnostic 
approach in fatigue treatment may has the advantage that it would also benefit chronic 
diseases where the CBT approach is not yet available and has not yet been tested. 
Another approach that quickly emerges over the last years is a personalized approach that 
focuses on tailoring the treatment to the individual. This approach has been recommended 
for medicine in general,69 but also for psychological treatments for chronic diseases.70 
Here, the treatment is tailored to the patient-specific risk factors. In this thesis, we show 
that several fatigue-related factors are similar across chronic diseases. In some disorders, 
however, these factors failed to reach significance or differed in strength (Chapter 7). 
For fatigue treatments, it would be favorable to combine the transdiagnostic approach 
with patient-centered health care. Fatigue treatments for chronic disorders may consist of 
generic modules that are often similar in chronic disorders such as sleep disturbances or 
physical activity, but also focus on more disease-specific factors such as diabetes distress 
in diabetes and patient-specific factors such as coping with pain or depressive symptoms. 
Combining elements from a trandiagnostic and a patient-tailored approach, would allow 
to focus on the individual patients’ needs and to broaden the fatigue treatment to other 
chronic diseases. 
Clinical implications
Screening and treatment of chronic fatigue in type 1 diabetes is not yet addressed in 
clinical guidelines. A recently published position statement of the American Diabetes 
Association suggests that psychosocial care should be more integrated in medical care.71 
One first step to integrate such care for type 1 diabetes treatment is the screening of 
patients for the presence of chronic fatigue. The Checklist Individual Strength is a relatively 
short instrument (20 items) that can be easily assessed. However, patients are often asked 
to fill in several questionnaires for depressive symptoms, diabetes distress, and/or anxiety. 
In order to prevent large screening batteries and to screen patients even more quickly 
for chronic fatigue, it would been desirable to use a single-item screening tool for the 
detection of fatigue. Research on patients with cancer-related fatigue has recently shown 
that one fatigue-related item in a problem list questionnaire is sufficient to detect fatigue.72 
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Both sensitivity–the proportion of patients correctly identified as having fatigue–and 
specificity–the proportion of patients correctly identified as having no fatigue–were high. 
If fatigue is detected as problematic by this single item, the Checklist Individual Strength 
could subsequently be used for a more thorough assessment of fatigue.72 Such a single 
item that can be assessed quickly could also be used to detect fatigue in type 1 diabetes. 
The NDF Dutch guidelines recommend to use the PHQ-9 questionnaire for the screening 
of depressive symptoms in patients with diabetes.73,74 The PHQ-9 is a valid, commonly 
used questionnaire that contains one item about fatigue (“feeling tired or having little 
energy”). As this questionnaire is already used in clinical practice, it could be a useful initial 
instrument for detecting fatigue in patients with diabetes; in case of high score, subsequent 
screening of the severity of fatigue and any associated disabilities is warranted. Here, 
questionnaires such as the Checklist Individual Strength75 and the Work and Social 
Adjustment Scale76 could be applied. 
In this thesis, we show that CBT is an effective treatment for chronic fatigue in type 1 
diabetes. While independent confirmation of these results are required, we believe the 
current evidence suffices to offer the treatment to patients with a similar profile to those 
in the study population. In essence, CBT for chronic fatigue in type 1 diabetes could be 
offered by psychologists already experienced with this CBT approach, but will require 
additional training. The intervention can likely be improved upon and made more accessible 
nationwide; for example, by using video-conferencing. One alternative approach would 
be to offer a minimal variant of the treatment which could be given by nurses. Clearly, 
more work is needed to implement CBT for patients with type 1 diabetes and chronic 
fatigue in clinical practice. 
Closing remarks 
Despite its prevalent and disturbing character, chronic fatigue is an understudied 
symptom of type 1 diabetes. The studies discussed in this thesis contribute to the 
understanding and management of chronic fatigue in type 1 diabetes. In patients with 
type 1 diabetes, chronic fatigue is significantly associated with cognitive-behavioral 
factors that can be addressed in CBT. Although future studies are necessary to replicate 
the results, CBT for chronic fatigue in type 1 diabetes appears to be effective in decreasing 
fatigue severity and functional impairment. A conceivable next step is screening and 
management of chronic fatigue in patients with type 1 diabetes in clinical practice. 
Hopefully, the studies discussed in this thesis will draw more attention to chronic fatigue 
in type 1 diabetes and contribute not only to further research in this field, but also to help 
in diminishing human suffering from this highly disturbing symptom. 
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Chronische vermoeidheid is een veelvoorkomend en belastend symptoom voor patiënten 
met diabetes type 1; een door onze groep uitgevoerd wetenschappelijk onderzoek uit 
2014 toonde aan dat 40% van de patiënten met diabetes type 1 last heeft van chronische 
vermoeidheid. Desondanks is er over dit onderwerp tot op heden weinig bekend. Het 
doel van de onderzoeken die in dit proefschrift worden beschreven was het vergroten 
van de kennis over chronische vermoeidheid bij patiënten met diabetes type 1. Met name de 
factoren die samenhangen met vermoeidheid en de effecten van een nieuwe behandeling 
zijn onderzocht. Hieronder worden de belangrijkste resultaten van de verschillende 
onderzoeken besproken. In hoofdstuk 1 wordt achtergrondinformatie over diabetes type 1 en 
vermoeidheid gegeven en worden de vraagstellingen van dit proefschrift geïntroduceerd. 
Om meer inzicht te krijgen in het verloop en mogelijke voorspellers van ernstige vermoeidheid 
in de groep patiënten met diabetes type 1 voerden wij een longitudinaal onderzoek uit. 
Deelnemers aan dit onderzoek werden gevraagd om twee keer vragenlijsten in te vullen: 
aan het begin – de baseline meting – en drie en een half jaar later: de follow-up meting. 
Omdat bekend is dat gezondheidsgerelateerde factoren, bepaalde gedachten over 
vermoeidheid en gedrag in reactie op moeheid gerelateerd zijn aan vermoeidheid bij 
diabetes type 1, verwachtten wij dat deze factoren ook ernstige vermoeidheid op lange 
termijn zouden kunnen verklaren. Daarnaast waren wij benieuwd naar de samenhang 
tussen ernstige vermoeidheid en het HbA1c gehalte, het gemiddelde van de bloedglucose-
spiegel in de voorafgaande 6-8 weken. Deze samenhang werd onderzocht in twee 
subgroepen: patiënten met een suboptimale en patiënten met een optimale glucose-
regulatie. De resultaten van dit onderzoek worden besproken in hoofdstuk 2. Bij drie van 
de vier patiënten bleek de ernstige vermoeidheid persisterend; patiënten scoorden zowel 
bij de baseline meting als bij de follow-up meting hoog op vermoeidheid. Voorspellers 
van ernstige vermoeidheid op de lange termijn waren depressieve symptomen, pijn, 
slaapproblemen, het idee weinig controle over de vermoeidheid te hebben, weinig 
vertrouwen in diabetes zelfzorg hebben, meer ernstige vermoeidheid tijdens de baseline 
meting en meer diabetesgerelateerde complicaties. Het HbA1c gehalte gemeten tijdens 
de baseline meting hing positief samen met ernstige vermoeidheid tijdens de follow-up 
meting, maar deze relatie was zwak en verdween als de relatie tussen alle variabelen 
en vermoeidheid tezamen werd bepaald. De belangrijkste conclusie is dat zonder 
behandeling ernstige vermoeidheid bij de meerderheid van patiënten met diabetes type 1 
blijft bestaan en dat gedragsfactoren een belangrijke rol spelen bij het in stand houden 
van de vermoeidheid.
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Onderzoek bij verschillende chronische ziekten heeft aangetoond dat pijn vaak samen- 
hangt met vermoeidheid. Dit was de aanleiding om de rol van pijn bij patiënten met 
ernstige vermoeidheid en diabetes type 1 te onderzoeken. Specifiek is gekeken naar het 
bestaan van pijn en naar de factoren die aan de pijn gerelateerd zijn. Hoofdstuk 3 beschrijft 
de uitkomsten van dit onderzoek. Pijn bleek een veelvoorkomende klacht bij vermoeide 
patiënten met diabetes type 1: circa drie van de vier patiënten rapporteerde pijn. Van de 
patiënten die pijn rapporteerden, had bij een kwart de pijn veel impact op het 
functioneren. Spier-, gewrichts-, rug- en hoofdpijn kwamen het meeste voor. De ernst van 
de pijn hing samen met de duur van diabetes, het aantal aan diabetes gerelateerde 
complicaties, de ernst van vermoeidheid, de ernst van de depressieve symptomen en de 
ernst van de beperkingen in het dagelijks functioneren. Tegen de verwachting in hing 
pijn niet samen met lichamelijke activiteit, en ook niet met het HbA1c gehalte. Aangezien 
pijn en ernstige vermoeidheid samenhangen, en allebei apart van elkaar bijdragen aan de 
beperkingen in het dagelijks functioneren, lijkt het belangrijk dat toekomstige interventies 
die als doel hebben de vermoeidheid bij patiënten met diabetes type 1 te verminderen 
zich ook richten op het beter hanteren van pijnklachten.
Omdat chronische vermoeidheid bij diabetes type 1 vaak voorkomt en leidt tot 
beperkingen in het dagelijks functioneren is een effectieve behandeling zeer gewenst. 
Tot op heden was een dergelijke behandeling echter niet beschikbaar. Eerder onderzoek 
bij verschillende chronische ziekten heeft laten zien dat Cognitieve Gedragstherapie 
(CGT) een effectieve behandeling voor chronische vermoeidheid kan zijn. CGT voor 
vermoeidheid richt zich op het veranderen van gedachten en gedragingen die de 
vermoeidheid in stand houden. Op basis van eerdere literatuur over de effecten van CGT 
bij andere chronische ziekten en onze bevindingen over chronische vermoeidheid bij 
diabetes type 1 is de Dia-Fit interventie ontwikkeld. Dia-Fit is een vorm van CGT die 
specifiek is ontwikkeld voor chronisch vermoeide patiënten met diabetes type 1. De 
effectiviteit van Dia-Fit is getest in een gerandomiseerd en gecontroleerd onderzoek: dat 
wil zeggen dat door middel van loting werd bepaald of patiënten wel of niet direct 
werden behandeld en de resultaten van de twee groepen vervolgens met elkaar werden 
vergeleken. De behandelinhoud van Dia-Fit en de opzet van het onderzoek zijn beschreven 
in hoofdstuk 4. Dia-Fit is gebaseerd op een model dat ervan uitgaat dat diabetes en 
mogelijke lichamelijke gevolgen van diabetes vermoeidheid uitlokken, en dat gedachten 
en gedragingen de vermoeidheid vervolgens in stand houden. Deze in stand houdende 
factoren worden in de behandeling aangepakt. Dia-Fit is een combinatie van face-to-face 
gesprekken met een therapeut en onderdelen die via een specifiek ontwikkeld internet-
portaal aangeboden worden. De behandeling bestond uit acht verschillende onderdelen. 
Vóór de start van de behandeling werd bij elke patiënt via vragenlijsten bepaald welke 
onderdelen nodig waren om de vermoeidheid te verminderen. Dit resulteerde in een 
behandeling op maat. 
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In hoofdstuk 5 worden de resultaten van het gerandomiseerde en gecontroleerde 
onderzoek beschreven. Hiervoor werden patiënten die de Dia-Fit behandeling volgden 
vergeleken met patiënten die op een wachtlijst geplaatst werden. In totaal namen 120 
chronisch vermoeide patiënten met diabetes type 1 deel aan het onderzoek. Van deze 
patiënten werd 70% geworven via vijf ziekenhuizen in de regio en 30% meldde zich zelf 
aan naar aanleiding van oproepen op sociale media. De primaire uitkomstmaat was de 
ernst van vermoeidheid gemeten met de vragenlijst ‘Checklist Individuele Spankracht’. 
Secundaire uitkomstmaten waren belemmeringen in het dagelijks functioneren gemeten 
met de vragenlijst ‘Sickness Impact Profile-8’, het HbA1c gehalte en de glucosevariabiliteit 
(schommelingen in de bloedsuikers). Patiënten die de wachtlijst hadden geloot kregen de 
Dia-Fit behandeling na de wachttijd van 5 maanden alsnog aangeboden. Zes maanden 
na afronding van de behandeling werd gekeken of de verwachte positieve effecten van 
de behandeling behouden bleven. Uit de meting direct na het afronden van de Dia-Fit 
behandeling en de wachtlijstperiode bleek dat patiënten die de Dia-Fit behandeling 
hadden gevolgd significant lager scoorden op vermoeidheid en minder belemmeringen 
in het dagelijks functioneren ondervonden dan patiënten uit de wachtlijstgroep. 
Het effect van de behandeling was groot. Ongeveer drie uit vier patiënten in de Dia-Fit 
behandelgroep rapporteerden een klinisch relevante afname van vermoeidheid, vergeleken 
met één uit vier patiënten in de wachtlijstgroep. De klinische variabelen HbA1c en glucose-
variabiliteit waren niet significant verschillend tussen de groepen. De follow-up meting 
van de Dia-Fit behandelgroep liet zien dat de scores op vermoeidheid weliswaar weer 
iets waren gestegen in vergelijking met de meting direct na behandeling, maar dat 
de meerderheid van de patiënten nog steeds een klinisch relevante verbetering op 
vermoeidheid rapporteerde. 
Vervolgens gingen wij na welke factoren het meest bijdroegen aan de effectiviteit van de 
Dia-Fit behandeling in het verminderen van de vermoeidheid. In hoofdstuk 6 worden de 
resultaten van deze zogenaamde mediatieanalyse besproken. Middels mediatieanalyse 
kan gekeken worden welke factoren bijdragen aan de positieve effecten van een 
behandeling. Mogelijke mediatoren die in deze studie bekeken werden waren gedachten 
en gedragingen. Een verandering in de volgende factoren verklaarde het behandeleffect 
ten dele: (1) afgenomen gerichtheid op vermoeidheid, (2) minder negatieve opvattingen 
over de relatie tussen symptomen en activiteit, (3) toegenomen ervaren controle over de 
klachten en (4) toename van zelfgerapporteerde fysieke activiteit. Om te onderzoeken of 
depressieve symptomen, die vaak voorkomen bij diabetes type 1 en geassocieerd zijn 
met vermoeidheid, het behandeleffect ook verklaren, werd deze factor tijdens een 
tweede stap aan de analyse toegevoegd. Afname van depressieve symptomen bleek 
inderdaad ook een mediator van het effect te zijn, maar de andere factoren bleken nog 
steeds relevant bij te dragen aan het behandeleffect. Patiënten werd gevraagd welke 
 behandelelementen zij het meest behulpzaam vonden. Als de meest bijdragende 
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elementen werden de gedragselementen van de behandeling zoals de regulatie van 
activiteiten en de optimalisatie van het slaap-waakritme ervaren. De resultaten van dit 
onderzoek suggereren dat gedachten rondom vermoeidheid en activiteiten een grote rol 
spelen in het positieve behandeleffect van CGT op chronische vermoeidheid bij diabetes 
type 1.
Ernstige vermoeidheid komt niet alleen bij diabetes type 1, maar ook bij veel andere 
chronische ziekten voor. De vraag die zich hierbij voordoet is of vermoeidheid een ziekte- 
specifiek of een generiek symptoom is. Om deze vraag te beantwoorden zijn de gegevens 
van 15 eerdere onderzoeken naar vermoeidheid bij uiteenlopende chronische ziekten bij 
in totaal 1696 patiënten geanalyseerd. Wij onderzochten in welke mate de vermoeidheid 
verklaard wordt door (1) de specifieke ziekte, (2) ‘transdiagnostische factoren’ die 
geassocieerd zijn met vermoeidheid bij verschillende chronische ziekten en (3) de 
interactie tussen deze factoren en de ziekte. De resultaten van dit onderzoek worden 
beschreven in hoofdstuk 7. De ernst van vermoeidheid bleek grotendeels te kunnen 
worden verklaard door de transdiagnostische factoren. Geslacht, leeftijd, verminderde 
motivatie, pijn, slaapproblemen, fysiek functioneren, concentratieproblemen, verminderde 
lichamelijke activiteit en een lage ervaren controle over de klachten waren geassocieerd 
met de ernst van vermoeidheid. De relatie van deze factoren met de ernst van vermoeidheid 
verschilde in sterkte tussen de verschillende ziekten, maar was niet verschillend in richting. 
Dit suggereert dat vermoeidheid niet specifiek is voor één ziekte, maar meer een generiek 
symptoom is met overeenkomstige vermoeidheidsgerelateerde factoren die bij verschillende 
chronische aandoeningen bestaan. In de toekomst is een transdiagnostische behandeling 
die rekening houdt met de specifieke behoeften van elke patiënt wenselijk. 
Hoewel chronische vermoeidheid een veelvoorkomend en belastend probleem in diabetes 
type 1 is, wordt er zowel in de wetenschap en ook in de praktijk weinig aandacht aan dit 
probleem geschonken. De onderzoeken van dit proefschrift kunnen bijdragen aan meer 
begrip en aan het ontwikkelen van betere manieren om om te gaan met chronische 
vermoeidheid bij diabetes type 1. De resultaten van de onderzoeken laten zien dat 
chronische vermoeidheid samenhangt met opvattingen en gedragsfactoren die effectief 
met cognitieve gedragstherapie aangepakt kunnen worden. Een volgende stap is het 
beschikbaar maken van de behandeling in de klinische praktijk en het uitbreiden van 
 wetenschappelijk onderzoek over chronische vermoeidheid bij diabetes type 1. Met de 
onderzoeken uitgevoerd in dit proefschrift hopen wij dat er meer aandacht komt voor 
chronische vermoeidheid bij diabetes type 1 waardoor patiënten die hiervan last onder- 
vinden beter geholpen kunnen worden. 
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Die vorliegende Dissertation befasst sich mit der Thematik der chronischen Müdigkeit bei 
Typ-1-Diabetespatienten. Primäres Ziel der Dissertation ist es, dieses wenig erforschte 
Themengebiet genauer zu ergründen. Dabei liegen die Schwerpunkte auf der Erfassung 
von Prädiktoren und assoziierten Faktoren der chronischen Müdigkeit bei Typ-1-Diabetes 
und der Erforschung einer neuen Behandlungsmethode für diese Zielgruppe.
In einer im Jahre 2014 verfassten Querschnittsstudie konnten wir demonstrieren, dass 
chronische Müdigkeit ein weitverbreitetes und schwerwiegendes Symptom der Typ-1- 
Diabetes ist. 40% der befragten Probanden wiesen chronische Müdigkeit auf. Diese 
Müdigkeit geht häufig mit funktionellen Einschränkungen auf körperlicher und/oder 
psychosozialer Ebene einher und zeichnet sich durch eine schwerwiegende Form mit 
einer Mindestdauer von sechs Monaten aus. Letztere Erkenntnisse bilden die Grundlage 
der Studien, die in der vorliegenden Dissertation präsentiert werden. In Kapitel 1 besprechen 
wir die vorhandene wissenschaftliche Literatur zur chronischen Müdigkeit bei Typ-1- 
Diabetespatienten, die, trotz der hohen Prävalenz und einhergehenden funktionellen 
 Einschränkungen, nur in geringer Anzahl vorhanden ist.
In der ersten Studie, die wir präsentieren, beschreiben wir einerseits den Verlauf und 
andererseits mögliche Prädiktoren der schwerwiegenden Müdigkeit bei Typ-1-Diabetes-
patienten. Probanden dieser Studie wurden gebeten, wiederholt Fragebögen auszufüllen; 
das erste Mal während einer sogenannten Nullmessung und das zweite Mal während 
einer Follow-up-Messung 3.5 Jahre später. Die aufgestellte Hypothese besagte, dass 
bestimmte Faktoren die schwerwiegende Müdigkeit vorhersagen können. Zum einen 
waren es Faktoren gesundheitsbezogener Art und zum anderen Faktoren, die bestimmte 
Gedanken und/oder Verhaltensweisen, die in Zusammenhang mit Müdigkeit stehen, 
 aufrechterhalten. Zudem überprüften wir die Hypothese, ob ein Zusammenhang 
zwischen schwerwiegender Müdigkeit und dem HbA1c-Wert der Patienten bestand. Der 
HbA1c-Wert ist die durchschnittliche Höhe des Blutzuckerwertes der vergangenen 
Wochen. Diesen möglichen Zusammenhang untersuchten wir in zwei unterschiedlichen 
Gruppen: Patienten mit einer suboptimalen und Patienten mit einer optimalen Blutzucker-
einstellung. Die Resultate dieser Studie werden in Kapitel 2 dargestellt. Drei Viertel der 
Patienten wiesen eine dauerhafte schwerwiegende Müdigkeit auf. Dies impliziert, dass 
diese Patienten sowohl bei der ersten als auch bei der zweiten Messung eine 
schwerwiegende Müdigkeit zeigen. Faktoren, die schwerwiegende Müdigkeit auf Dauer 
vorhersagten waren depressive Symptome, Schmerz, Schlafprobleme, eine niedrige 
Selbstwirksamkeitserwartung der Müdigkeit, ein hoher Schweregrad der Müdigkeit bei 
der ersten Messung und eine große Anzahl an Diabeteskomplikationen. Der HbA1c-Wert 
der ersten Messung korrelierte positiv mit der schwerwiegenden Müdigkeit der zweiten 
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Messung, allerdings war dieser Zusammenhang schwach und verschwand gänzlich 
nachdem der HbA1c-Wert zusammen mit den anderen vorhersagenden Faktoren 
analysiert wurde. Zusammenfassend wird aus den Resultaten dieser Studie deutlich, dass 
schwerwiegende Müdigkeit ohne Behandlung bei einem Großteil der Typ-1-Diabetes-
patienten auf Dauer beständig ist.
Wissenschaftliche Studien unterschiedlichster chronischer Krankheitsbilder haben 
ergeben, dass Müdigkeit häufig mit Schmerz verbunden ist. Dies führt uns zu der 
Annahme, dass Schmerz auch bei Typ-1-Diabetespatienten mit chronischer Müdigkeit ein 
wichtiger Faktor sein könnte. Ziel dieser Studie, die wir in Kapitel 3 beschreiben, ist es, die 
Prävalenz und assoziierten Faktoren von Schmerz in einer Population von Typ-1-Diabete-
spatienten mit chronischer Müdigkeit zu untersuchen. Die Resultate dieser Studie zeigen, 
dass Schmerz ein weitverbreitetes Symptom dieser Zielgruppe ist, da drei Viertel der 
Probanden Schmerzsymptome aufwiesen. Allerdings empfanden nur ein Viertel 
derjenigen, die Schmerz aufwiesen, die Symptome als sehr einschränkend. Myalgie 
 (Muskelschmerzen), Gelenk-, Rücken- und Kopfschmerzen zählten zu den meist erwähnten 
Schmerzsymptomen. Schmerz war assoziiert mit der Dauer der Diabetes, der Anzahl von 
Diabeteskomplikationen, dem Schweregrad der Müdigkeit, depressiven Symptomen und 
funktionellen Einschränkungen auf körperlicher und/oder psychosozialer Ebene. Entgegen 
unserer Erwartungen war Schmerz weder mit körperlicher Aktivität noch mit dem 
HbA1c-Wert assoziiert. Da Schmerz und schwerwiegende Müdigkeit zusammenhängen, 
und beide Faktoren unabhängig voneinander Einfluss auf die funktionellen Einschränkungen 
im täglichen Leben haben, wäre es wichtig, Schmerzsymptome in zukünftigen Müdig-
keitsbehandlungen für Typ-1-Diabetespatienten zu besprechen. 
Da chronische Müdigkeit ein weitverbreitetes und schwerwiegendes Symptom der 
Typ-1-Diabetes ist, es allerdings an effektiven Behandlungsmöglichkeiten fehlt, ist ein 
Schwerpunkt dieser Dissertation die Erarbeitung einer neuen Behandlung für Typ-1-Dia-
betespatienten mit chronischer Müdigkeit sowie die Überprüfung der Wirksamkeit dieser 
Behandlung. Wissenschaftliche Studien, die Behandlungsoptionen für Müdigkeit in 
anderen chronischen Krankheitsbildern untersucht haben, konnten feststellen, dass 
kognitive Verhaltenstherapie wiederholt als effektive Behandlung bei chronischer 
Müdigkeit befunden wurde. Der Einsatz kognitiver Verhaltenstherapie bei Müdigkeit 
beruht auf der Umstrukturierung von Denk- und Verhaltensmustern, die die Müdigkeit 
aufrechterhalten. Anhand der Literatur, die die positiven Effekte kognitiver Verhaltens-
therapie in anderen Krankheitsbildern beschreibt, und der ersten Erkenntnisse über 
chronische Müdigkeit bei Typ-1-Diabetes wurde von uns die sogenannte „Dia-Fit-Behand-
lung“ entwickelt. „Dia-Fit“ ist somit eine kognitive Verhaltenstherapie für Typ-1-Diabetes-
patienten mit chronischer Müdigkeit. Die Effektivität – bzw. Wirksamkeit – der „Dia-Fit-
Behandlung“ wurde in einer randomisierten kontrollierten Studie untersucht. Der Aufbau 
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dieser Studie und eine ausführliche Inhaltsbeschreibung der Behandlung werden in 
Kapitel 4 dargestellt. Die „Dia-Fit-Behandlung“ beruht auf der Annahme, dass Diabetes 
und/oder mögliche somatische Diabeteskomplikationen die Müdigkeit auslösen, während 
bestimmte Denk- und Verhaltensmuster die Müdigkeit aufrechterhalten. Das Ziel von 
„Dia-Fit“ ist es, diese dysfunktionalen Kognitionen und Verhaltensmuster umzustrukturie-
ren. Die Behandlung besteht aus acht Modulen bei denen persönliche Face-to-Face 
Gespräche mit einem Psychologen mit Online Einheiten, ausgeführt am Computer bzw. 
Laptop, kombiniert werden; eine sogenannte „Blended Care Struktur“. Außerdem wird die 
Behandlung individuell auf jeden Patienten zugeschnitten, indem zu Beginn durch 
Fragebögen die Probleme der Patienten in Zusammenhang mit ihrer Müdigkeit ermittelt 
und entsprechende, für den Patienten sinnvolle Module, ausgewählt werden. Dieses 
Verfahren nennt man auch „tailoring“.
In Kapitel 5 beschreiben wir die Resultate der randomisierten kontrollierten Studie, die die 
Wirksamkeit der „Dia-Fit Behandlung“ untersucht. In dieser Studie wurden 120 Typ-1-Dia-
betespatienten mit chronischer Müdigkeit nach dem Zufallsprinzip der Behandlungs-
gruppe („Dia-Fit“) oder einer Warteliste-Kontrollgruppe zugeordnet. Die Rekrutierung der 
Probanden verlief über verschiedene Wege. 70% der Probanden konnten an fünf unter-
schiedlichen Krankenhäusern der Niederlande und 30% durch Aufrufe zur Studienteilna-
me in sozialen Medien gewonnen werden. Der primäre Endpunkt der Studie war der 
Schweregrad der Müdigkeit, gemessen mithilfe des Fragebogens „Checklist Individual 
Strength“. Die sekundären Endpunkte der Studie waren die funktionellen Einschränkungen 
auf körperlicher und psychosozialer Ebene, gemessen mit dem „Sickness Impact Profile-8“, 
der HbA1c-Wert und die glykämische Variabilität. Letzteres besagt eine Messung von 
Schwankungen der Glukosekonzentration im Blut. Die Endpunkte wurden zu Beginn der 
Studie und nach fünf Monaten, also nach Abschluss der „Dia-Fit-Behandlung“ sowie der 
Wartezeit, gemessen. Aus ethischen Gesichtspunkten bekamen Patienten der Warteliste-
Kontrollgruppe das Angebot, die „Dia-Fit-Behandlung“ nach der Wartezeit von fünf 
Monaten durchzuführen. Sechs Monate nach Abschluss der „Dia-Fit-Behandlung“ wurden 
die Endpunkte erneut gemessen. Die Resultate der Studie zeigen, dass Patienten nach der 
„Dia-Fit-Behandlung“ eine signifikante Verringerung der Müdigkeit und der funktionellen 
Einschränkungen im Vergleich zu der Warteliste-Kontrollgruppe vorwiesen. Die Größe 
dieses Effektes war hoch. Ungefähr drei Viertel der behandelten Patienten wiesen eine 
klinisch relevante Verminderung der Müdigkeit auf. Im Vergleich dazu waren es in der 
Warteliste-Kontrollgruppe nur ungefähr ein Viertel der Patienten. Allerdings bestand kein 
Unterschied bezüglich des HbA1c-Wertes und der glykämischen Variabilität zwischen 
beiden Gruppen. Bei der Follow-up-Messung nach sechs Monaten ließ sich wieder ein 
leichter Anstieg der Müdigkeit bei der Behandlungsgruppe erkennen. Allerdings wies der 
Großteil der Patienten noch immer eine klinisch relevante Verringerung der Müdigkeit auf. 
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In der vorliegenden Dissertation weisen wir nicht nur die Wirksamkeit der „Dia-Fit- 
Behandlung“ nach, sondern untersuchen auch, welche Wirkmechanismen zu dem positiven 
Effekt der Behandlung beitragen. In Kapitel 6 werden die Resultate einer sogenannten 
Mediatoranalyse besprochen. Anhand einer Mediatoranalyse wird geprüft, welche 
Faktoren die positiven Effekte einer Behandlung erklären. Mögliche Mediatoren dieser 
Studie waren Kognitionen und Verhaltensfaktoren. Aus den Resultaten der Studie lässt 
sich schließen, dass eine Veränderung des Grades der folgenden Faktoren zu dem 
positiven Effekt der „Dia-Fit-Behandlung“ beitrug: erstens die Fokussierung auf Müdig-
keitssymptome, zweitens negative Gedanken über den Zusammenhang zwischen 
 Müdigkeitssymptomen und körperlichen Aktivitäten, drittens Selbstwirksamkeitser-
wartung und viertens wahrgenommene körperliche Aktivität. Da depressive Symptome 
oft ebenfalls in Zusammenhang mit Typ-1-Diabetes und Müdigkeit stehen, untersuchten 
wir die Frage, ob eine Veränderung des Grades depressiver Symptome auch zu dem 
positiven Effekt der „Dia-Fit-Behandlung“ beitrug. Zu diesem Zweck wurde in einem 
zweiten Schritt der Mediatoranalyse die Variable depressive Symptome hinzugefügt. 
Das Ergebnis zeigt, dass unsere Hypothese bestätigt wird. Verändert sich der Grad der 
depressiven Symptome, zeigt sich ein positiver Effekt der „Dia-Fit-Behandlung“. Allerdings 
blieben die zuvor gefundenen Mediatoren konstant, das heißt nicht nur eine Veränderung 
des Grades der depressiven Symptome, sondern auch eine Veränderung des Grades 
der Kognitionen bezüglich Müdigkeit und Aktivität trugen zu dem positiven Effekt der 
„Dia-Fit-Behandlung“ bei. Um zu untersuchen welche Behandlungselemente Patienten 
am hilfreichsten empfanden, wurden sie nach Abschluss der Behandlung danach gefragt. 
Elemente bezüglich der Umstrukturierung von Verhaltensmuster sowie der Regulation 
der Aktivitäten und der Optimierung des Schlafrhythmus wurden als am hilfreichsten 
bewertet. Die Resultate dieser Studie zeigen, dass primär Kognitionen bezüglich Müdigkeit 
und Aktivitäten Wirkmechanismen der „Dia-Fit-Behandlung“ sind. Somit kommt es zu 
einem positiven Behandlungseffekt in der kognitiven Verhaltenstherapie bei Typ-1-
Diabetes patienten mit chronischer Müdigkeit. 
Schwerwiegende Müdigkeit ist sowohl bei Typ-1-Diabetes als auch bei anderen 
chronischen Krankheitsbildern prävalent. Es stellt sich die Frage, ob Müdigkeit ein krank-
heitsspezifisches oder krankheitsübergreifendes Symptom ist. Zur Klärung dieser Frage 
analysierten wir Daten von 1696 Patienten aus 15 Studien, die Müdigkeit in unterschied-
lichsten Krankheitsbildern untersucht haben. Wir wollten überprüfen wie viel Varianz der 
Müdigkeit – bzw. welcher Anteil von Müdigkeit – erklärt wird durch: erstens die spezifische 
Krankheit, zweitens die Faktoren, die krankheitsübergreifend mit Müdigkeit assoziiert 
werden – auch transdiagnostische Faktoren genannt – und drittens die Interaktion 
zwischen diesen Faktoren und der spezifischen Krankheit. Die Resultate dieser Studie 
präsentieren wir in Kapitel 7. Der Großteil der Müdigkeitsvarianz wurde durch die trans-
diagnostischen Faktoren erklärt. Geschlecht, Alter, Motivationsprobleme, Schmerz, 
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Schlafprobleme, körperliche Funktionsfähigkeit, Konzentrationsprobleme, eine niedrige 
körperliche Aktivität und eine niedrige Selbstwirksamkeitserwartung waren mit dem 
Schweregrad der Müdigkeit assoziiert. Der Zusammenhang zwischen diesen Faktoren 
und dem Schweregrad der Müdigkeit war unterschiedlich groß, abhängig von dem 
Krankheitsbild. Allerdings wies die Richtung des Zusammenhangs keine Unterschiede auf. 
Dieses zeigt, dass Müdigkeit ein krankheitsübergreifendes Symptom ist, welches in unter-
schiedlichen chronischen Krankheitsbildern ähnlich ist. Wünschenswert wären zukünftige 
Behandlungsmodelle die transdiagnostische Grundlagen aufweisen, allerdings auch die 
persönlichen Bedürfnisse von Patienten berücksichtigen. 
Zusammenfassend lässt sich sagen, dass chronische Müdigkeit ein weitverbreitetes und 
schwerwiegendes Problem der Type-1-Diabetes ist, dem allerdings sowohl in der Praxis als 
auch in der Wissenschaft noch wenig Aufmerksamkeit gewidmet wird. Die vorliegende 
Dissertation trägt zu dem Verständnis und der Behandlung der chronischen Müdigkeit in 
Typ-1-Diabetespatienten bei. So zeigen die Resultate der Studien, dass chronische Müdigkeit 
in dieser Zielgruppe mit dysfunktionalen Kognitionen und bestimmten Verhaltensmustern 
zusammenhängt, die wirksam mit kognitiver Verhaltenstherapie umstrukturiert werden 
können. Im Hinblick auf die Zukunft ist es wichtig, weitere Forschung zu betreiben, und 
die Behandlung von chronischer Müdigkeit in der Praxis zu etablieren. Die Studien dieser 
Dissertation haben uns diesem Ziel einen Schritt nähergebracht und einen ersten Beitrag 
dazu geleistet, dass Typ-1-Diabetespatienten mit chronischer Müdigkeit besser behandelt 
werden können.
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